For a woman who feels well and has no known inherited high risk of ovarian cancer, the question sounds straightforward: could a blood test check for the disease before symptoms appear?

There is still no recommended routine ovarian cancer screening test for women at average risk. A newly registered U.S. study will evaluate a possible approach — and what happens to women when that test raises an alarm.

The SOARA study, NCT07872644, plans to enroll up to 1,750 postmenopausal women aged 50 and older to evaluate the Evident Ovarian Cancer Screening Test. Sponsored by Mercy BioAnalytics, it will examine test specificity, safety and the consequences of positive results.

The central question is not simply whether the blood test can detect cancer. It is also whether it can avoid sending too many women without cancer into a chain of additional appointments, scans and potentially invasive procedures.

For patients and their doctors, both answers matter.

Why ovarian cancer still has no routine screening test for most women

A blood test is an appealing idea for a disease that can be difficult to recognize early. But testing someone who feels well is different from investigating symptoms or an ovarian mass.

Screening looks for disease in people who have no symptoms. Most people being screened will not have the cancer the test is looking for.

The American Cancer Society states that no ovarian cancer screening tests are recommended for women without symptoms or high risk. The CA-125 blood test and transvaginal ultrasound have been studied extensively, but their use in average-risk women has led to additional testing and surgery without reducing ovarian cancer deaths.

CA-125 can rise for reasons unrelated to cancer, while some ovarian cancers do not produce a high result. Ultrasound can reveal an abnormality without establishing whether it is cancerous.

That leaves an important unmet need. But a new test has to do more than produce a promising laboratory result: the entire screening process must offer a favorable balance of benefits and harms.

What happens after a positive blood test?

SOARA will follow participants for approximately 12 months. Blood collection is planned through a mobile phlebotomy service.

Under the study plan, women with a positive Evident result will undergo a transvaginal ultrasound and may choose additional Evident testing during follow-up. Further clinical decisions remain with their treating healthcare provider. Women with negative results will not be required to undergo additional study procedures.

A positive screening result is not a cancer diagnosis. It is the beginning of an investigation.

For a woman receiving that result, the immediate questions may be practical as well as medical: What does this mean? How soon can I see someone? Will I need another scan? Could I need an operation?

The study will track adverse events, invasive diagnostic procedures, ovarian cancer diagnoses and the psychological burden reported after positive results.

That is an important feature of the research. A false positive is not simply an incorrect answer in a laboratory dataset. It can change what happens to a person.

Why false alarms matter so much

When screening is offered to a population in which cancer is uncommon, even a small false-positive rate can affect many women who do not have the disease.

A suspicious ovarian finding can be particularly difficult to resolve. Depending on the clinical findings, establishing a diagnosis may ultimately require surgery rather than another blood test alone.

The National Cancer Institute describes the potential harms of ovarian cancer screening, including anxiety, additional procedures and unnecessary operations after false-positive results. Those procedures can carry risks such as infection, bleeding and injury to nearby organs.

This is why specificity matters. It describes how often a test correctly gives a negative result in people who do not have the disease.

It is different from sensitivity, which describes how often the test detects the disease when it is present. It is also different from the probability that a woman with a positive result has cancer.

A useful screening test needs more than an impressive detection rate. It must also keep false alarms and their consequences acceptably low.

Who is SOARA intended for?

The study is for postmenopausal women aged 50 or older who have at least one ovary and no personal history of ovarian cancer. Women with known hereditary cancer syndromes or genetic risk factors, those already under surveillance for elevated ovarian cancer risk, and those undergoing investigation for suspicious symptoms are excluded.

This distinction matters: SOARA is evaluating screening in an average-risk population, not diagnosing a suspicious mass or managing women with known inherited high risk.

“Average risk” does not mean “no risk.” It identifies the population in which researchers want to understand whether a screening strategy can be useful without causing disproportionate harm.

What does Evident look for in the blood?

Evident is not simply another CA-125 measurement. Its approach also differs from blood tests that primarily search for circulating tumor DNA.

According to the developer’s description of the technology, the assay examines extracellular vesicles and particles: tiny structures released by cells into the bloodstream.

These structures can carry biological signals from the cells that produced them. The technology looks for combinations of cancer-associated biomarkers found together on individual particles.

The rationale is that several signals occurring together may be more informative than a single marker that can also be present in people without cancer.

Whether that approach performs well enough for routine screening is the question that clinical validation must address.

What the earlier research showed — and what it did not

A 2025 study published in Gynecologic Oncology evaluated the technology in stored blood samples from women who had participated in the UK Collaborative Trial of Ovarian Cancer Screening, or UKCTOCS. The samples had been collected before the women’s cancers were clinically diagnosed.

In the blinded analysis, the test detected 34 of 41 high-grade serous cancers in samples taken within 12 months before diagnosis: a sensitivity of 82.9%. Specificity was 97.7% among 1,176 controls without ovarian cancer.

Among early-stage high-grade serous cancers, it detected eight of nine cases. That is encouraging, but nine cases are too few to give a precise estimate of early-stage performance. These findings should not be generalized to every ovarian cancer subtype.

A specificity of 97.7% also illustrates why false positives cannot be ignored: if that rate held in another population, about 23 of every 1,000 women without cancer would receive a positive result. That is an arithmetic illustration, not an observed SOARA result.

The earlier study supports further investigation. It does not establish that offering the test routinely improves women’s health.

Why studying stored samples is not the same as screening women

The earlier research had an important strength: its samples were collected before diagnosis, rather than only from women already known to have cancer.

But the new assay was evaluated retrospectively. Its results did not guide those women’s care at the time their blood was drawn.

SOARA takes the next step by using the test prospectively and observing the clinical pathway that follows.

The difference is not just technical. It is the difference between asking, “Would this sample have tested positive?” and asking, “What happened to the woman after she received that result?”

That second question includes the experience of women whose investigations ultimately find no cancer.

Permission to conduct the study is not FDA approval of the test

On September 21, 2026, Mercy BioAnalytics announced that the FDA had approved its Investigational Device Exemption application for Evident.

That decision permits use of the investigational test in the specified SOARA study, subject to the required institutional review board approval.

It does not mean the FDA has approved or cleared Evident as an ovarian cancer screening test. The company explicitly makes that distinction in its announcement.

For readers, the important difference is between permission to investigate a medical test and evidence that it should become routine care.

Even finding cancer earlier would not answer every question

Ovarian cancer screening has already shown why earlier detection and improved outcomes cannot be treated as interchangeable.

In UKCTOCS, more than 200,000 postmenopausal women were randomly assigned to multimodal screening, ultrasound screening or no screening.

The multimodal strategy increased the proportion of cancers diagnosed at earlier stages. Yet after a median follow-up of more than 16 years, the trial found no significant reduction in deaths from ovarian and tubal cancer.

Those findings do not establish that a different test could never help. They show why a change in stage at diagnosis cannot, on its own, prove that screening saves lives.

SOARA is a single-group study with approximately one year of follow-up, not a randomized comparison of long-term mortality in screened and unscreened women. It therefore cannot, by itself, establish that Evident screening reduces ovarian cancer deaths.

What it can contribute is prospective evidence about specificity, safety and the burden of follow-up investigations — essential parts of evaluating a screening strategy.

What does this mean for women now?

The study does not change current recommendations for routine screening in women at average risk who have no symptoms.

It is not, by itself, a reason to request CA-125 testing, ultrasound or a new blood test as a routine ovarian cancer check.

Women with a strong family history or known inherited cancer risk need a different, individualized discussion about risk assessment and prevention.

And screening is not the same as investigating symptoms. Persistent unexplained bloating, pelvic or abdominal pain, feeling full unusually quickly, or urinary changes should be discussed with a healthcare professional. These symptoms can have many causes; they should not be ignored while waiting for a future screening test.

A negative screening result would not make new or persistent symptoms unimportant either.

The real test is what happens after the blood is drawn

SOARA is listed as not yet recruiting in the October 2026 registration, with an estimated start in November 2026.

Its importance lies in a question that is easy to overlook when a new cancer blood test makes headlines.

A blood draw may be simple. The decisions that follow it may not be.

For a woman without symptoms, the value of screening depends on more than the possibility of finding cancer. It also depends on how often the test raises a false alarm, what investigations follow and whether the overall process improves her chances of staying well.

SOARA will help examine those consequences. The larger question — whether this approach can ultimately reduce deaths from ovarian cancer — remains to be answered.

Clinical trial record: NCT07872644 on ClinicalTrials.gov

After months of breast cancer treatment and surgery, a patient can receive one of the most reassuring pathology results possible: no residual invasive cancer is found in the breast or regional lymph nodes.

Then a blood test detects tumor DNA.

What should doctors do when conventional pathology shows a pathologic complete response, but circulating tumor DNA suggests that a molecular trace of the cancer may still remain?

A newly registered randomized Phase 2 trial involving 358 patients with HER2-positive breast cancer will test whether that hidden molecular signal should lead to more intensive treatment.

The study, NCT07856303, will compare the HER2-directed antibody-drug conjugate SHR-A1811 with trastuzumab plus pertuzumab in patients who achieved a pathologic complete response after preoperative treatment but still have detectable circulating tumor DNA, or ctDNA, after surgery.

The trial focuses on an increasingly important question in cancer medicine: if doctors can detect molecular evidence associated with cancer before a recurrence can be seen on scans or found by conventional testing, can acting on that warning actually prevent the cancer from returning?

What does a pathologic complete response actually mean?

When systemic treatment is given before breast cancer surgery, doctors can examine the tissue removed during the operation to see how completely the cancer responded.

A pathologic complete response, or pCR, is one of the strongest responses possible.

In this study, pCR is defined as ypT0/is ypN0. In practical terms, that means pathologists find no residual invasive carcinoma in the breast or regional lymph nodes. Residual ductal carcinoma in situ, or DCIS, is permitted.

This distinction matters. A pathologic complete response does not literally prove that every cancer cell has disappeared from the entire body.

For patients with HER2-positive breast cancer, achieving pCR after neoadjuvant treatment is generally associated with a substantially lower risk of recurrence. But recurrence can still occur, particularly in patients whose disease was more advanced at diagnosis.

Pathologists can examine the tissue that was removed. They cannot directly determine whether a very small number of malignant cells may remain somewhere else in the body.

That is the gap researchers hope ctDNA may help to fill.

How can tumor DNA remain detectable when no invasive cancer is found?

Circulating tumor DNA consists of small fragments of genetic material released by cancer cells into the bloodstream.

Very sensitive blood tests can sometimes detect these fragments when conventional imaging shows no tumor and when there is no visible evidence of recurrent disease.

After treatment intended to cure an early-stage cancer, such a finding may represent what researchers call molecular residual disease, or MRD.

But a positive ctDNA result is not the same thing as finding a metastasis.

It does not tell doctors where any remaining cancer cells might be, how many there are or whether a particular patient will definitely experience a recurrence.

What it can potentially provide is information about risk.

European Society for Medical Oncology recommendations on circulating tumor DNA note that detecting molecular residual disease after potentially curative treatment has strong clinical validity as a predictor of future relapse in several cancers.

But ESMO also makes an important distinction: there has not been sufficient evidence to routinely change treatment on the basis of an MRD result because clinical utility — whether acting on the test actually improves patient outcomes — still has to be demonstrated.

Randomized trials are needed to answer that question.

NCT07856303 is designed to do exactly that in a carefully selected group of patients with HER2-positive breast cancer.

The patients will have two very different post-treatment signals

The study is targeting a specific and unusual clinical situation.

Participants must originally have had stage IIB to IIIC HER2-positive invasive breast cancer without distant metastases.

Before surgery, they must have completed at least six cycles and at least 16 weeks of standard neoadjuvant systemic therapy.

After definitive breast surgery and appropriate assessment of the axillary lymph nodes, their pathology must show no remaining invasive carcinoma in the breast or regional nodes.

But another test then has to point in the opposite direction.

Between 14 and 42 days after the final definitive surgery — and before postoperative systemic treatment begins — a central laboratory must detect ctDNA in the patient's blood.

At the same time, there must be no clinical, pathological or radiological evidence of local recurrence or distant metastatic disease.

So the patients entering the trial will have what appears to be an excellent response by conventional standards, while a molecular blood test continues to detect cancer-related DNA.

Will intensified therapy reduce the risk of recurrence?

The 358 participants will be randomly assigned in a 1:1 ratio to two postoperative treatment strategies.

The experimental group will receive SHR-A1811 at 4.8 mg/kg by intravenous infusion once every three weeks for 14 cycles.

The comparison group will receive trastuzumab plus pertuzumab once every three weeks. Including the HER2-targeted treatment already given before surgery, the protocol aims for approximately one year of perioperative dual HER2-directed therapy.

The study is open-label, meaning patients and treating clinicians will know which treatment was assigned.

But the primary question is not simply whether the stronger treatment makes ctDNA disappear.

The main endpoint is invasive disease-free survival three years after randomization.

Researchers will measure whether patients remain free from invasive breast cancer recurrence, regional or distant recurrence, contralateral invasive breast cancer, another invasive primary cancer or death.

The study will also follow distant disease-free survival and overall survival for up to five years, as well as brain metastases and treatment-related adverse events.

That choice of endpoint is important. The trial is ultimately testing whether changing treatment because of molecular residual disease improves outcomes that matter to patients — not merely whether a blood-test result changes.

What is SHR-A1811?

SHR-A1811, also known as trastuzumab rezetecan, is a HER2-directed antibody-drug conjugate, or ADC.

Antibody-drug conjugates are designed to combine the targeting ability of an antibody with a potent anticancer drug. The antibody recognizes a target on cancer cells and helps deliver the attached payload to those cells.

According to the National Cancer Institute Drug Dictionary, trastuzumab rezetecan uses a trastuzumab-based antibody directed at HER2 and carries a topoisomerase I inhibitor payload.

The drug is already being investigated in several HER2-expressing cancers, including breast cancer.

A previously reported randomized Phase 2 study tested SHR-A1811 as preoperative therapy in 265 patients with stage II–III HER2-positive breast cancer.

In that study, 63.2% of patients receiving SHR-A1811 alone achieved a pathologic complete response, compared with 64.4% of patients treated with nab-paclitaxel, carboplatin, trastuzumab and pertuzumab. The difference between those groups was not statistically significant.

The study also illustrates why intensifying treatment cannot be considered only in terms of potential anticancer activity.

Grade 3 or higher treatment-related adverse events occurred in 44.8% of patients receiving SHR-A1811 alone, and one patient developed grade 2 interstitial lung disease.

The new postoperative trial therefore has to answer a genuine risk-benefit question: if ctDNA identifies patients at unusually high risk despite a pathologic complete response, does an ADC-based strategy reduce future recurrence enough to justify additional treatment and toxicity?

Current treatment already changes according to what surgery finds

HER2-positive early breast cancer is already an example of treatment being adjusted according to the response seen after preoperative therapy.

ESMO clinical practice guidance for early breast cancer recommends HER2-directed treatment across the neoadjuvant and adjuvant periods for a total duration of about one year.

For patients who achieve a pathologic complete response after standard preoperative therapy, anti-HER2 treatment is generally continued to complete the planned course.

The situation is different when surgery finds residual invasive disease.

Those patients are at higher risk of recurrence, and postoperative treatment with the antibody-drug conjugate T-DM1 is recommended instead of simply continuing trastuzumab-based therapy.

NCT07856303 introduces another possible layer of risk assessment.

What if surgical pathology places a patient in the favorable pCR group, but a blood test detects a molecular signal suggesting that her risk may be higher than pathology alone indicates?

The promise of ctDNA also creates a difficult problem

The attraction of molecular residual disease testing is easy to understand.

Today, recurrent cancer is often identified only after it becomes large enough to appear on imaging, produce symptoms or cause another measurable clinical sign.

A sufficiently sensitive blood test might detect molecular evidence of disease much earlier.

But detecting something earlier is only clinically useful if doctors know what to do about it.

A biomarker can be very good at identifying people with a higher risk of recurrence and still fail to improve patient outcomes if changing treatment does not alter that risk.

There is also another danger.

More intensive treatment can cause additional toxicity. If some ctDNA-positive patients would never have developed a clinical recurrence, automatically escalating treatment could expose them to harm without providing benefit.

This is the critical difference between a test being prognostic and being useful for guiding treatment.

NCT07856303 goes beyond asking whether ctDNA predicts relapse. By randomizing ctDNA-positive patients between two treatment strategies, the investigators can test whether acting on the molecular result changes what ultimately happens to patients.

Later ctDNA results will not automatically change treatment

There is another important feature of the trial design.

ctDNA will be used to identify which patients are eligible to enter the randomized study, but subsequent ctDNA results will not routinely be used to change their treatment.

After randomization, ctDNA findings are planned to remain blinded to both investigators and participants until the database for the primary analysis is locked, unless the protocol is later modified through an ethics-approved amendment.

This allows researchers to test the assigned treatment strategies without repeatedly altering therapy according to later molecular test results.

A positive ctDNA test is not currently a reason to intensify treatment on your own

The new study should not be interpreted as evidence that every patient with detectable ctDNA after treatment for early breast cancer needs a more intensive drug regimen.

The trial has not yet shown that SHR-A1811 improves invasive disease-free survival in patients who have achieved pCR but remain ctDNA-positive.

It also does not mean that a patient who achieved a pathologic complete response and has never undergone ctDNA testing should seek additional treatment because microscopic disease might theoretically remain.

For early-stage cancers, using ctDNA to detect molecular residual disease and direct treatment remains an active field of clinical research rather than an established routine standard.

The study is newly registered, is being led by Fudan University at Fudan University Shanghai Cancer Center in China and is currently listed as not yet recruiting.

When an excellent pathology result may not tell the whole story

For decades, cancer treatment decisions have depended heavily on what imaging can see and what pathologists can find under a microscope.

Those tools remain fundamental.

But increasingly sensitive blood tests are beginning to reveal another layer of information: molecular signals that can sometimes remain detectable even when conventional tests find no residual invasive cancer.

The next question is much harder than simply detecting those signals.

Can treating molecular residual disease before a visible recurrence appears actually prevent that recurrence?

For patients with HER2-positive breast cancer who achieve a pathologic complete response but remain ctDNA-positive after surgery, NCT07856303 will test whether that molecular warning is enough to justify a more intensive postoperative treatment strategy.

The answer is not known yet.

And until a randomized study shows that acting on ctDNA improves outcomes, the molecular signal should be understood as an important research marker — not proof that visible cancer remains and not, by itself, a reason to change treatment outside a clinical trial.

Clinical trial record: NCT07856303 on ClinicalTrials.gov

For many people who have had a heart attack or coronary stent, a small aspirin tablet can remain part of everyday life for decades. The emergency passes, years go by and no new heart attack or stroke occurs — but the aspirin remains.

But does it always need to remain part of treatment for life?

Two large Scandinavian studies involving about 14,000 adults aged 65 and older are preparing to test a question that could eventually affect one of the most familiar routines in heart care: whether some older people with stable coronary disease can safely stop long-term low-dose aspirin years after their original heart event.

The newly registered RELEASE-Norway study, NCT07854795, plans to randomize 7,000 people to either continue their daily aspirin or stop it. A companion Danish Phase 4 trial, DAN-RELEASE, is designed to enroll another 7,000.

The studies are not evidence that patients should stop aspirin now. Long-term antiplatelet treatment remains recommended for many people with established coronary disease, and stopping aspirin or another prescribed antiplatelet medicine without medical advice can be dangerous. The RELEASE program is testing a narrower question: does the balance between preventing heart attacks and causing serious bleeding change in some older patients who have remained stable for years?

The aspirin can remain long after the heart attack is over

Low-dose aspirin has been a cornerstone of secondary prevention for decades. It reduces the ability of platelets to form blood clots and can lower the risk of another heart attack or ischemic stroke in people who already have cardiovascular disease.

Immediately after a heart attack or coronary intervention, the reason for taking antiplatelet treatment is often clear.

The decision may become less straightforward years later.

A patient may now be 75 rather than 65. The coronary event and stent procedure happened several years ago. Cholesterol may be tightly controlled with modern lipid-lowering therapy. Blood pressure treatment, smoking cessation and coronary procedures have also improved substantially compared with the era in which much of the original evidence for long-term aspirin was generated.

At the same time, ageing changes the other side of the equation: aspirin can cause bleeding.

That is the balance the RELEASE studies are designed to revisit.

The same effect that prevents clots can also increase bleeding

Aspirin makes platelets less likely to stick together. That can be protective when the danger is a clot blocking a coronary artery.

But platelets are also part of the body's normal system for stopping bleeding.

Long-term aspirin therefore involves a trade-off. It may help prevent heart attacks and ischemic strokes while increasing the risk of bleeding, including major gastrointestinal bleeding and potentially serious bleeding inside the skull.

This balance becomes particularly important in older adults because the risk of major bleeding generally rises with age.

Current European Society of Cardiology guidance continues to recommend long-term single-antiplatelet therapy for people with established chronic coronary disease, generally with aspirin or clopidogrel.

RELEASE is not starting from the assumption that this treatment is unnecessary. It is asking whether the balance between protection from cardiovascular events and the risk of serious bleeding may change in some older patients who have remained stable for years.

Why researchers are re-testing a decades-old treatment practice

The investigators behind RELEASE point to an unusual feature of modern cardiology: treatment of coronary disease has changed dramatically, while aspirin has remained one of its most familiar long-term preventive medicines.

The RELEASE-Norway trial record notes that much of the evidence supporting lifelong aspirin in secondary prevention comes from studies conducted roughly 40 to 50 years ago.

Since then, heart care has changed. Modern PCI and coronary stents are different. Statins and other lipid-lowering treatments are much more effective. Risk-factor management has improved, and acute coronary events are diagnosed and treated earlier.

None of this means the older evidence for aspirin is invalid.

It raises a more specific question: does exactly the same balance of benefit and harm still apply to an older patient who has remained clinically stable for several years while receiving modern cardiovascular treatment?

Who will be studied in Norway?

RELEASE-Norway is deliberately not testing aspirin withdrawal immediately after a heart attack or stent procedure.

Participants must be at least 65 years old and currently taking low-dose aspirin of no more than 150 mg per day.

They must have had an acute coronary syndrome treated with percutaneous coronary intervention, or PCI, between two and eight years before entering the study. Since that event, they must have had no new myocardial infarction or stroke and no additional coronary PCI or bypass surgery.

In other words, the trial is targeting a very particular group: older adults with established coronary disease whose original acute event is years behind them and who have remained clinically stable.

People who need antiplatelet therapy for another reason are excluded, as are those who currently need anticoagulants or P2Y12 inhibitors. Patients with certain high-risk coronary features, including a previous stent thrombosis, are also excluded.

These restrictions are important. Even if RELEASE eventually supports aspirin withdrawal in some participants, the findings would not mean that everyone who has had a heart attack or coronary stent should stop treatment.

Half will continue aspirin and half will stop

RELEASE-Norway is a Phase 4 randomized study that plans to enroll 7,000 people at major hospitals across Norway.

Participants will be assigned in a 1:1 ratio. One group will continue its usual low-dose aspirin. In the other group, aspirin will be discontinued.

The study is open-label, meaning patients and treating doctors will know which strategy has been assigned, while clinical outcomes will be assessed in a blinded manner. Norwegian national health registries will allow researchers to follow major events across a very large group of patients for a median of about three years.

Crucially, researchers will not simply count heart attacks.

The primary outcome deliberately weighs both sides of the aspirin decision. It includes cardiovascular death, intracranial bleeding, myocardial infarction including stent thrombosis, ischemic stroke and other major bleeding requiring hospital care.

That reflects the real decision facing doctors and patients: protection from clotting has to be considered alongside harm from bleeding.

Denmark is asking almost the same question in another 7,000 people

Norway is not investigating this issue in isolation.

The companion DAN-RELEASE study is also a Phase 4 randomized trial designed to enroll 7,000 adults aged 65 or older and compare continuation of long-term low-dose aspirin with discontinuation.

The Danish population is somewhat broader. Participants can have a history of myocardial infarction, PCI or coronary artery bypass surgery more than two years earlier, provided they have remained free from subsequent ischemic cardiovascular events and further coronary revascularization.

Its primary outcome also combines serious cardiovascular events with serious bleeding rather than treating either side of the equation in isolation.

Together, the Norwegian and Danish studies are designed to include about 14,000 older adults.

That scale matters because both recurrent cardiovascular events and major bleeding are relatively uncommon in clinically stable patients. Thousands of participants are needed to compare the two strategies reliably.

This is not the same question as aspirin for someone who has never had heart disease

The distinction is important because aspirin use has already been reconsidered substantially in older adults who have never had a heart attack, stroke or established cardiovascular disease.

That is known as primary prevention.

RELEASE is studying secondary prevention: people who definitely have coronary disease and have already experienced a significant coronary event or procedure.

The cardiovascular benefit of antiplatelet treatment in secondary prevention is much better established. These new studies are therefore asking a harder and more specific question — not whether aspirin can work, but whether its overall benefit continues indefinitely in selected older patients who have been stable for years.

Why the question can become more personal with age

For an older patient, a treatment decision rarely involves only one condition or one medicine.

A person may also be taking drugs for blood pressure and cholesterol, perhaps treatment for diabetes, arthritis or other chronic conditions. Kidney function may change. Falls can become more important. A history of stomach ulcers or previous bleeding may matter more than it did years earlier.

That makes the familiar instruction to take a medicine “for life” worth examining with modern evidence — while avoiding assumptions that stopping it must be better simply because a patient is older.

RELEASE-Norway plans subgroup analyses by age, frailty and the extent of coronary disease. Researchers will also examine adherence, recurrent cardiovascular hospitalizations, quality of life, angina symptoms and patient-reported outcomes.

The goal is not simply to remove one tablet from a medication list. It is to understand which patients continue to benefit from aspirin and whether that balance changes as they age.

What could the studies change?

If stopping aspirin produces an acceptable overall cardiovascular outcome while reducing serious bleeding, the findings could challenge the assumption that every stable older coronary patient needs aspirin indefinitely.

If heart attacks, ischemic strokes or other cardiovascular events increase meaningfully after withdrawal, the trials could instead provide contemporary evidence that continued antiplatelet treatment remains worthwhile many years after the original event.

Either result could be clinically useful.

But those results do not exist yet.

RELEASE-Norway was newly registered in October 2026 and is currently listed as not yet recruiting, with an estimated study start in February 2027. Participants are expected to be followed for a median of about three years, and final study completion is currently estimated for 2031.

Until reliable results are available, RELEASE should not be interpreted as a reason for people with previous coronary disease to stop aspirin on their own. Whether aspirin or another antiplatelet treatment remains appropriate depends on why it was prescribed, the person's coronary history, other medicines and the individual risks of both clotting and bleeding.

A small daily tablet with a very large unanswered question

Low-dose aspirin is easy to overlook. It is inexpensive, familiar and may have occupied the same place in someone's pill organizer for years.

That familiarity is exactly what makes the RELEASE question interesting.

Heart care has changed dramatically since lifelong aspirin became established in secondary prevention. Now two Scandinavian trials involving about 14,000 older adults will test whether the treatment should remain lifelong for every stable patient — or whether, for some people, there may eventually be a point when the balance of protection and bleeding risk changes.

For now, the answer remains unknown. That is why the question needs a large randomized trial rather than an assumption.

Clinical trial record: RELEASE-Norway, NCT07854795 on ClinicalTrials.gov

For a patient told that a small breast cancer needs treatment, the next step is often surgery. Even when the tumor is only a centimeter or two across and has favorable features, removing it with a lumpectomy is usually part of breast-conserving treatment.

A newly registered pilot study is asking a much more unusual question: could some carefully selected patients leave the tumor in place and treat it instead with one highly focused radiation session, followed by endocrine therapy?

The SOLIS study, NCT07844759, plans to test that approach in just 30 people with small estrogen receptor-positive, HER2-negative breast cancers. Unlike previous studies of radiation given before breast surgery, SOLIS is designed from the outset to omit the planned lumpectomy.

That makes the study potentially important — but also very early. SOLIS is a small, single-center pilot with no comparison group, and it is not yet recruiting. Its first job is to determine whether the approach is safe enough to study further, not to prove that surgery can already be replaced.

Why avoiding lumpectomy would be such a major change

For most people with early invasive breast cancer, local treatment still involves surgery. A lumpectomy removes the cancer along with a margin of surrounding tissue while preserving most of the breast, and radiation is commonly given afterward to lower the risk of the cancer returning in the same breast.

The National Cancer Institute describes lumpectomy followed by radiation as an established breast-conserving treatment for appropriately selected patients.

SOLIS reverses that familiar sequence. Instead of removing the tumor and then using radiation to treat possible remaining cancer cells, researchers will deliver an ablative radiation treatment while the tumor is still intact — and intentionally leave out the planned lumpectomy.

For patients, that changes the question dramatically. Researchers are not simply trying to shorten a radiation course. They are asking whether surgery itself might eventually be avoidable for a very narrowly selected group of people with favorable early breast cancer.

One radiation treatment — but not “no treatment”

Participants in SOLIS will receive a single session of stereotactic radiation therapy. This type of treatment uses detailed imaging and highly precise radiation planning to concentrate a large dose on a small target while limiting exposure to surrounding tissue.

The protocol calls for 24 Gy to the planning target volume, with a simultaneous integrated boost of 30 Gy to the clinical tumor target.

Participants will also receive endocrine therapy — an aromatase inhibitor or tamoxifen — beginning within 30 days after radiation. The protocol recommends continuing endocrine treatment for five years.

So SOLIS is not testing whether a small breast cancer can simply be left alone. It is testing whether one form of local treatment — surgery — might eventually be replaced by a precisely targeted radiation treatment combined with long-term hormone-blocking therapy.

Only a very selected group will qualify

The eligibility criteria are intentionally narrow.

The cancer must be an invasive ductal carcinoma or another favorable histologic type, limited to a single area of the breast and no larger than 2 centimeters. It must be estrogen receptor-positive, HER2-negative and grade 1 or 2, with no clinical evidence that cancer has reached the lymph nodes.

The tumor must also be positioned far enough from the skin and chest wall for the radiation plan to meet the study's safety limits.

Most participants will be 65 or older. People between 50 and 64 may participate when surgery is considered medically unsuitable or when they have declined surgery, and no more than 10 of the study's 30 participants can come from this younger group.

People with higher-risk disease are excluded. That includes grade 3 tumors, HER2-positive or triple-negative breast cancer, lymph-node or distant spread, multifocal disease and certain inherited cancer-predisposition variants, including pathogenic BRCA1, BRCA2, PALB2 or TP53 variants.

These restrictions are crucial to understanding the study. SOLIS is not testing whether surgery can be abandoned for early breast cancer in general. It is exploring that possibility in a very small population selected for particularly favorable tumor characteristics.

Why researchers think a single radiation treatment is worth testing

The idea of treating an intact breast tumor with one highly focused radiation dose did not begin with SOLIS.

One important earlier study was ABLATIVE, a prospective study involving women aged 50 or older with low-risk, estrogen receptor-positive, HER2-negative breast cancer.

Participants received a single dose of partial-breast radiation while the tumor was still present. They then underwent breast-conserving surgery six or eight months later.

When the treated areas were removed and examined under a microscope, 15 of the 36 participants had no residual invasive cancer identified.

That finding showed that a single precisely targeted radiation treatment can produce a complete pathological response in some carefully selected breast tumors.

But there is an important limit to what ABLATIVE tells us: every participant still underwent surgery. Doctors therefore had the entire treated area available for microscopic examination, and the study did not test whether leaving the breast unoperated was safe.

SOLIS takes the next, more difficult step by planning from the beginning not to remove the treated tumor surgically.

If there is no surgery, how will doctors know whether the cancer is gone?

This is one of the central challenges of a non-operative approach.

Normally, surgery gives pathologists the removed tumor and surrounding tissue to examine under a microscope. Without lumpectomy, researchers need other ways to determine whether viable cancer remains.

SOLIS will use multiparametric breast MRI and FDG PET/CT imaging to follow the treated area. More importantly, the protocol requires tissue sampling at 12 months to look directly for residual invasive cancer.

Researchers will also record whether a participant ultimately needs salvage surgery, whether cancer returns in the treated breast, cosmetic outcomes and patient-reported quality of life. Follow-up for several of these outcomes will continue for up to three years.

If residual cancer is detected or surgery later becomes necessary, that will be part of the study's outcome — not evidence that the approach had already been proven to work.

The first question is safety, not whether radiation can replace surgery

This is perhaps the most important detail for anyone reading about SOLIS.

The trial's primary endpoint is not whether one radiation treatment eliminates the cancer. The main outcome is the proportion of participants who experience at least moderate radiation-related skin side effects — Grade 2 or higher — during the first 90 days after treatment.

The study also uses a predefined safety-monitoring plan that can stop enrollment if toxicity becomes unacceptable.

The absence of residual invasive cancer on mandatory tissue sampling at 12 months is a secondary outcome. Other secondary measures include imaging response, later side effects, the need for salvage surgery and recurrence in the treated breast.

With only 30 participants and no group receiving standard treatment for comparison, SOLIS cannot establish that single-dose radiation without lumpectomy is as safe or as effective as conventional breast-conserving treatment.

What it can do is answer an earlier question: is this approach sufficiently safe and promising to justify testing it in a much larger study?

Why avoiding surgery could matter to patients

Lumpectomy is considerably less extensive than mastectomy, and many patients recover quickly. But it is still an operation.

It can mean anesthesia, pain, a scar, changes in breast shape or sensation, recovery time and, in some cases, another procedure if cancer cells are found at the edge of the removed tissue.

A non-operative option could therefore be particularly meaningful for some older patients, people whose other medical conditions make surgery more difficult, or patients who strongly prefer to avoid an operation when there is a medically sound alternative.

This is part of a broader direction in breast cancer research known as treatment de-escalation: asking not only how aggressively doctors can treat cancer, but whether some carefully selected patients can safely receive less treatment.

But “less” is only an improvement if cancer control is not sacrificed. A tumor that shrinks or disappears on imaging can still contain microscopic living cancer cells. That is why tissue sampling and long-term follow-up are critical before a non-operative approach could ever become routine care.

This study is not a reason to skip surgery today

SOLIS has major limitations by design. Thirty participants at one center cannot establish a new standard of breast cancer treatment.

The study is also not randomized, so it will not directly compare one-dose radiation without lumpectomy with the current surgical approach.

And although several outcomes will be followed for three years, hormone receptor-positive breast cancer can recur much later. Larger studies and substantially longer follow-up would be necessary before doctors could determine whether routinely omitting surgery is safe.

For now, surgery remains a standard part of treatment for most people with early invasive breast cancer.

The bigger question behind SOLIS

The interest in SOLIS is not that it promises a shortcut or that a single radiation treatment has already been shown to replace an operation.

It is the question the study is willing to ask.

As breast cancers are detected earlier and treatments become increasingly tailored to the biology of individual tumors, researchers are also asking whether every traditional part of treatment is necessary for every patient.

For a very small group with favorable tumors, SOLIS will test one of the boldest versions of that idea: instead of surgically removing a small cancer, can doctors target it precisely with one radiation treatment, add endocrine therapy and then verify that the cancer has been controlled without a lumpectomy?

The answer is not known. That is exactly why this 30-person pilot matters — and why any future results will need to be treated as an early step rather than proof that surgery can be replaced.

Clinical trial record: NCT07844759 on ClinicalTrials.gov

Losing weight with Wegovy or Zepbound can be a major treatment success. But it also raises a practical question: what happens next? If the medication is working, does keeping the weight off mean staying on a weekly injection for years?

A new Phase 3 trial from Pfizer is testing whether that routine could eventually become much less frequent. VESPER-Switch plans to enroll about 660 adults who have already lost weight while taking weekly semaglutide or tirzepatide. Some will continue their current weekly treatment, while others will switch to berobenatide, an investigational GLP-1 receptor agonist designed to be given once a month.

The key word is testing. There are no VESPER-Switch results yet. Berobenatide is not approved for routine use, and the study does not yet show that switching to a monthly injection can prevent weight regain or maintain weight as well as continuing semaglutide or tirzepatide.

The question starts after the weight has already come off

Most obesity-drug trials begin with a familiar question: how much weight can a treatment help people lose?

VESPER-Switch is different. Its participants have already lost weight on semaglutide or tirzepatide. The trial starts from that new, lower body weight and asks what happens next.

Semaglutide is the active ingredient in Wegovy, while tirzepatide is the active ingredient in Zepbound. Both treatments are normally injected once a week. Berobenatide, also known as PF-08653944 and previously as MET-097i, has been developed to last much longer in the body and is being studied as a once-monthly treatment.

That would mean reducing scheduled injections from roughly 52 a year to about 12.

For someone facing long-term treatment, that is a meaningful difference in treatment burden. But convenience alone does not tell us whether weight control will be maintained — or whether people would actually stay on treatment longer in everyday practice.

What VESPER-Switch will actually do

The Pfizer-sponsored study is randomized and open-label, meaning participants are assigned by chance to a treatment group and know which treatment they receive.

One group will continue subcutaneous semaglutide or tirzepatide. The other will switch to subcutaneous berobenatide given once monthly. There is no placebo group: everyone receives active treatment.

Pfizer says participation will last about 11 months and can include up to 12 clinic visits. Participants will also receive guidance on healthy eating and physical activity during the study.

The main outcome is straightforward: researchers will measure the percentage change in body weight from the start of VESPER-Switch to Week 32. They will also look at the change in weight in kilograms and track adverse events and other safety measures.

That baseline matters. It comes after participants have already responded to semaglutide or tirzepatide. So the study is not simply asking how much weight berobenatide can produce from an original starting weight. It is examining what happens to weight after successful treatment when weekly therapy is either continued or replaced by a monthly drug.

The publicly posted study record does not specify the milligram dose of berobenatide to be used in the monthly switch group.

Why keeping weight off is a separate clinical problem

For many people, obesity treatment does not end when a target amount of weight has been lost. Research with current incretin-based medicines has shown that stopping effective therapy can be followed by substantial weight regain.

In the STEP 1 trial extension, participants who had received semaglutide 2.4 mg lost an average of 17.3% of their body weight during the treatment phase. During the year after semaglutide and the structured lifestyle intervention were stopped, participants in the extension regained about two-thirds of their previous weight loss on average.

A similar pattern appeared with tirzepatide in the SURMOUNT-4 trial. Participants initially lost an average of 20.9% of their body weight during 36 weeks of tirzepatide treatment. Those subsequently switched to placebo regained substantial weight over the following year, while those who continued tirzepatide maintained and extended their weight loss.

These findings do not mean that every patient will regain the same amount of weight or that people must remain on the same medicine indefinitely. But they support a broader clinical point: maintaining weight loss can require an ongoing treatment strategy rather than simply stopping medication once weight has come down.

VESPER-Switch is testing one possible version of that strategy — not stopping treatment altogether, but changing from one active therapy to another that can be given less often.

What is berobenatide?

Berobenatide is an investigational ultra-long-acting GLP-1 receptor agonist. Like semaglutide, it targets the GLP-1 receptor, which is involved in appetite, satiety and metabolic regulation.

Tirzepatide works differently because it activates both GIP and GLP-1 receptors. That distinction is important: switching from tirzepatide to berobenatide is not simply changing the dosing schedule of the same type of drug.

Pfizer has already generated Phase 2b data supporting less frequent berobenatide dosing. In the VESPER-3 study, participants began with weekly berobenatide and then moved to monthly berobenatide dosing. Weight loss continued after that planned transition.

That result helps explain why monthly dosing is now being taken into Phase 3, but it does not answer the VESPER-Switch question. Those participants switched from weekly berobenatide to monthly berobenatide. They did not switch from semaglutide or tirzepatide to a different drug.

VESPER-Switch is designed to test that more clinically relevant transition directly.

Who is being recruited?

Pfizer says the study is for adults aged 18 or older with overweight or obesity who are currently taking semaglutide or tirzepatide for obesity management and have already lost weight on treatment.

People taking compounded semaglutide or tirzepatide are not eligible, according to Pfizer’s participant information. The study also excludes people with diabetes, as well as people with a history of acute or chronic pancreatitis or a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

The publicly posted eligibility criteria do not state a minimum percentage of weight that a participant must previously have lost or a minimum duration of prior semaglutide or tirzepatide treatment. Final eligibility is determined by the study team.

Pfizer currently lists VESPER-Switch as recruiting on its weight-management clinical trials site. The ClinicalTrials.gov record, last updated September 29, still lists the study as “not yet recruiting,” so the two public sources are currently out of sync.

What would the study tell us — and what would it not?

If people who switch to monthly berobenatide are able to maintain their weight during the study, while the weekly-treatment group provides an active comparison, the results could help answer whether reducing injection frequency is a realistic maintenance strategy after successful weight loss.

But several questions would remain.

The study is not evidence that berobenatide is better than semaglutide or tirzepatide. It does not yet show that switching prevents weight regain. And even if monthly dosing proves effective in the trial, receiving fewer injections does not automatically mean that patients will adhere to treatment better in the real world.

The trial also lasts about 11 months, so it cannot by itself tell us what happens after several years of monthly therapy. And because people with diabetes are excluded, its findings will not automatically apply to patients using incretin-based treatment in the setting of diabetes.

Could long-term obesity treatment become simpler?

The arrival of highly effective medications such as Wegovy and Zepbound changed what is possible in medical weight management. Their success has also made the next question harder to ignore: what is the best way to preserve that weight loss over the long term?

For some patients, continuing the same weekly treatment may remain the right approach. Others may eventually have different options.

A monthly injection would not solve every challenge of chronic obesity treatment. Effectiveness, side effects, cost, access and individual response may matter far more than dosing frequency. But if a less frequent treatment can preserve the benefit already achieved, reducing injections from about once a week to once a month could make long-term therapy substantially simpler.

That is what makes VESPER-Switch different from another race to produce a larger weight-loss percentage. The study is asking what comes after the initial success: once the weight has come off, can maintaining it become easier?

Clinical trial record: NCT07845500 on ClinicalTrials.gov

For years, the biggest advances in obesity medicines have centered on GLP-1 and related incretin drugs. Now a different hormone pathway is moving into large Phase III trials. Petrelintide, a once-weekly long-acting analog of the hormone amylin, is entering a registrational program that is expected to include about 7,000 people — including roughly 3,900 participants in its largest obesity trial.

The new Phase III program, called ZUPREME, is being developed by Zealand Pharma and Roche. Its largest study, ZUPREME-3 (NCT07843498), will compare once-weekly petrelintide with placebo in adults living with obesity or overweight and at least one weight-related health condition, but without type 2 diabetes.

Two parallel Phase III trials will extend the program into people with type 2 diabetes and those with established cardiovascular disease.

That scale matters. Petrelintide is no longer being tested only as an early experimental alternative in the crowded weight-loss pipeline. The new studies are intended to generate the evidence needed for potential regulatory applications.

But there is an important distinction: entering Phase III does not mean the drug has already been proven to work in a large population, and it does not mean petrelintide is approved. The current Roche trial listing for ZUPREME-3 still describes the study as not yet recruiting.

Why petrelintide is different from the GLP-1 drugs

The simplest reason petrelintide is attracting attention is that it is not another GLP-1 receptor agonist.

Semaglutide, the active drug in Wegovy, acts on the GLP-1 receptor. Tirzepatide, sold for obesity as Zepbound in the United States, combines GIP and GLP-1 receptor activity.

Petrelintide instead mimics amylin, a hormone naturally produced by pancreatic beta cells and released alongside insulin after food intake.

Amylin participates in the biological signaling of satiety — helping the body register that enough food has been consumed. Zealand Pharma describes petrelintide as a long-acting human amylin analog designed for once-weekly subcutaneous administration.

That creates an important distinction in a field increasingly associated in the public mind with GLP-1 drugs: substantial weight loss may potentially be achieved through more than one hormonal pathway.

It does not, however, mean that petrelintide is already a proven replacement for semaglutide or tirzepatide.

A 3,900-person Phase III trial without type 2 diabetes

ZUPREME-3 is a randomized, double-blind, placebo-controlled Phase III study expected to enroll approximately 3,900 adults.

Participants can have a body mass index of at least 30 kg/m², or a BMI of at least 27 kg/m² together with at least one weight-related comorbidity. People with known type 2 diabetes are excluded from this particular trial.

Participants will receive once-weekly petrelintide or placebo in addition to a reduced-calorie diet and increased physical activity.

The study includes a 12-week dose-escalation period followed by maintenance treatment through week 64. Safety follow-up continues afterward, with the main efficacy assessment focused on the percentage change in body weight from baseline to week 64.

People who complete the week-64 visit can also become eligible for an optional open-label extension in which petrelintide is offered regardless of their original study group.

The Phase III program is much larger than ZUPREME-3

The broader development strategy shows why the September Phase III announcement is more significant than the registration of a single obesity trial.

According to Zealand Pharma's Phase III program announcement, three trials are expected to enroll about 7,000 people in total.

ZUPREME-3 plans to enroll approximately 3,900 people with overweight or obesity and weight-related comorbidities but without type 2 diabetes.

ZUPREME-4 (NCT07843485) is expected to enroll around 600 participants with overweight or obesity and type 2 diabetes.

ZUPREME-5 (NCT07843472) is substantially larger, with approximately 2,500 participants who have overweight or obesity together with established cardiovascular disease, with or without type 2 diabetes.

ZUPREME-5 includes treatment through the week-64 primary efficacy assessment followed by a longer event-maintenance phase, and the study may last as long as three years.

Its inclusion of people with established cardiovascular disease is particularly important because obesity treatment increasingly needs to demonstrate value beyond a number on the scale.

However, the existence of a cardiovascular-disease trial should not be interpreted as evidence that petrelintide already prevents heart attacks or strokes. Those benefits have not been established.

Why did petrelintide advance to Phase III?

The Phase III decision follows encouraging results from the randomized Phase II ZUPREME-1 study.

The earlier trial enrolled 493 people with obesity or overweight and weight-related comorbidities, with 485 participants included in the randomized analysis reported in the full publication.

Participants received different once-weekly doses of petrelintide or placebo for 42 weeks, including dose escalation.

By week 42, petrelintide produced mean body-weight reductions of up to 10.7%, compared with 1.7% with placebo using the efficacy estimand. Using a treatment-policy approach that reflects outcomes regardless of treatment discontinuation or other intercurrent events, reductions reached up to 10.2% with petrelintide versus 1.4% with placebo.

The Phase II trial is available in the ICH GCP clinical trials registry, and the full results were published in The Lancet Diabetes & Endocrinology in late September 2026.

The tolerability story needs some nuance

One of the most closely watched aspects of petrelintide has been gastrointestinal tolerability.

Zealand Pharma and Roche have emphasized that most gastrointestinal adverse events in ZUPREME-1 were mild and that relatively few participants stopped treatment because of them.

But “placebo-like tolerability” should not be interpreted as meaning that every gastrointestinal symptom occurred at exactly the same rate as placebo.

In the Phase II data presented at the American Diabetes Association meeting, nausea occurred in 19.6% of petrelintide-treated participants versus 6.2% with placebo.

Vomiting was less frequent overall — 3.0% with petrelintide compared with 6.2% with placebo — while diarrhea and constipation remained below 7.5% in both groups. About 1.5% of participants receiving petrelintide discontinued because of gastrointestinal adverse events.

The majority of these gastrointestinal events were reported as mild.

These findings help explain the interest in the drug, but they are not enough to conclude that petrelintide is better tolerated than GLP-1 medicines.

Is petrelintide better than Wegovy or Zepbound?

Phase III will not directly answer that question.

ZUPREME-3 compares petrelintide with placebo — not with semaglutide, tirzepatide or another active obesity medication.

That means percentages from separate trials should not simply be placed side by side and treated as a head-to-head comparison.

Different obesity trials can vary in treatment duration, participant characteristics, dose escalation, lifestyle programs, statistical methods and how missing data are handled.

Petrelintide therefore needs to establish its own efficacy, safety, tolerability and durability before clinicians can understand where it might fit alongside existing treatments.

Why another hormonal pathway matters

The expansion beyond GLP-1 is clinically relevant because obesity is not a uniform disease and no single medication is likely to be ideal for every patient.

The World Health Organization classifies obesity as a chronic, relapsing disease. In 2022, an estimated 890 million adults worldwide were living with obesity.

Modern obesity pharmacotherapy has changed rapidly, but differences in response, adverse effects, access, treatment persistence and associated diseases remain important.

A successful amylin-based therapy could therefore add a distinct biological tool rather than simply creating another drug aimed at the same receptor.

There is also a second possibility: combining pathways.

Roche and Zealand Pharma are separately studying petrelintide together with enicepatide, an investigational GLP-1/GIP receptor agonist. That combination program is distinct from the current Phase III petrelintide monotherapy studies.

What the new Phase III trials still need to prove

The Phase II results answer only part of the question.

Phase III must establish whether the magnitude of weight loss can be reproduced across thousands of people and maintained through longer treatment.

Researchers will also need to understand how reliably participants can reach and remain on maintenance doses, how adverse events change as exposure expands, and whether treatment effects are consistent across different demographic and clinical groups.

The trials will examine additional measures including waist circumference, HbA1c, cardiometabolic risk factors, physical functioning and eating behaviors.

The cardiovascular-disease population in ZUPREME-5 also broadens the evidence base into a group at particularly high medical risk.

What Phase III cannot yet tell us is whether petrelintide will ultimately receive regulatory approval, how it would be priced, whether it would replace or complement existing obesity drugs, or whether its real-world tolerability will remain favorable over many years of chronic treatment.

A new path, not the end of GLP-1

Petrelintide's move into Phase III should not be framed as the end of the GLP-1 era.

GLP-1 and GIP/GLP-1 medicines have already transformed obesity treatment, and their role continues to expand.

The more interesting development is that the field may no longer depend on a single hormonal strategy.

Petrelintide is now testing whether an amylin-based approach can produce clinically meaningful and durable weight loss at the scale required for a potential new obesity medicine.

If the approximately 7,000-person ZUPREME program confirms the efficacy and safety signals seen in Phase II, clinicians may eventually have another major hormonal pathway available for chronic weight management.

For now, however, petrelintide remains investigational — and the move into Phase III marks the beginning of that larger test, not its conclusion.

Primary source: Zealand Pharma and Roche, global registrational Phase III ZUPREME program for petrelintide.

What if varicose veins could be closed without inserting a needle or catheter into the vein — and without using heat? A first-in-human study is now testing a non-thermal focused ultrasound system designed to close abnormal superficial veins from outside the body using mechanical cavitation.

Four patients have so far been treated in Romania in the EASY-VEIN NT investigation. According to developer Veinsound, after completion of an initial safety cohort, patients in the performance group underwent treatment along the great saphenous vein in less than 12 minutes and without anesthesia. Preliminary observations at one week included vein occlusion and changes in the vein wall — but these are very early findings, and no conclusions about safety or effectiveness can yet be drawn.

The technology was also highlighted at the recent annual congress of the French Society of Vascular Medicine, where physicians and other healthcare professionals were invited to try the non-thermal ultrasound device at the company’s exhibition stand as the EASY-VEIN NT study gets underway.

The stronger clinical development is the launch of the EASY-VEIN NT first-in-human investigation, which moves a technology previously studied mainly in laboratory and animal models into its first patients.

What is different about this varicose vein treatment?

Many treatments for significant varicose veins work by deliberately closing an abnormal superficial vein so that blood is redirected through healthier veins.

How they achieve that closure varies considerably.

Endovenous laser and radiofrequency ablation use heat. Foam sclerotherapy involves injecting a chemical sclerosant. Other non-thermal methods can use catheters, medical adhesives or mechanical techniques inside the vein.

Veinsound is testing something different: treating the vein from outside the body with focused ultrasound, without relying on thermal ablation.

The experimental device uses high-intensity focused ultrasound, or HIFU, to concentrate acoustic energy on a small segment of the targeted vein.

Instead of intentionally heating the vein wall, the system is designed to induce cavitation — the rapid formation, oscillation and collapse of microscopic bubbles or cavities within the ultrasound field.

The resulting mechanical forces are intended to damage the inner surface of the abnormal vein, leading to its closure and subsequent remodeling.

Why “non-thermal” matters

Focused ultrasound itself is not entirely new in venous medicine.

Other HIFU systems have been investigated for varicose veins and chronic venous insufficiency, including approaches that use focused ultrasound to generate heat in the targeted vein.

What distinguishes the Veinsound approach is that the intended mechanism is mechanical cavitation rather than thermal ablation.

That distinction could matter because established thermal ablation procedures usually require access to the vein and commonly use local tumescent anesthesia around it to reduce discomfort and protect surrounding tissues.

A genuinely extracorporeal, non-thermal approach could potentially eliminate several procedural steps.

Whether it can do so while providing comparable long-term effectiveness and safety remains an open clinical question.

Why treat a varicose vein at all?

Varicose veins are not merely a cosmetic issue for many patients.

They develop when superficial veins become enlarged and their valves no longer direct blood efficiently back toward the heart. Blood can flow backward and pool in the leg, increasing venous pressure.

Some people have few symptoms. Others experience aching, heaviness, itching, swelling or discomfort, while more advanced chronic venous disease can lead to skin changes, inflammation and venous ulcers.

According to NICE guidance, visible varicose veins in the legs are estimated to affect at least one-third of the population, although prevalence estimates vary.

For people with confirmed varicose veins and truncal reflux, current NICE recommendations prioritize endothermal ablation when suitable, followed by ultrasound-guided foam sclerotherapy and then surgery when the preceding options are unsuitable.

International vascular guidelines also consider both thermal and non-thermal approaches to superficial venous reflux, depending on anatomy, clinical circumstances, available expertise and patient preferences. The Society for Vascular Surgery, American Venous Forum and American Vein and Lymphatic Society guidelines specifically address thermal versus non-thermal ablation techniques.

The first four patients have now been treated

Veinsound announced in September 2026 that EASY-VEIN NT had entered first-in-human testing.

The investigation is being conducted in Romania after a favorable opinion from the National Bioethics Committee and authorization from the Romanian National Agency for Medicines and Medical Devices, according to the company.

A procedure documented by Veinsound took place at Sanconfind Medical Center in Câmpina on September 8.

At the time of the company’s study-launch announcement, the principal investigator had treated four patients with the AIFU system.

Following completion of the safety cohort, the company reported that patients in the performance group were treated along the great saphenous vein in less than 12 minutes and without anesthesia.

The great saphenous vein is the large superficial vein running along the inner leg and is commonly involved in superficial venous reflux.

What has actually been observed so far?

The first human observations are interesting, but extremely preliminary.

Veinsound reported uncomplicated initial procedures and said that ultrasound assessment one week later showed findings including vein occlusion and vein-wall remodeling.

These observations have not yet been published as peer-reviewed clinical results.

Four treated patients are also far too few to establish either safety or effectiveness.

At this stage, the findings are best viewed as an early feasibility signal: investigators have been able to deliver the intended treatment in humans and have observed short-term changes consistent with the mechanism the device is designed to produce.

That is very different from proving that the treated vein remains closed months or years later, that symptoms improve durably or that the procedure performs as well as established treatments.

The human study follows preclinical research

The move into human treatment follows several years of laboratory and animal research into mechanical focused ultrasound.

A 2025 study published in Ultrasound in Medicine & Biology investigated whether mechanical HIFU could produce vein occlusion through cavitation without injecting microbubble contrast agents.

In a sheep model, researchers were able to trigger cavitation in a saphenous vein, stop blood flow and confirm vein-wall damage and occlusion by histological examination. The study is available through PubMed.

A second preclinical study, published in Phlebology, examined four lateral saphenous veins in two sheep treated with different ultrasound exposure durations.

Duplex ultrasound showed occlusion in all four treated veins. Histological analysis found complete obliteration in 15 of 16 examined vein sections and partial obliteration in the remaining section.

The investigators also found substantial injury to the inner vein lining and fibrosis of the vessel wall — changes consistent with the intended mechanism of closing the vein.

The full abstract and study details are available on PubMed.

Both preclinical publications included Veinsound employees and/or company shareholders among the authors. That does not invalidate the findings, but independent replication and larger clinical studies will be particularly important as the technology progresses.

The animal studies also showed why ultrasound dose matters

The preclinical work was not entirely free of unwanted tissue effects.

In the Phlebology study, reversible skin injury occurred with one of the longer ultrasound exposures, and mild remodeling of tissue around the vein was observed in several treated sites.

The researchers concluded that appropriate sonication time was important for limiting unwanted effects.

This issue becomes especially important in human treatment.

Focused ultrasound has to deliver enough mechanical energy to alter the targeted vein while avoiding damage to skin, nerves, arteries and other surrounding structures.

A central purpose of early clinical development is therefore not merely to show that a vein can be closed, but to identify a reproducible treatment window in which it can be closed safely.

Where does artificial intelligence enter the procedure?

Veinsound calls its platform AI-Focused Ultrasound, or AIFU.

According to the company’s product description, the system combines therapeutic focused ultrasound with real-time imaging, computer-vision-based vein identification and AI-supported safety and dose-management functions.

The probe is placed on the patient’s leg using ultrasound coupling gel. The target vein is visualized, the treatment segment is selected and the procedure is monitored using ultrasound imaging.

The therapeutic mechanism itself is still the focused ultrasound and cavitation. The AI functions are intended to assist identification, targeting, monitoring and safety rather than produce the biological effect on the vein.

Why avoiding a catheter could matter

Modern treatment of varicose veins is already much less invasive than traditional vein-stripping surgery.

Endovenous laser and radiofrequency procedures are widely performed as outpatient treatments, and many patients return to normal activities relatively quickly.

But endovenous procedures still require access to the vein.

Foam sclerotherapy requires an injection. Thermal ablation typically involves placing a catheter into the vein and administering local anesthesia. Other catheter-based non-thermal treatments also require venous access.

If an external ultrasound probe could reproducibly close an incompetent vein without puncturing it, the procedure could become simpler for selected patients.

That potential advantage still needs to be demonstrated in clinical trials and eventually compared directly with established treatment options.

What EASY-VEIN NT still needs to answer

The most important unanswered questions are now clinical rather than purely technical.

Does the treated vein remain closed after three months, six months and one year?

Do symptoms such as pain, heaviness and swelling improve?

How frequently does the vein reopen?

How well does the method work in veins of different diameters or in more complex anatomy?

How often would repeat treatment be required?

And what adverse events emerge when substantially more patients are treated?

Relevant safety outcomes will need to include thrombosis, skin injury, nerve or surrounding-tissue damage and other treatment-related complications.

Longer follow-up is essential because successful technical closure shortly after a procedure does not necessarily predict durable clinical success.

Several important study details are not yet publicly available

Veinsound says completion of EASY-VEIN NT is expected in the first quarter of 2027.

However, the company’s public study-launch materials do not provide some details needed for a full independent assessment of the protocol, including the total planned enrollment and a detailed list of prespecified efficacy and safety endpoints.

The announcement also does not cite a ClinicalTrials.gov identifier.

Veinsound states that the investigation was authorized under the EU Medical Device Regulation framework and by the Romanian National Agency for Medicines and Medical Devices.

Until a more detailed public protocol or peer-reviewed report becomes available, interpretation therefore has to rely partly on information released by the developer.

Why the first-in-human step matters — and why caution matters too

For patients, the attraction is easy to understand.

A treatment performed from outside the leg, without heat or venous catheterization, would represent a substantially different experience from many current procedures.

For vascular physicians, however, procedural simplicity is only part of the equation.

A new treatment ultimately has to demonstrate reliable vein closure, sustained improvement in symptoms, acceptable recurrence rates and a safety profile that compares favorably with methods that already work well.

That evidence does not yet exist for EASY-VEIN NT.

Veinsound itself states that no conclusions about safety or efficacy can be drawn until the study is completed and the results undergo scientific review. The device remains investigational, is not commercially available and has not received a CE mark or FDA clearance.

The important development is therefore not that varicose veins can now routinely be treated with non-thermal focused ultrasound.

It is that a technology previously demonstrated mainly in preclinical experiments has now crossed into first-in-human testing.

If larger and longer studies eventually confirm that an incompetent vein can be closed reliably from outside the body without heat or venous access, the approach could represent a genuinely different branch of varicose vein treatment.

For now, the first four patients mark the beginning of that test — not its conclusion.

Primary source: Veinsound: launch of the EASY-VEIN NT first-in-human study.

What if lowering dangerous LDL cholesterol no longer required taking pills every day or receiving injections again and again? A new randomized Phase 2 trial will test a very different strategy: one intravenous infusion designed to durably inactivate the PCSK9 gene in liver cells and produce a sustained reduction in LDL cholesterol.

HEART-3 will enroll 175 adults who already have atherosclerotic cardiovascular disease or are at high risk of developing it. Participants will receive one of three doses of the experimental gene-editing therapy VERVE-102 or placebo. The immediate question is straightforward: how much lower will LDL cholesterol be 90 days after a single treatment? The larger question is whether one genetic intervention could eventually provide long-lasting LDL control without repeated dosing.

The newly registered HEART-3 trial (NCT07839936) is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Verve Therapeutics.

The study plans to enroll 175 adults aged 18 to 70 with established atherosclerotic cardiovascular disease (ASCVD) and/or a high risk of ASCVD who still require additional lowering of low-density lipoprotein cholesterol, or LDL-C.

Participants will be assigned to one of four groups: three will receive different single intravenous doses of VERVE-102, while the fourth will receive a single placebo infusion.

As of late September 2026, HEART-3 is listed as not yet recruiting, with study enrollment expected to begin in October 2026.

Why the idea of a one-time cholesterol treatment is so unusual

High LDL cholesterol is normally managed as a chronic condition.

For people with established cardiovascular disease or particularly high risk, lowering LDL may involve treatment for years or decades. The 2026 US dyslipidemia guideline continues to place statins at the foundation of lipid-lowering therapy, with additional drugs used when LDL remains above the appropriate target.

Those additional options can include ezetimibe, bempedoic acid and therapies that target PCSK9. Some PCSK9-directed medicines are given by injection, while other approaches reduce production of the protein through RNA interference. In 2026, the FDA also approved the first daily oral PCSK9 inhibitor.

The current treatment landscape therefore already offers several ways to lower LDL. The unusual part of VERVE-102 is not the biological target itself.

It is the attempt to act on that target once, at the DNA level.

Instead of repeatedly blocking PCSK9 protein or repeatedly suppressing its production, VERVE-102 is designed to make a durable edit in liver cells so that they produce much less functional PCSK9 over the long term.

Why PCSK9 has become such an important cholesterol target

PCSK9 is a protein made largely by the liver. Its role is closely connected to LDL receptors on the surface of liver cells.

Those receptors remove LDL cholesterol from the bloodstream.

PCSK9 promotes the breakdown of LDL receptors. When there is more active PCSK9, fewer LDL receptors are available to clear cholesterol from the blood. Blocking PCSK9 therefore allows more receptors to remain active and can substantially reduce circulating LDL-C.

This mechanism is already well validated in cardiovascular medicine.

People who naturally inherit loss-of-function variants in the PCSK9 gene tend to have lower LDL cholesterol and lower rates of coronary heart disease. Medicines that pharmacologically inhibit PCSK9 have subsequently confirmed that the target can be used to lower LDL in patients.

VERVE-102 takes the concept one step further: rather than repeatedly inhibiting PCSK9, it attempts to reproduce a protective loss-of-function state by editing the gene itself.

What exactly does VERVE-102 change?

VERVE-102 is an investigational in vivo adenine base-editing therapy.

“In vivo” means that the editing takes place inside the patient rather than removing cells, editing them in a laboratory and returning them to the body.

The treatment contains messenger RNA encoding an adenine base editor together with a guide RNA that directs the editor to a specific site within the PCSK9 gene. These components are packaged inside lipid nanoparticles designed to deliver them to liver cells.

Once inside the cell, the editor is designed to make a specific DNA-letter change — an A-to-G substitution — that disrupts PCSK9 function.

This is different from traditional CRISPR approaches that use nucleases to create a double-strand break in DNA. Base editing is designed to change a particular DNA base without producing that type of double-strand break.

The goal is a durable change in the targeted liver cells.

VERVE-102 is therefore not simply another drug circulating in the bloodstream until it is cleared. The drug-delivery components disappear, but the intended DNA edit is designed to persist.

The treatment targets liver cells, not inherited DNA

The words “gene editing” can understandably raise questions about inherited genetic changes.

VERVE-102 is being developed as a somatic gene-editing treatment. Its intended target is adult liver cells, not embryos, eggs or sperm.

The aim is to change PCSK9 activity in the treated patient, not to create a hereditary genetic modification deliberately passed to future generations.

That distinction is important, but it does not remove the need for long-term safety monitoring. Because the intended DNA change is durable, researchers need to understand not only what happens in the first weeks after treatment but also whether unexpected consequences emerge years later.

HEART-3 will test three doses against placebo

The Phase 2 study uses a parallel, double-blind design.

Neither participants nor investigators will know whether an individual participant received VERVE-102 or placebo during the blinded portion of the trial.

Three experimental groups will receive different single intravenous doses of VERVE-102, while the comparator group will receive a single intravenous placebo infusion.

The publicly available registry does not currently specify the numerical doses for the three Phase 2 groups.

The primary endpoint is the percentage change in LDL-C from baseline to Day 90.

Researchers will also follow several lipid-related measures through Day 365, including:

LDL cholesterol, circulating PCSK9, total cholesterol, non-HDL cholesterol and apolipoprotein B.

This makes HEART-3 a study of biological efficacy and safety — not yet a trial designed to determine whether the treatment prevents heart attacks or strokes.

Why LDL reduction matters — but is not the same as proving fewer heart attacks

LDL cholesterol is a major causal driver of atherosclerosis.

Long-term exposure to elevated LDL promotes cholesterol accumulation inside artery walls, contributing to plaques that can eventually lead to coronary artery disease, myocardial infarction, ischemic stroke and peripheral arterial disease.

For that reason, lowering LDL is a central component of cardiovascular prevention, particularly for people who already have ASCVD.

But an LDL-lowering result and a cardiovascular-outcomes result are not the same thing.

HEART-3 can show whether VERVE-102 produces a larger and more durable fall in LDL cholesterol than placebo over the study period.

It is not designed to prove that VERVE-102 prevents myocardial infarction, stroke or cardiovascular death.

Demonstrating those outcomes would require substantially larger trials with longer follow-up.

Why VERVE-102 reached a randomized Phase 2 trial

The decision to move forward follows results from the earlier Heart-2 Phase 1 study (NCT06164730).

That study enrolled adults with heterozygous familial hypercholesterolemia or premature coronary artery disease who required additional LDL lowering.

Results from the first 35 treated participants were published in the New England Journal of Medicine in 2026.

Participants received a single VERVE-102 infusion at one of six dose levels ranging from 0.3 to 1.0 mg of total RNA per kilogram of body weight.

The study found a clear dose-response relationship.

Average reductions in circulating PCSK9 ranged from 51% at the lowest dose to 88% at the highest dose.

Average LDL-C reductions ranged from 9% at the lowest dose to 62% at the highest dose.

At the highest dose, the mean absolute reduction in LDL cholesterol was 78 mg/dL.

Those numbers helped establish that editing PCSK9 in human liver cells could produce a substantial biological effect after a single treatment.

The most important Phase 1 observation may be durability

A large fall in LDL immediately after treatment would be interesting, but it would not by itself justify the idea of one-time gene editing.

The central promise of the approach depends on durability.

In the Phase 1 study, LDL and PCSK9 reductions appeared sustained throughout available follow-up. At the time of the published analysis, 15 participants had been followed for at least one year.

That is an important signal, but it is still very different from proving that one treatment will remain effective for decades.

The first patients have simply not been followed long enough to answer that question.

HEART-3 will provide a more controlled comparison through the first year, while separate long-term follow-up is intended to track people exposed to Verve’s investigational gene-editing therapies for much longer.

Why patients will be followed for up to 15 years

A separate long-term study of Verve’s investigational cardiovascular gene-editing therapies is designed to follow treated participants for 15 years after their first dose.

The reason is fundamental to gene editing: unlike a conventional medicine that can usually be stopped if problems arise, an intended durable DNA edit cannot simply be withdrawn from the body.

Researchers therefore need to look for delayed safety signals as well as determine how long the lipid-lowering effect persists.

Long-term questions include whether the targeted edit remains stable, whether unexpected health effects appear later, and whether rare off-target changes could have clinical consequences.

These questions become particularly important if gene editing is ultimately considered for cardiovascular prevention, where patients may otherwise live for decades after treatment.

What safety findings were seen in the first study?

The Phase 1 trial was primarily designed to evaluate safety rather than establish clinical benefit.

No dose-limiting toxic effects were reported among the 35 participants included in the published interim analysis.

Researchers observed mild-to-moderate infusion-related reactions and temporary elevations in alanine aminotransferase, a liver enzyme.

An episode of aspiration pneumonitis occurred in a participant with gastroesophageal reflux disease.

The early safety results allowed development to continue, but 35 participants are far too few to characterize uncommon adverse effects.

HEART-3 substantially increases the number of people exposed under randomized conditions, but even 175 participants cannot establish the complete long-term safety profile of a durable genetic intervention.

Who will enter HEART-3?

The new study is broader than the initial Phase 1 trial.

Participants must have established ASCVD and/or be at high risk for ASCVD and require additional LDL-C lowering.

Eligible participants are between 18 and 70 years old.

The registry lists several key exclusions, including confirmed or suspected homozygous familial hypercholesterolemia, chronic liver disease, and current or recent treatment with a PCSK9 inhibitor.

This means the Phase 2 population is designed to test VERVE-102 beyond the narrowly defined group of patients in the earliest study while still selecting people for whom substantial LDL lowering is clinically relevant.

Could one infusion really replace cholesterol medication?

That is the obvious question — but HEART-3 cannot answer it yet.

The existence of a one-time gene-editing treatment does not automatically mean patients could stop statins or every other cardiovascular medication.

Current treatment decisions depend on the individual patient’s LDL level, overall cardiovascular risk, previous cardiovascular events, other lipid abnormalities and additional medical conditions.

HEART-3 is specifically testing the LDL-lowering effect of VERVE-102 versus placebo.

It is not a trial of stopping all long-term cardiovascular therapy.

Even if VERVE-102 produces durable LDL reductions, doctors would still need evidence showing how it should be combined with — or potentially substitute for — existing lipid-lowering treatments.

Gene editing also changes the risk-benefit calculation

The attraction of a one-time intervention is easy to understand.

Many cardiovascular therapies work extremely well when taken consistently, but prevention often requires adherence over decades. Missed tablets, treatment fatigue, access problems and repeated injections can all reduce the real-world benefit of otherwise effective drugs.

A genuinely durable treatment could largely remove adherence from the LDL-lowering equation.

But durability has another side.

A daily tablet can be discontinued. An injectable medicine eventually wears off. A successful DNA edit is specifically intended not to wear off quickly.

That makes the threshold for confidence in long-term safety unusually high.

The same property that could make one-time gene editing attractive — durability — is also the reason physicians and regulators will scrutinize delayed effects so closely.

VERVE-102 is entering a rapidly changing cholesterol-treatment landscape

Another important point is that VERVE-102 is not being developed in a therapeutic vacuum.

The 2026 US dyslipidemia guideline emphasizes earlier and more intensive management of atherogenic cholesterol in people at increased cardiovascular risk.

Statins remain a foundation of therapy, with several non-statin options available when further LDL reduction is required.

PCSK9 itself can already be targeted using established injectable medicines. Inclisiran can reduce PCSK9 synthesis using RNA interference, and in July 2026 the FDA approved the first oral PCSK9 inhibitor for adults with hypercholesterolemia.

VERVE-102 therefore has to offer more than simply demonstrating that PCSK9 is a useful cholesterol target. That has already been established.

The real test is whether editing PCSK9 once can offer a sufficiently durable benefit with a safety profile acceptable for a common chronic cardiovascular problem.

What HEART-3 has not shown yet

No results from HEART-3 are available.

The trial has not shown that VERVE-102 prevents heart attacks or strokes.

It has not shown that one infusion can replace years of statin therapy or other lipid-lowering medicines.

It has not established that the LDL reduction will persist for the remainder of a patient’s life.

And although early Phase 1 findings were encouraging, they came from a small, open-label study without a placebo comparator.

The purpose of HEART-3 is precisely to subject the approach to a more rigorous test: more patients, randomized treatment, blinding and direct comparison with placebo.

Why HEART-3 is an important test for cardiovascular gene editing

Many of the most advanced gene-editing therapies have initially been developed for rare and severe genetic diseases, where patients may have few treatment options.

High LDL cholesterol and atherosclerotic cardiovascular disease are very different.

They affect enormous numbers of people, and doctors already have multiple effective treatments.

That raises the bar.

For gene editing to move into mainstream cardiovascular prevention, it would need to provide a compelling balance of effectiveness, durability, practicality and long-term safety compared with therapies physicians already know how to use.

HEART-3 is therefore about more than whether LDL falls after VERVE-102.

It represents a larger test of whether durable in vivo gene editing can begin moving from small early-stage experiments into treatment strategies for common chronic disease.

For patients, the appeal is obvious: the possibility that one treatment could provide years of LDL lowering instead of requiring constant medication.

For physicians, the question is more demanding: can a durable genetic intervention become predictable and safe enough to justify using it for a disease that can already be treated effectively in other ways?

HEART-3 is one of the first randomized trials designed to start answering that question.

Official clinical trial record: ClinicalTrials.gov: HEART-3, NCT07839936.

Could stem cells delivered through the nose during the first week of life reduce the long-term consequences of brain injury — including the risk of cerebral palsy? The new randomized Phase 2 iSTOP-CP trial will enroll 162 newborns with brain injury caused by perinatal stroke or oxygen deprivation and follow their development for two years.

The approach is unusual: donor-derived bone marrow mesenchymal stromal cells are given as nasal drops rather than injected into the brain or bloodstream. Researchers will compare the treatment with placebo, with motor development at age 2 as the trial’s primary outcome.

The newly registered iSTOP-CP study (NCT07831746) is a randomized, placebo-controlled Phase 2 trial led by University Medical Center Utrecht in the Netherlands.

It plans to enroll 162 newborns with MRI-confirmed hypoxic-ischemic brain injury caused by either perinatal arterial ischemic stroke or perinatal asphyxia.

Each baby will receive a single intranasal dose of bone marrow-derived mesenchymal stromal cells or a matching placebo within the first seven days after birth.

As of late September 2026, the study is listed as not yet recruiting.

Why brain injury in the first days of life can have lifelong consequences

The newborn brain is still developing rapidly. An interruption in blood flow or oxygen delivery around birth can therefore damage areas involved in movement, cognition, vision, hearing and other functions.

Two major causes included in iSTOP-CP are perinatal arterial ischemic stroke, in which blood flow to part of the brain is blocked, and brain injury following perinatal asphyxia, when a baby experiences insufficient oxygen and blood flow around the time of birth.

Some affected children develop normally, while others later experience cerebral palsy, developmental delay, epilepsy, cognitive difficulties or sensory impairments.

The difficulty for doctors and parents is that the full consequences may not be apparent during the newborn period. Motor problems associated with cerebral palsy often become clearer only months later as the child develops.

Cooling already helps some newborns — but it cannot repair all brain injury

There is already an established neuroprotective treatment for some newborns with moderate-to-severe hypoxic-ischemic encephalopathy after perinatal asphyxia.

Therapeutic hypothermia, in which a newborn’s body temperature is carefully lowered soon after birth, can reduce mortality and major neurodevelopmental disability in eligible term and near-term infants.

But cooling must be started very early, does not prevent disability in every child and is not an established treatment for perinatal arterial ischemic stroke.

There is also currently no established regenerative therapy that can restore brain tissue already damaged by these conditions.

That is the gap the investigators behind iSTOP-CP hope mesenchymal stromal cells might eventually help address.

Why give stem cells through the nose?

The cells used in iSTOP-CP are bone marrow-derived mesenchymal stromal cells, or MSCs, obtained from healthy donors.

They are not intended to replace damaged neurons by simply turning into new brain cells.

Instead, researchers believe MSCs may release signaling molecules that influence inflammation, support tissue repair and stimulate the brain’s own regenerative processes.

The intranasal route is particularly unusual.

Animal studies have suggested that MSCs administered into the nasal cavity can reach regions of injured brain tissue and influence inflammatory and regenerative processes. However, findings in animal models do not establish that the same therapeutic effect occurs in human newborns.

Using nasal administration also avoids neurosurgery and intravenous cell infusion, making the approach potentially less invasive if it proves effective and safe.

The treatment is given during a very narrow window

Timing is central to the iSTOP-CP strategy.

Eligible infants must receive the study treatment within seven days after birth.

The rationale is that the biological response to brain injury changes rapidly during the first days after damage occurs. Inflammation, cell death and repair processes are already underway, creating a possible early therapeutic window.

The researchers are therefore not trying to treat established cerebral palsy months or years later.

They are testing whether intervening shortly after the original brain injury can alter the developmental trajectory before permanent motor disability becomes apparent.

Who can enter the iSTOP-CP trial?

The study will enroll infants born at approximately 35 weeks of gestation or later who have evidence of significant hypoxic-ischemic brain injury on MRI or magnetic resonance spectroscopy.

The brain injury must be related to either perinatal arterial ischemic stroke or perinatal asphyxia.

Infants who have received therapeutic hypothermia can still be eligible.

Participants will be randomized 1:1 to receive the intranasal MSC treatment or a matching placebo.

Randomization is also stratified according to the cause of brain injury and, in babies with stroke, according to the territory affected.

The study excludes several situations in which the cause or prognosis of brain injury could be substantially different, including certain congenital, chromosomal or metabolic disorders and intracranial hemorrhage as the primary brain injury.

The main outcome will not simply be whether cerebral palsy is diagnosed

The study’s name — iSTOP-CP, or intranasal Stem Cells to Treat Perinatal brain injury to combat Cerebral Palsy — makes cerebral palsy central to its purpose.

But the primary endpoint is more precise than simply counting cerebral palsy diagnoses.

The main outcome is the motor composite score on the Dutch version of the Bayley Scales of Infant and Toddler Development, Fourth Edition, measured at approximately 24 months corrected age.

The Bayley assessment evaluates both fine and gross motor development and provides a standardized score that allows investigators to compare overall motor performance between children who received MSCs and those who received placebo.

This matters because the consequences of newborn brain injury exist on a spectrum. A child may have subtle motor impairment without meeting criteria for cerebral palsy, while another may develop clear CP.

Looking at motor development as a continuous outcome can therefore detect differences that a simple yes-or-no cerebral palsy diagnosis might miss.

Researchers will follow much more than movement

Children in iSTOP-CP will be followed through several developmental assessments during their first two years of life.

Secondary outcomes include cognitive development, sensorineural disability, safety and neuroimaging markers of brain repair.

Brain MRI will be used to investigate whether the treatment is associated with structural changes consistent with neuroregeneration.

The study will also examine biological markers in blood and assess health-related quality of life for both children and their parents.

Researchers are also including a health-economic evaluation to determine whether the treatment could be cost-effective if it ultimately proves beneficial.

That broader approach matters for families because the burden of neonatal brain injury extends beyond a motor score. Developmental therapies, medical appointments, uncertainty about prognosis and long-term caregiving needs can affect the entire household.

The idea has already been tested in 10 newborns

iSTOP-CP did not emerge directly from animal experiments.

An earlier first-in-human study called PASSIoN tested intranasal bone marrow-derived mesenchymal stromal cells in 10 newborns with perinatal arterial ischemic stroke.

The results were published in The Lancet Neurology.

Each infant received a single intranasal dose of approximately 45–50 million MSCs within seven days of the first signs of stroke.

The primary purpose was safety and feasibility — not proving that the treatment improved neurological development.

All ten infants tolerated intranasal administration. No serious adverse events related to treatment were observed during the initial safety follow-up, and one infant developed a mild transient fever that required no clinical intervention.

Those findings showed that giving MSCs intranasally to newborns with stroke was technically feasible and sufficiently well tolerated to justify further research.

Two-year results were encouraging — but cannot prove the cells worked

The same 10 children were later assessed at age 2.

A 2025 follow-up analysis reported no treatment-related adverse events during longer-term follow-up.

Two of the 10 children developed mild cerebral palsy. Researchers also reported better motor performance than in a selected historical registry cohort of children with comparable stroke characteristics.

Brain imaging showed several findings that investigators considered compatible with more favorable development of motor pathways.

Those observations are scientifically interesting, but they do not demonstrate that the stem cells caused the better outcomes.

PASSIoN had only 10 treated infants, no randomized placebo group, and the later comparison with untreated children was post hoc and based on historical registry data.

The children could therefore have developed differently for reasons unrelated to the treatment.

That limitation is the main reason iSTOP-CP is so important: it moves the idea from a small safety study into a much larger randomized placebo-controlled test.

Why a placebo-controlled trial is essential here

Neurodevelopment after perinatal brain injury varies considerably from one child to another.

The size and location of the injury, its cause, gestational age, seizures, additional illnesses and many other factors can influence later development.

That makes uncontrolled studies particularly difficult to interpret.

If a small group of children develops better than expected, researchers cannot know whether the treatment caused the improvement unless outcomes are compared with a sufficiently similar untreated group.

Randomization helps distribute those known and unknown factors between the treatment and placebo groups.

Blinding also reduces the risk that expectations influence developmental assessments.

For a treatment being considered for highly vulnerable newborns, that level of evidence is critical before it could ever become routine care.

Why the term “stem cell therapy” needs some context

Stem cell treatments attract intense public interest, but the term covers very different technologies.

The cells in iSTOP-CP are mesenchymal stromal cells derived from donor bone marrow. They are not embryonic stem cells and are not gene therapy.

The treatment also remains experimental.

Parents should not interpret the existence of iSTOP-CP as evidence that commercially offered stem cell treatments for cerebral palsy or childhood brain injury are effective.

The specific cell product, preparation, dose, route of administration, treatment timing and patient population all matter, and the iSTOP-CP intervention is being tested within a tightly controlled clinical trial.

What iSTOP-CP has not shown yet

No efficacy results from iSTOP-CP are available.

The trial has not shown that intranasal MSCs prevent cerebral palsy.

It has not shown that the treatment improves motor development, cognition or brain repair compared with placebo.

It also has not established whether the therapy adds benefit for infants who already receive therapeutic hypothermia after perinatal asphyxia.

The previous 10-patient PASSIoN study provides a safety foundation and a reason to test the approach further, but its encouraging developmental findings cannot be treated as proof of efficacy.

The new trial is designed precisely to determine whether those early signals hold up when the treatment is tested rigorously in a much larger group.

Why this trial is worth watching

The central idea behind iSTOP-CP is unusually ambitious: intervene not after cerebral palsy has become clinically established, but during the first days after the brain injury that can eventually cause it.

If infants receiving intranasal MSCs show meaningfully better motor development at age 2 than infants receiving placebo, the study would provide strong randomized evidence that this regenerative strategy can improve outcomes after severe perinatal brain injury.

That would still not mean every treated child could avoid cerebral palsy or other disability, and further studies would likely be needed before routine clinical use.

If no meaningful difference is found, the result will be equally important because it would show that the encouraging observations from the small first-in-human study did not translate into a measurable clinical benefit in a controlled trial.

For parents, neonatologists and neurologists, the key question is therefore no longer simply whether stem cells can be delivered safely through the nose — that has already been explored in a small group.

The much harder question now is whether giving them during the first week of life can actually change how an injured newborn brain develops over the next two years.

Official clinical trial record: ClinicalTrials.gov: iSTOP-CP, NCT07831746.

Could treating food allergy before age 2 help children develop lasting tolerance?

Could the first two years of life be a window to change the course of food allergy? A new randomized trial will enroll 120 babies and toddlers with peanut, tree nut or sesame allergy and compare early oral immunotherapy with allergen avoidance. Researchers will look beyond short-term desensitization to ask a harder question: whether some children can remain tolerant when regular allergen exposure changes after treatment.

The new SAFARI study (NCT07825662) will include children up to 24 months old with confirmed IgE-mediated allergy to peanut, tree nuts and/or sesame.

The study, led by Copenhagen Studies on Asthma in Childhood in collaboration with Herlev and Gentofte Hospital in Denmark, plans to enroll 120 children. Participants will be randomly assigned either to oral immunotherapy (OIT) or to a control group following allergen avoidance.

The trial is currently listed as not yet recruiting. Treatment and follow-up will extend over more than two years for some participants, and the study is expected to continue until 2031.

The central question is not simply whether very young children can become less reactive while receiving treatment. Researchers also want to know whether starting treatment this early could produce a more durable change in the immune response.

Food allergy treatment is already changing — but avoidance still matters

For families of children with food allergy, daily management has traditionally centered on avoiding the trigger food, reading labels, preventing accidental exposure and knowing how to respond if a reaction occurs.

That remains an essential part of care, but it is no longer the whole story.

Current European allergy guidelines recommend peanut oral immunotherapy for eligible children and adolescents to achieve desensitization.

In the United States, the FDA-approved peanut oral immunotherapy product Palforzia can be initiated from 1 year of age in children with confirmed peanut allergy.

Palforzia is intended to reduce the risk and severity of allergic reactions after accidental peanut exposure. Children receiving it must still avoid peanuts, and treatment itself can trigger allergic reactions.

Another option has also emerged in the United States: the FDA has approved omalizumab from age 1 for certain people with one or more IgE-mediated food allergies to reduce the risk of allergic reactions after accidental exposure.

But major questions remain — particularly for very young children, tree nut allergy and sesame allergy, and for the possibility of achieving a response that persists when regular treatment changes or stops.

SAFARI will compare daily immunotherapy with allergen avoidance

SAFARI is a randomized controlled study with two initial groups.

Children assigned to oral immunotherapy will receive small amounts of the food to which they are allergic. The dose will be increased gradually over approximately six months, followed by about 12 months of daily maintenance treatment.

The planned maintenance dose is 300 mg of food protein per day.

Children in the control group will follow standard care based on avoiding the relevant food allergen.

At the end of the treatment period, approximately 18 to 24 months after randomization, children will undergo an oral food challenge to determine how much of the allergenic food they can tolerate under medical supervision.

A successful response is defined in the protocol as tolerating an oral food challenge containing up to 4,000 mg of food protein.

The researchers will also distinguish children who show a partial increase in their reaction threshold from those who do not respond sufficiently or have to discontinue OIT because of allergic reactions.

Desensitization is not the same as lasting tolerance

This distinction is one of the most important parts of the study.

Oral immunotherapy can make a person desensitized: while regularly consuming a controlled amount of the allergen, they may be able to tolerate substantially more of it before developing symptoms.

That can be clinically valuable because it may reduce the risk posed by small accidental exposures.

But desensitization does not necessarily mean that the underlying allergy has disappeared.

If regular allergen exposure stops, some patients lose part or all of that protection.

Researchers therefore use another concept, often called sustained unresponsiveness, to describe the ability to tolerate the food after regular immunotherapy has been stopped or allergen exposure has changed.

SAFARI is specifically designed to explore this distinction.

After completing OIT and successfully passing the end-of-treatment food challenge, children in the immunotherapy group will undergo a second randomization. Some will continue regular consumption of the allergenic food, while others will avoid it for six months.

They will then undergo another oral food challenge.

This second stage is intended to help researchers determine whether the increased tolerance achieved during treatment persists when regular allergen exposure changes — rather than measuring only how well OIT works while it is taken every day.

Why start before age 2?

The idea that very early childhood could represent an important treatment window is not based on SAFARI alone.

The immune system is still developing rapidly during infancy and early childhood, raising the possibility that food allergy may be more modifiable during this period than later in life.

One of the strongest pieces of evidence has come from the IMPACT trial, which studied peanut oral immunotherapy in children aged 1 to 3 years.

In that randomized placebo-controlled study, 71% of children receiving peanut OIT became desensitized, compared with 2% receiving placebo.

The more difficult outcome was remission after treatment stopped. After 26 weeks of peanut avoidance, 21% of children who had received OIT still tolerated the target amount of peanut, compared with 2% in the placebo group.

An exploratory analysis also found that younger children were more likely to reach remission. That finding helped generate interest in whether intervention even earlier in life could offer an advantage.

However, those results were specific to peanut allergy and children aged 1 to 3. They do not prove that treatment before age 2 will produce lasting tolerance, nor that the same effect will occur with tree nuts or sesame.

SAFARI is designed to address some of those unanswered questions directly.

The trial goes beyond peanut allergy

Much of the strongest clinical evidence for food oral immunotherapy has focused on peanut.

SAFARI is broader. Children may enter with confirmed allergy to peanut, tree nuts or sesame.

That matters because the available treatments and the amount of randomized evidence are not the same for every food allergy.

Tree nut and sesame allergies can cause serious reactions and may persist for years, yet standardized approved oral immunotherapy options are much more limited than for peanut.

Researchers have already begun studying OIT for these foods in younger children.

A real-world study published in 2025, for example, followed 52 children aged 24 months or younger who began oral immunotherapy for peanut, tree nut or sesame allergy. Most reactions observed during treatment were mild, supporting the feasibility of studying this approach more rigorously in infants and toddlers.

But retrospective experience cannot provide the same level of evidence as a randomized comparison with an allergen-avoidance control group.

That is one of the gaps SAFARI aims to fill.

Researchers will also look inside the developing immune system

SAFARI is not designed only to ask whether a child passes or fails a food challenge.

The researchers also want to understand why some children respond to oral immunotherapy while others do not.

Samples collected during the study will allow investigators to examine changes in immune markers, gene expression, the microbiome, metabolism and other biological pathways.

The protocol includes analyses involving blood, urine, stool and several types of skin, airway and other biological samples.

The goal is to identify biological patterns associated with successful treatment or with the natural development of tolerance.

If reliable biomarkers can eventually be identified, they could help answer a question that is currently difficult for both doctors and parents: which children are most likely to benefit from oral immunotherapy, and which may face the burden and risks of treatment without achieving a durable response?

The study will measure the burden on families too

Food allergy affects more than laboratory values or the amount of allergen tolerated during a challenge.

For parents of very young children, it can mean constant label checking, anxiety around meals and childcare, concerns about restaurants and travel, and fear that someone may accidentally give the child the wrong food.

Oral immunotherapy introduces a different burden. Treatment involves regular dosing over many months, dose escalation, clinical visits and the possibility of allergic reactions during therapy.

SAFARI will therefore also ask parents about food allergy-related quality of life, anxiety and coping.

This is particularly relevant when comparing active treatment with avoidance: a therapy may increase the amount of food a child can tolerate, but families also need to know what that treatment requires in everyday life.

Oral immunotherapy can itself cause allergic reactions

OIT deliberately exposes an allergic child to the food that can trigger a reaction. It therefore requires medical supervision and is not something parents should attempt on their own.

Allergic reactions can occur during dose escalation or maintenance treatment. Gastrointestinal symptoms are also possible, and food immunotherapy can be unsuitable for children with certain conditions, including uncontrolled asthma or eosinophilic esophagitis.

Current allergy guidelines recommend that allergen-specific immunotherapy be conducted by clinical teams experienced in food immunotherapy and in managing possible adverse reactions, including anaphylaxis.

SAFARI will specifically track reactions, dose reductions, delayed dose increases, treatment interruptions and children who are unable to complete the planned escalation schedule.

Safety is therefore part of the central research question — especially because the participants are infants and toddlers.

What SAFARI has not shown yet

SAFARI was newly registered in September 2026 and is currently listed as not yet recruiting.

No results from the study are available.

The trial has not shown that oral immunotherapy before age 2 prevents lifelong food allergy.

It has not shown that starting OIT in infancy is better than starting later.

It has also not established that young children with peanut, tree nut and sesame allergy will respond in the same way.

Even if children become desensitized during therapy, that does not automatically mean that they will remain tolerant after regular treatment changes or stops.

Those are precisely the questions the study is intended to investigate.

Why this trial is worth watching

The most interesting question in SAFARI is not whether oral immunotherapy can raise the reaction threshold while a child is receiving it. There is already substantial evidence that OIT can achieve desensitization in many children with peanut allergy.

The bigger question is whether very early treatment can alter the longer-term course of food allergy.

If children treated before age 2 are more likely to maintain a higher level of tolerance after treatment changes, that could support the idea that infancy represents a particularly important therapeutic window.

If that effect is not seen, the study will still provide valuable information about the limits of early intervention, differences between allergens, and the burden and safety of prolonged OIT in very young children.

Either way, SAFARI should not be interpreted as evidence that parents should begin giving allergenic foods to a child who already has a diagnosed food allergy.

It is a controlled clinical trial designed to determine whether carefully supervised treatment during one of the earliest stages of life can do more than temporarily raise the threshold for an allergic reaction.

Official clinical trial record: ClinicalTrials.gov: SAFARI, NCT07825662.

Tirzepatide, best known as a treatment for diabetes and obesity, is now being tested for methamphetamine use disorder. The new randomized Phase 2 trial will enroll 228 adults. Researchers want to determine whether weekly injections can reduce methamphetamine use — with outcomes assessed not only through participant reports, but also through regular urine drug tests. 

The new T-STEM study (NCT07825857) will compare weekly tirzepatide with placebo over 26 weeks and moves an early hypothesis about the effects of GLP-1/GIP-targeting drugs on addiction into a fully randomized, double-blind, placebo-controlled trial, although for now the study includes only adults with a BMI of 25 kg/m² or higher.

The study is being conducted by UT Southwestern Medical Center in collaboration with the National Institute on Drug Abuse (NIDA). It plans to enroll 228 adults aged 18 to 65 with moderate or severe methamphetamine use disorder.

The central question is simple but clinically important: can a drug developed for metabolic disease help people substantially reduce or stop methamphetamine use?

For now, the answer is unknown. The study is currently listed as not yet recruiting, with an estimated start in October 2026, and no efficacy data from T-STEM are available yet.

There are still no FDA-approved medications for methamphetamine addiction

Methamphetamine use disorder can negatively affect the cardiovascular system, the brain, mental health and everyday functioning, while repeated use can lead to intense cravings and compulsive drug-seeking behavior.

Unlike opioid use disorder, for which several approved medications are available, there is currently no medication approved by the FDA specifically for methamphetamine use disorder.

The FDA recently issued updated guidance intended to support the development of treatments for stimulant use disorders. The agency's 2026 draft guidance describes how clinical trials can assess reductions in stimulant use without requiring complete abstinence as the only meaningful outcome.

Behavioral therapy remains the foundation of treatment. Contingency management, which provides structured incentives for meeting treatment goals, has one of the strongest evidence bases in stimulant use disorders. Cognitive behavioral therapy and other psychosocial approaches are also used.

Several medications have also been investigated. For example, a combination of injectable naltrexone and oral bupropion reduced methamphetamine use in a randomized trial, but this has not resulted in FDA approval of a medication specifically for this purpose.

Why might a diabetes and obesity drug affect addiction?

Tirzepatide activates receptors for two hormones: GLP-1 and GIP. It is already used in clinical practice for type 2 diabetes and long-term weight management under approved indications.

The interest in addiction medicine is linked to a different potential effect.

GLP-1 signaling operates not only in the gut and pancreas, but also in brain networks involved in reward, motivation and appetite regulation. Preclinical studies have suggested that drugs acting on this system may reduce the reinforcing effects of some psychoactive substances. Observational studies have also identified a possible association between the use of GLP-1-targeting drugs and lower rates of certain outcomes related to substance use.

Researchers now want to determine whether these signals translate into a meaningful clinical effect.

According to the description of the NIDA-funded project, earlier open-label studies in adults with methamphetamine use disorder showed high adherence to weekly tirzepatide injections, along with signals of reduced methamphetamine use and craving.

But open-label observations cannot prove that tirzepatide itself caused the improvements. Participants know what treatment they are receiving, there is no placebo comparison, and expectations or other changes during treatment can influence the results.

T-STEM is designed to test this hypothesis more rigorously.

The study will compare tirzepatide directly with placebo

T-STEM is a randomized, double-blind, placebo-controlled Phase 2 trial.

Participants will be randomly assigned to receive either tirzepatide or placebo as weekly subcutaneous injections for 26 weeks, followed by another six weeks of observation.

Tirzepatide will be started at 2.5 mg per week. The dose may be increased by 2.5 mg every four weeks up to a maximum of 15 mg per week, or the highest dose the participant can tolerate.

Participants, clinicians, investigators and outcome assessors will not know who is receiving the active drug and who is receiving placebo.

This design allows researchers to separate a true drug effect from changes that might occur simply because a person has entered an intensive treatment program.

The primary endpoint is based on urine drug testing

One of the key features of T-STEM is how treatment response will be assessed.

The primary endpoint is the proportion of participants who achieve at least six methamphetamine-negative urine drug screens out of eight tests conducted between weeks 23 and 26.

This gives researchers an objective biological measure and avoids relying solely on what participants report about how much methamphetamine they have used.

Researchers will also assess:

• self-reported reductions in methamphetamine use;
• current and recent methamphetamine craving;
• achievement of early remission;
• treatment discontinuation rates;
• serious adverse events.

The study therefore aims to answer two questions at the same time: whether tirzepatide is sufficiently safe and tolerable for this patient group, and whether there is a strong enough efficacy signal to justify larger trials.

This is not the first time tirzepatide has been tested in stimulant use disorder

T-STEM is not the first clinical study of tirzepatide in people with stimulant use disorders.

An earlier study at UT Southwestern Medical Center, TRI-MR (NCT07693608), is testing tirzepatide in a much smaller open-label group that includes people with methamphetamine, cocaine or prescription stimulant use disorder.

That study also includes behavioral therapy and repeated brain imaging, and its participants have overweight or obesity.

An earlier pilot study also examined tirzepatide specifically in people with obesity and methamphetamine use disorder.

The new study is different because it moves the concept into a larger randomized, placebo-controlled trial focused specifically on methamphetamine use disorder.

This transition is scientifically important. Small open-label studies can show whether an idea is feasible and whether a possible efficacy signal is worth pursuing, but they cannot establish that the drug itself caused the observed improvements.

The study does not include every person with methamphetamine addiction

There is an important limitation in the study population.

Participants must have a body mass index (BMI) of at least 25 kg/m². This means that, in addition to moderate or severe methamphetamine use disorder, they must also have overweight or obesity.

They must also have active methamphetamine use and want to reduce or stop using it.

This means that even if T-STEM produces positive results, they cannot automatically be applied to people with methamphetamine use disorder who have a lower BMI.

The study also excludes some people with serious medical or psychiatric conditions, recent use of GLP-1 receptor agonists, certain diabetes treatments, pregnancy and several other safety-related conditions.

This is another reason not to interpret T-STEM as a test of tirzepatide for every person with methamphetamine use disorder.

Why this study could matter beyond methamphetamine

Interest in drugs that target GLP-1 receptors has rapidly expanded beyond diabetes and obesity.

Researchers are studying tirzepatide and related drugs in alcohol, cannabis and other substance use disorders. This is partly because reward systems involved in eating behavior overlap to some extent with neural systems linked to craving and reinforcement in addiction.

However, this field remains experimental.

An effect on appetite or body weight does not automatically mean that a drug will reduce drug-seeking behavior, and results from one type of addiction cannot simply be transferred to another.

The NIDA project supporting T-STEM views the study as a step toward determining whether GLP-1-targeting treatments deserve larger Phase 3 development programs for methamphetamine and other stimulant use disorders.

What T-STEM has not shown yet

The registration of T-STEM is an important development in addiction research, but it is important not to confuse the launch of a new clinical trial with a proven treatment result.

It has not yet been shown that tirzepatide helps people stop using methamphetamine.

T-STEM has not yet started recruiting, no participants have completed the treatment course, and no randomized efficacy data are available.

Tirzepatide is also not FDA-approved for methamphetamine use disorder or other stimulant use disorders.

The study must first show that the drug can produce a meaningful reduction in methamphetamine use compared with placebo while maintaining an acceptable safety and tolerability profile.

Only then would larger confirmatory trials be justified.

Why this study is worth watching

Methamphetamine use disorder remains an area with a major treatment gap: behavioral therapy can help, but there is still no approved medication specifically intended to treat the disorder.

At the same time, drugs targeting GLP-1 have generated substantial interest because their effects may extend beyond glucose control and body weight.

T-STEM puts one of the most discussed hypotheses in this field to a more rigorous test.

If tirzepatide leads to significantly more methamphetamine-negative urine tests than placebo, reduces craving and remains acceptably tolerated over six months, it would provide a strong signal that metabolic signaling pathways could be a promising therapeutic target in stimulant use disorder.

If it does not, the study will be no less informative: it will show where enthusiasm around GLP-1-targeting drugs may not translate into real clinical benefit.

The most important point is not that a weight-loss drug has already become a treatment for addiction.

It is that this hypothesis is now moving from small uncontrolled studies into a randomized trial capable of testing whether the effect is real.

Clinical trial: T-STEM, NCT07825857.

A new Phase 3 trial will evaluate whether a once-daily dry-powder inhaler can preserve lung function in progressive pulmonary fibrosis, testing a long-acting prostacyclin prodrug in a field where lung damage remains irreversible.

Insmed has registered the PALM-PPF study, NCT07805785, a randomized, double-blind, placebo-controlled trial that plans to enroll approximately 800 adults with progressive pulmonary fibrosis (PPF) across international sites.

The study investigates treprostinil palmitil inhalation powder (TPIP), an investigational prodrug engineered for sustained, local release of treprostinil directly within pulmonary tissue. Delivered once daily via a capsule-based dry-powder inhaler, TPIP aims to deliver continuous prostacyclin-pathway activation without the frequent dosing required by existing inhaled formulations.

The primary endpoint will assess the change from baseline in forced vital capacity (FVC) at week 52, with long-term follow-up extending up to 104 weeks to monitor clinical worsening, acute exacerbations of interstitial lung disease, patient-reported symptoms, and all-cause mortality.

PPF represents a progressive phenotype across diverse lung diseases

Progressive pulmonary fibrosis is not an isolated disease entity. It describes a progressive, self-sustaining fibrotic phenotype that can complicate a broad spectrum of interstitial lung diseases (ILDs).

These disorders cause chronic inflammation, tissue destruction, and progressive matrix deposition in the pulmonary interstitium. Over time, expanding fibrosis stiffens the lungs, restricts ventilation, and compromises alveolar gas exchange.

PPF occurs across diverse etiologies, including connective tissue disease-associated ILDs (such as systemic sclerosis or rheumatoid arthritis-associated lung disease), fibrotic hypersensitivity pneumonitis, idiopathic nonspecific interstitial pneumonia (iNSIP), and occupational lung disorders.

By definition, PALM-PPF excludes patients with idiopathic pulmonary fibrosis (IPF), an independent entity with established standard-of-care pathways, focusing instead on non-IPF fibrosing ILDs that demonstrate documented disease progression despite conventional management.

Antifibrotic options have expanded, but lung tissue is not restored

Standard management of underlying ILDs typically begins with immunosuppression for autoimmune disorders or strict avoidance of environmental triggers. When fibrosis exhibits a progressive course, targeted antifibrotic therapy is introduced to curb respiratory decline.

The oral tyrosine kinase inhibitor nintedanib (Ofev) was the first agent approved for chronic fibrosing ILDs with a progressive phenotype, based on Phase 3 data demonstrating a significant reduction in the annual rate of FVC decline.

The therapeutic field expanded in late 2025 when the U.S. Food and Drug Administration approved the phosphodiesterase-4B (PDE4B) inhibitor nerandomilast (Jascayd) for progressive pulmonary fibrosis.

Approval was supported by the 1,178-patient Phase 3 FIBRONEER-ILD trial, in which 52-week FVC decline was 72 mL with nerandomilast 18 mg and 85 mL with 9 mg, compared with 151 mL in the placebo cohort.

While oral antifibrotics meaningfully decelerate functional loss, neither nintedanib nor nerandomilast removes existing fibrous scar tissue. Many patients continue to lose pulmonary capacity, driving demand for complementary therapeutic mechanisms.

PALM-PPF accommodates modern background therapy

A notable feature of the PALM-PPF protocol is its alignment with the modern treatment landscape. The trial does not require participants to discontinue effective standard therapy.

Eligible patients may participate while maintained on stable background doses of approved oral antifibrotics, including nintedanib or nerandomilast. Patients who are not taking an approved antifibrotic due to intolerance, contraindication, or clinical choice are also eligible under specified protocol criteria.

This design allows the study to evaluate TPIP both as an add-on therapy over contemporary oral regimens and as a single-agent intervention in non-antifibrotic-treated cohorts.

Engineering sustained pulmonary release: What is TPIP?

Treprostinil palmitil is a synthetic lipid-conjugated prodrug of treprostinil, a prostacyclin analogue historically utilized for its vasodilatory and antiproliferative properties in pulmonary vascular disorders.

Standard inhaled treprostinil requires aerosolization via specialized nebulizers three to four times daily due to rapid clearance from the pulmonary bed. In contrast, TPIP is formulated as a dry powder consisting of treprostinil conjugated to a palmitate lipid chain.

Once deposited in the alveolar space, the prodrug is retained locally within lung tissue and slowly cleaved by endogenous esterases into free, active treprostinil. This delivery system is intended to provide sustained receptor engagement throughout a 24-hour dosing interval, avoiding high systemic peak concentrations that often trigger tolerability issues.

Preclinical models have identified antifibrotic and anti-inflammatory signaling linked to prostanoid IP and EP2 receptor activation, including down-regulation of myofibroblast differentiation and pro-fibrotic cytokine release. However, laboratory signals do not establish clinical efficacy in patients.

From vascular hemodynamics to parenchymal preservation

Clinical interest in treprostinil as an antifibrotic candidate originated in secondary pulmonary hypertension studies.

Nebulized treprostinil is approved in the United States for pulmonary hypertension associated with interstitial lung disease (PH-ILD) following the pivotal INCREASE trial. A subsequent post-hoc analysis of INCREASE published in 2021 revealed that patients receiving inhaled treprostinil experienced unexpected improvements in forced vital capacity compared with placebo, particularly those with idiopathic parenchymal disease.

Although exploratory, those findings prompted dedicated clinical trials testing whether direct inhalation of prostacyclin analogues alters parenchymal fibrosis independently of pulmonary arterial pressure.

The prostacyclin hypothesis advances in Phase 3 programs

The broader scientific hypothesis received direct Phase 3 validation earlier in 2026 when United Therapeutics published results from its Phase 3 TETON program in idiopathic pulmonary fibrosis.

In the pivotal TETON-2 trial, nebulized treprostinil administered four times daily demonstrated a statistically significant reduction in 52-week FVC decline (median change of approximately -50 mL with inhaled treprostinil versus -136 mL with placebo) alongside a 29% reduction in clinical worsening events. The FDA accepted a supplemental New Drug Application (sNDA) for treprostinil in IPF in early September 2026.

Concurrently, a parallel trial is already examining nebulized treprostinil specifically in progressive non-IPF fibrosis. The Phase 3 TETON-PPF trial, NCT05943535, completed enrollment of 754 patients in mid-August 2026, with topline results projected in the second half of 2027.

PALM-PPF enters a field where proof-of-concept for the molecule exists, but tests a distinct, long-acting dry-powder delivery system designed to simplify treatment burden to once daily.

Key endpoints: Lung function and clinical stability

The primary outcome of PALM-PPF is absolute change in FVC (mL) from baseline to week 52. In progressive fibrosing lung disease, spirometric FVC decline remains the gold-standard surrogate for disease progression and mortality risk.

Beyond spirometry, the protocol incorporates secondary measures assessing real-world disease stabilization over an extended period of up to 104 weeks:

• Time to first clinical worsening event (defined by pre-specified composite thresholds of FVC drop, non-elective respiratory hospitalization, or death)
• Time to first acute ILD exacerbation
• Changes in diffusing capacity of the lung for carbon monoxide (DLCO)
• Patient-reported dyspnea, cough severity, and respiratory quality-of-life scores
• All-cause and respiratory-related mortality

Assessing outcomes through 104 weeks is clinically vital to determine whether slowing a physiological marker like FVC preserves functional independence and delays acute life-threatening decompensations.

Clinical status and evidence boundaries

While the study registration marks a significant expansion of the TPIP program, critical evidential caveats remain:

• Trial status: Registered on September 4, 2026, PALM-PPF is currently listed as not yet recruiting, with clinical site activation scheduled to begin in late 2026.
• No PPF efficacy data: No clinical efficacy data have been generated for TPIP in progressive pulmonary fibrosis cohorts.
• Formulation differences: TPIP is an investigational prodrug with distinct pharmacokinetics; positive results from nebulized treprostinil (TETON program) cannot be conflated with evidence of efficacy or safety for once-daily dry-powder TPIP.
• Absence of head-to-head evidence: There are no comparative trials assessing the efficacy, safety, or adherence profiles of TPIP versus approved oral antifibrotics or nebulized treprostinil formulations.
• Regulatory status: Treprostinil palmitil remains an unapproved investigational agent globally, without marketing authorization for PPF, pulmonary hypertension, or any other indication.

If Phase 3 data confirm that once-daily inhaled TPIP can preserve functional lung capacity and forestall clinical worsening alongside modern oral therapies, the drug could establish an inhaled antifibrotic class in progressive pulmonary fibrosis. Definitive answers will depend on the trial's execution over the coming years.

Official clinical trial registry: ClinicalTrials.gov: NCT07805785 (PALM-PPF)

Fresh Phase 3 results, new approvals and newly launched trials are changing how researchers approach cancer, COPD, obesity, Alzheimer’s disease, kidney disease and other major global health threats.

Some of the most important medical developments reported or launched in late August and early September 2026 are targeting diseases that together account for millions of deaths and years of disability worldwide. From precision cancer therapy and earlier Alzheimer’s intervention to new approaches in COPD, kidney disease and childhood obesity, here are nine disease areas where the evidence is beginning to shift.

Medicine rarely changes because of a single “breakthrough.” More often, progress comes when years of laboratory work finally reach large clinical trials capable of answering a harder question: does a new idea actually help people live longer or live better?

This review is not a strict ranking of the world’s leading causes of death. The nine areas were selected because they combine a large global burden of death or disability with important new clinical results, regulatory developments or trial activity available through September 10, 2026.

The stage of evidence also matters. Some developments below are positive Phase 3 results or regulatory approvals. Others are newly launched trials testing whether encouraging earlier findings hold up in larger populations. Starting a clinical trial is not evidence that a treatment works, and those distinctions are preserved throughout.

1. Cancer: treatment is becoming increasingly specific to the biology of each tumor

Cancer remains one of the world’s largest causes of premature death. The World Health Organization estimates that nearly 10 million people died from cancer in 2024, or close to one in six deaths worldwide. Lung cancer alone caused an estimated 1.86 million deaths.

There is no single “cancer treatment.” Depending on tumor type and stage, patients may receive surgery, radiation, chemotherapy, targeted drugs, immunotherapy or combinations of these approaches.

What stands out in several important 2026 studies is the increasing effort to choose treatment according to the molecular and immune biology of an individual tumor rather than relying only on where the cancer originated.

Tarlatamab improves survival as first-line maintenance in small-cell lung cancer

One of the freshest late-stage results came on September 8, when Amgen announced that the Phase 3 DeLLphi-305 trial had met its primary endpoint in extensive-stage small-cell lung cancer.

The study tested tarlatamab plus durvalumab against durvalumab alone as maintenance treatment in patients whose cancer had not progressed after initial treatment with durvalumab, platinum chemotherapy and etoposide.

The combination produced a statistically significant and clinically meaningful improvement in overall survival. The study also met secondary endpoints for progression-free survival and objective response rate.

That is important because small-cell lung cancer is particularly aggressive. It can initially respond well to chemotherapy, but relapse is common and long-term outcomes remain poor.

Tarlatamab is a bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, helping bring immune cells into contact with the cancer.

The result does not mean chemotherapy has been replaced. Patients in DeLLphi-305 first received standard chemo-immunotherapy. The new strategy is intended to improve what happens after that initial treatment.

Amgen has so far reported high-level Phase 3 findings; full numerical survival data will be important for judging the actual magnitude of benefit.

Personalized mRNA treatment reaches a Phase 3 milestone in melanoma

A different form of precision oncology reached an important milestone in August.

On August 19, Merck and Moderna reported that the Phase 3 INTerpath-001 study of intismeran autogene plus pembrolizumab met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected high-risk melanoma.

Intismeran autogene is an individualized mRNA-based neoantigen therapy. Instead of giving every patient an identical product, researchers analyze mutations in a person’s tumor and use that information to create an mRNA treatment intended to train the immune system to recognize selected tumor-specific targets.

The result is notable because it moves personalized mRNA cancer treatment into positive Phase 3 territory.

But one important endpoint remains unresolved: overall survival follow-up is continuing. The current findings therefore show delayed recurrence and distant spread, not yet proof that the personalized treatment helps patients live longer.

KRAS-targeted tablets move directly against chemotherapy in pancreatic cancer

Pancreatic cancer illustrates another major shift in precision medicine.

Metastatic pancreatic adenocarcinoma has historically been dominated by multidrug chemotherapy. Common first-line options include regimens based on fluorouracil, irinotecan and oxaliplatin, as well as gemcitabine plus nab-paclitaxel.

On August 26, the U.S. Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who had already received systemic treatment or were not candidates for multiagent systemic therapy.

Now the newly registered Phase 3 RASolute 309 study, NCT07805954 is taking a harder step.

Approximately 400 patients with previously untreated metastatic KRAS G12D-mutated pancreatic adenocarcinoma will be randomized to receive the oral combination of zoldonrasib plus daraxonrasib or standard gemcitabine plus nab-paclitaxel.

The primary questions are progression-free survival and overall survival.

That makes the trial more than another early biomarker study. It asks whether a mutation-selected oral treatment strategy can compete directly with established first-line chemotherapy.

Daraxonrasib’s approval in previously treated disease does not establish that the two-drug combination will be superior in untreated KRAS G12D disease. That is precisely what RASolute 309 now needs to prove.

Why these cancer developments matter together

The three approaches are very different, but they illustrate the same larger trend.

Small-cell lung cancer therapy is exploiting a tumor-associated surface target. Melanoma treatment is being individualized around mutations unique to a patient’s tumor. Pancreatic cancer researchers are selecting therapy according to a common driver mutation.

Precision oncology is therefore becoming less about finding one universal cancer drug and more about identifying which biological vulnerability matters in which patient, at which stage of disease.

2. Heart disease and stroke: intensive prevention is moving before the first major event

Cardiovascular disease remains the world’s leading cause of death. The World Health Organization estimates that 19.8 million people died from cardiovascular diseases in 2022, representing about 32% of all global deaths. Around 85% of those deaths were caused by heart attacks and strokes.

Prevention already rests on several pillars: not smoking, physical activity, blood-pressure and diabetes control, healthy nutrition and lowering LDL cholesterol when cardiovascular risk warrants treatment.

Statins remain the foundation of LDL-lowering therapy. Other treatments, including ezetimibe and PCSK9-targeting drugs, are used when additional LDL reduction is needed.

VESALIUS-CV pushes LDL lowering further into high-risk prevention

At the end of August, a prespecified analysis of the Phase 3 VESALIUS-CV trial provided an important new signal about how early intensive LDL lowering might be useful.

The study included more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Evolocumab, the PCSK9 inhibitor marketed as Repatha, was added to existing statin or other LDL-lowering treatment.

In findings reported by Amgen on August 31, evolocumab was associated with a 20% reduction in the risk of death. The difference began to emerge after approximately 1.5 years and continued during a median follow-up of 4.6 years.

The population was not simply made up of people with mildly elevated cholesterol. Participants had substantial underlying cardiovascular risk, including established atherosclerotic disease without previous myocardial infarction or stroke, or high-risk diabetes.

That distinction matters because these results should not be interpreted as evidence that everyone with elevated LDL needs an injectable PCSK9 inhibitor.

The broader implication is more specific: for selected people already at high risk, waiting until the first heart attack or stroke before intensifying prevention may be too late.

3. COPD: biologic treatment may reach a broader group of patients

Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death worldwide, according to the World Health Organization, causing approximately 3.4 million deaths in 2023.

Current treatment focuses on stopping smoking and other harmful exposures, inhaled bronchodilators, inhaled corticosteroids for selected patients, vaccination, pulmonary rehabilitation and oxygen therapy when indicated.

Despite optimized inhaled therapy, some patients continue to experience exacerbations that can require steroids, antibiotics or hospitalization and can accelerate loss of lung function.

Biologic drugs are beginning to change this landscape, but much of the recent progress has focused on patients with particular inflammatory profiles.

Tozorakimab cuts exacerbations across eosinophil levels

On September 8, AstraZeneca reported full Phase 3 results from the OBERON and TITANIA trials of tozorakimab, an antibody targeting IL-33 signaling.

All participants continued inhaled standard-of-care therapy.

Among former smokers, tozorakimab reduced the annual rate of moderate or severe COPD exacerbations by 29% in OBERON and 34% in TITANIA compared with placebo. In the broader population of current and former smokers, the reductions were 30% and 29%, respectively.

A particularly interesting finding was that benefit appeared across prespecified blood eosinophil groups, including patients with low eosinophil levels.

This matters because it suggests IL-33 inhibition may potentially reach a broader COPD population than biologics selected primarily around high eosinophil counts.

The results were published in the New England Journal of Medicine, and the FDA is reviewing a Biologics License Application for tozorakimab under Priority Review.

The drug is not yet an established replacement for inhaled COPD therapy. It was studied as an add-on in people who continued to have exacerbations despite existing treatment.

4. Obesity: the GLP-1 treatment debate is moving into younger children

Obesity is now classified by the World Health Organization as a chronic, relapsing disease shaped by biological, behavioral and environmental factors.

In 2022, approximately 890 million adults worldwide were living with obesity. Among children and adolescents aged 5 to 19, about 160 million were living with obesity.

Lifestyle and family-based interventions remain central to childhood obesity care. Pharmacological treatment has become available for some adolescents, but therapeutic options for younger children remain much more limited.

Semaglutide reaches its Phase 3 endpoint in children aged 6 to under 12

On September 7, Novo Nordisk announced the first results from the Phase 3 STEP Young trial of once-weekly subcutaneous semaglutide in children aged 6 to under 12 years with obesity.

Children in both the semaglutide and placebo groups received lifestyle intervention, including a reduced-calorie diet and increased physical activity.

The trial met its primary endpoint of greater BMI reduction with semaglutide.

After 68 weeks, 40.4% of children receiving semaglutide no longer met the trial’s BMI-based definition of obesity, compared with 0% in the placebo group.

The company reported that the overall safety and tolerability profile was consistent with previous semaglutide experience in adults and adolescents.

These are important Phase 3 topline results, but they also open questions that cannot be answered by a 68-week efficacy number alone.

Long-term treatment beginning in childhood raises issues around growth, nutrition, duration of therapy, adherence, psychological wellbeing and what happens to body weight after medication is stopped.

The result therefore does not mean lifestyle support has become irrelevant or that routine semaglutide treatment for all young children with obesity is established. It shows that pharmacological obesity treatment is now being seriously tested at an age where the evidence base has historically been much thinner.

5. Alzheimer’s disease: researchers are moving treatment before memory loss begins

About 57 million people worldwide were living with dementia in 2021, according to the World Health Organization, with nearly 10 million new cases occurring each year. Alzheimer’s disease accounts for an estimated 60% to 70% of dementia cases.

Dementia is the world’s seventh leading cause of death and one of the major causes of disability and dependence among older adults.

Current disease-modifying anti-amyloid therapies are aimed at selected people who already have early symptomatic Alzheimer’s disease and biomarker confirmation. They can slow decline, but they do not cure the disease.

One of the biggest questions now is whether intervention can move still earlier.

PrevenTRON moves Alzheimer’s treatment into the presymptomatic stage

Roche’s Phase 3 PrevenTRON study, NCT07717411 plans to enroll approximately 1,600 cognitively unimpaired adults who have biomarker evidence of Alzheimer’s pathology and are considered at increased risk of progressing to symptomatic disease.

In early September, Surrey and Borders Partnership NHS Foundation Trust announced that it had become the first UK and European site, and the third site worldwide, to offer participation in PrevenTRON.

The investigational treatment, trontinemab, is an anti-amyloid antibody engineered with Roche’s Brainshuttle technology to improve delivery across the blood-brain barrier.

Blood tests are being used as part of the screening process to identify people most likely to be eligible before more definitive assessment of Alzheimer’s pathology.

The strategy is based on a key feature of Alzheimer’s disease: amyloid and other pathological changes can begin many years before noticeable memory problems.

If intervention at that stage can delay the onset of mild cognitive impairment or dementia, Alzheimer’s treatment could begin to resemble cardiovascular prevention, where biological risk is addressed before the major clinical event occurs.

But this remains a hypothesis. Trontinemab has not been shown to prevent Alzheimer’s disease in symptom-free people. The clinical value of removing amyloid before symptoms appear is exactly what the Phase 3 program needs to determine.

6. Chronic kidney disease: finerenone benefit extends beyond diabetes

Kidney disease has become an increasingly important cause of global mortality. WHO data show kidney diseases rising from the 19th leading cause of death in 2000 to the ninth in 2021, with deaths increasing by about 95% over that period.

Chronic kidney disease can progress silently for years while simultaneously increasing the risk of cardiovascular disease, heart failure and kidney failure.

Modern management can include blood-pressure control, renin-angiotensin system blockade where appropriate and SGLT2 inhibitors, alongside treatment of the underlying cause. Finerenone has already built an important role in chronic kidney disease associated with type 2 diabetes.

FIND-CKD shows kidney protection in people without diabetes

The Phase 3 FIND-CKD trial tested finerenone in 1,584 adults with chronic kidney disease who did not have diabetes.

Over 32 months, the annual decline in estimated glomerular filtration rate was slower with finerenone than with placebo.

According to the Phase 3 findings reported by Bayer, the drug also reduced the risk of a prespecified composite kidney-or-cardiovascular outcome by 23%.

A fresh prespecified analysis presented at the European Society of Cardiology Congress showed a similar direction of benefit in people whose CKD was attributed to hypertensive nephropathy.

That is clinically important because hypertension is a common cause of progressive kidney damage and many patients with CKD do not have diabetes.

Finerenone blocks the mineralocorticoid receptor, a pathway involved in inflammatory and fibrotic processes affecting the kidneys and cardiovascular system.

Safety still matters. In FIND-CKD, hyperkalemia-related adverse events occurred in 17.0% of participants receiving finerenone versus 13.3% receiving placebo, although serious events and treatment discontinuations related to hyperkalemia were uncommon.

The evidence therefore broadens the biological case for finerenone beyond diabetic CKD, but availability and approved indications remain jurisdiction-specific.

7. MASH: the field is moving from liver-biopsy improvement toward preventing cirrhosis

Metabolic dysfunction-associated steatohepatitis, or MASH, is a progressive form of metabolic liver disease in which excess liver fat is accompanied by inflammation and liver-cell injury.

It is strongly associated with obesity, type 2 diabetes and other metabolic risk factors. In some patients, progressive fibrosis can lead to cirrhosis, liver failure, liver cancer or transplantation.

The treatment landscape has already changed substantially.

In the United States, the FDA granted accelerated approval to resmetirom in 2024 for adults with noncirrhotic MASH/NASH and moderate-to-advanced fibrosis. In 2025, the agency also granted an accelerated MASH indication to semaglutide in adults with moderate-to-advanced fibrosis.

Both developments were based on improvements in liver histology, with confirmatory studies continuing to determine whether those changes translate into fewer serious clinical outcomes.

That makes the next generation of trials especially important: the bar is no longer simply reducing liver fat or producing weight loss.

Pemvidutide enters Phase 3 with long-term liver outcomes built in

Altimmune initiated the global Phase 3 PERFORMA program in August, and the trial is now listed as recruiting.

The PERFORMA trial, NCT07795164 plans to enroll approximately 1,800 adults with noncirrhotic MASH and F2 or F3 fibrosis.

Pemvidutide is an investigational dual glucagon/GLP-1 receptor agonist. Researchers are testing two doses against placebo.

At 52 weeks, the major histological questions include whether treatment can resolve MASH without worsening fibrosis and whether it can improve fibrosis by at least one stage without worsening MASH.

But PERFORMA is designed to go further. Its long-term clinical outcome endpoint follows participants for approximately five years and includes progression to cirrhosis, liver-related events, liver transplantation or death.

Altimmune confirmed in August that the global Phase 3 study had been initiated after positive Phase 2b development.

That is the key transition for the field. Improving a biopsy after a year can support an accelerated approval pathway; showing that fewer people progress to cirrhosis or serious liver complications would demonstrate a much more direct patient benefit.

Pemvidutide has not yet been proven to prevent cirrhosis or reverse fibrosis in Phase 3. Those are questions the new program is designed to answer.

8. Osteoarthritis: gene therapy aims for longer-lasting effects inside the joint

Osteoarthritis illustrates why global disease burden cannot be measured by deaths alone.

About 528 million people worldwide were living with osteoarthritis in 2019, according to the World Health Organization, and the knee is the most commonly affected joint. Musculoskeletal disorders collectively account for the largest number of years lived with disability globally.

For many patients, knee osteoarthritis means years of pain, stiffness, difficulty walking and loss of independence.

Current treatment remains largely focused on symptoms and function: exercise and rehabilitation, weight management, pain medicines, selected intra-articular injections and ultimately joint replacement for advanced disease.

There is still no widely used injection proven to regenerate a substantially damaged osteoarthritic knee.

Two-year PCRX-201 results show promise, but the evidence remains early

In August, researchers published two-year results in Annals of the Rheumatic Diseases from a Phase 1 study of enekinragene inzadenovec, or PCRX-201, an experimental gene therapy administered as a single injection into the knee.

PCRX-201 uses a non-replicating adenoviral vector to deliver the gene for interleukin-1 receptor antagonist, or IL-1Ra, with the aim of producing anti-inflammatory activity locally inside the joint.

The open-label Phase 1 study included 72 participants with moderate-to-severe knee osteoarthritis.

The treatment showed very limited distribution outside the knee. Among participants who remained in the study, exploratory measures of pain, stiffness and function showed improvements that persisted to 104 weeks.

But there is an important limitation: 33 of 72 participants, or 45.8%, had discontinued the study by week 104. The symptom analyses were exploratory and based on observed data rather than a large placebo-controlled efficacy comparison.

So the results are encouraging enough to justify further study, but they do not establish cartilage regeneration or disease modification.

A randomized Phase 2 study, NCT06884865, is now evaluating PCRX-201 against a control in people with painful knee osteoarthritis, with safety and tolerability as major objectives and pain and joint function among the exploratory efficacy measures.

This is the kind of field where Phase 2 evidence matters particularly strongly: osteoarthritis has an enormous patient population, and claims about “repairing” joints can easily move much faster than the clinical data.

9. Global infections: vaccines and new regimens have to work outside controlled trials

Noncommunicable diseases dominate global mortality, but infectious diseases continue to kill millions of people and create enormous disability, particularly in lower-income countries.

Tuberculosis remains the world’s leading cause of death from a single infectious agent. WHO estimates that 10.7 million people developed TB and 1.23 million died from it in 2024.

Malaria remains another major threat. According to the World Health Organization, an estimated 282 million malaria cases and 610,000 deaths occurred in 2024. Around 95% of malaria deaths occurred in the WHO African Region, and children under 5 accounted for about three quarters of malaria deaths there.

R21 malaria vaccination moves into the real-world effectiveness phase

WHO now recommends two malaria vaccines, RTS,S/AS01 and R21/Matrix-M, for prevention of Plasmodium falciparum malaria in children living in endemic areas, prioritizing moderate- and high-transmission settings.

R21/Matrix-M has already demonstrated efficacy in randomized trials. The next question is what happens after a vaccine leaves the controlled environment of a clinical trial.

The AVERT study, NCT07749911 is recruiting and plans to evaluate real-world R21/Matrix-M effectiveness in approximately 20,000 children younger than 5 in Burkina Faso and Uganda.

It uses a prospective test-negative case-control design: researchers will compare vaccination histories among children seeking care for suspected malaria who test positive with those who test negative.

Routine programs are messier than clinical trials. Vaccine doses may be delayed or missed, protection can change over time, transmission intensity varies and families use other malaria-prevention measures at the same time.

That is precisely why AVERT matters. The study is not trying to prove again that R21 can work under trial conditions; it is trying to determine how much protection survives under everyday health-system conditions.

Vaccination is an addition to, not a replacement for, insecticide-treated nets, vector control, appropriate chemoprevention, rapid diagnosis and effective antimalarial treatment.

Tuberculosis researchers are assembling new drug combinations

Tuberculosis presents a different challenge. Even drug-susceptible pulmonary TB requires multidrug therapy, and treatment length and antimicrobial resistance remain major problems.

A new Phase 2 regimen-development study, NCT07773610 is bringing together several promising candidates, including TBAJ-587, BTZ-043, quabodepistat and ganfeborole, alongside pretomanid, linezolid and the standard HRZE regimen.

The study is specifically being conducted in adults with newly diagnosed, sputum-positive, drug-susceptible pulmonary tuberculosis.

Its early treatment arms are designed to compare antibacterial activity and safety and to decide which combinations deserve larger trials.

This is not yet evidence that any of these regimens can replace or shorten standard TB treatment. The significance is strategic: developers are increasingly assembling multiple new drugs into future regimens rather than evaluating every candidate in isolation.

What these studies say about where medicine is moving

Taken together, these developments do not point to one universal medical revolution. They point to several shifts happening at the same time.

Medicine is moving earlier. Cardiovascular therapy is being intensified before a first heart attack or stroke, while Alzheimer’s researchers are asking whether biological disease can be intercepted before memory symptoms appear.

Treatment is becoming more biologically specific. Cancer therapies increasingly target individual mutations or tumor antigens, and COPD biologics are being designed around defined inflammatory pathways.

Metabolic medicine is moving beyond weight and glucose. The same hormonal pathways that transformed obesity and diabetes treatment are now being studied against liver fibrosis and other complications of metabolic disease.

Researchers are also being pushed toward harder outcomes. A favorable biomarker is useful, but survival, heart attacks, strokes, kidney failure, cirrhosis, functional disability and real-world vaccine effectiveness matter more to patients.

And the distinction between promise and proof remains essential.

A drug entering Phase 3 has not yet passed Phase 3. Removing amyloid does not automatically mean dementia will be prevented. Weight loss does not by itself prove that liver fibrosis will stop progressing. An exploratory improvement after gene therapy is not evidence that cartilage has regenerated. And a vaccine that performs well in a randomized trial still has to work when delivered through ordinary health systems.

That is why some of the most consequential medical research is less dramatic than the word “breakthrough” suggests.

The studies worth watching are the ones large and rigorous enough to determine whether a promising biological idea ultimately changes what happens to patients.

This review reflects publicly available clinical, regulatory and epidemiological information checked through September 10, 2026.

A new Phase 3 trial is testing whether two oral targeted drugs can challenge chemotherapy as the first treatment given to people with one of the most common molecular forms of metastatic pancreatic cancer.

The RASolute 309 study, registered as NCT07805954, will compare the combination of zoldonrasib and daraxonrasib with standard gemcitabine plus nab-paclitaxel in patients whose tumors carry the KRAS G12D mutation.

The global randomized Phase 3 trial plans to enroll approximately 400 adults with previously untreated metastatic pancreatic adenocarcinoma.

Its two primary endpoints are particularly important: progression-free survival and overall survival. In other words, the study is not simply asking whether tumors shrink. It is testing whether the oral targeted combination can delay disease progression and ultimately help patients live longer.

Pancreatic cancer remains one of the hardest cancers to treat

Pancreatic cancer has long been among the most lethal common malignancies.

One major reason is that the disease often causes few specific symptoms while it is still confined to the pancreas. By the time it is diagnosed, many patients already have locally advanced or metastatic disease that cannot be removed surgically.

Pancreatic ductal adenocarcinoma, or PDAC, accounts for the vast majority of pancreatic cancers and is particularly resistant to many systemic treatments.

For people with metastatic disease, treatment has historically relied mainly on combinations of cytotoxic chemotherapy rather than highly effective tumor-specific targeted drugs.

What patients receive today

Several chemotherapy combinations are currently used as first-line treatment for metastatic pancreatic adenocarcinoma.

One long-established option is gemcitabine plus nab-paclitaxel, the regimen chosen as the control arm in RASolute 309.

Other patients may receive regimens built around fluorouracil, irinotecan and oxaliplatin, including modified FOLFIRINOX.

Another first-line option in the United States is NALIRIFOX, which combines liposomal irinotecan, oxaliplatin, fluorouracil and leucovorin. The FDA approved this regimen in 2024 after a Phase 3 study showed median overall survival of 11.1 months compared with 9.2 months for gemcitabine plus nab-paclitaxel.

These regimens can control disease and extend survival, but they are intensive treatments and can cause substantial toxicity, including fatigue, gastrointestinal symptoms, neuropathy and suppression of blood-cell counts.

That is why a treatment capable of attacking a dominant molecular driver of pancreatic cancer has been a major goal for decades.

KRAS is the central driver in most pancreatic cancers

More than 90% of pancreatic ductal adenocarcinomas contain mutations in genes of the RAS pathway.

Among them, KRAS G12D is the most common individual subtype and is found in roughly 40% of pancreatic cancers.

The mutation leaves KRAS signaling abnormally active, continuously sending signals that encourage cancer cells to grow and survive.

For many years, mutant RAS proteins were considered extremely difficult to drug directly. The emergence of compounds that can bind and inhibit active RAS has therefore become one of the most important developments in modern precision oncology.

Zoldonrasib and daraxonrasib target RAS in different ways

Zoldonrasib, previously known as RMC-9805, is an oral inhibitor designed specifically for tumors carrying the KRAS G12D mutation.

Daraxonrasib, previously known as RMC-6236, is a broader RAS(ON) inhibitor capable of targeting several oncogenic RAS variants.

The rationale for combining them is to apply pressure to the cancer at two levels: one drug is highly selective for KRAS G12D, while the other inhibits a broader range of active RAS proteins.

Researchers hope this dual approach may produce deeper or more durable suppression of RAS signaling than either strategy alone.

That biological rationale is plausible, but whether the combination actually improves survival in newly diagnosed metastatic pancreatic cancer is exactly what RASolute 309 must establish.

Daraxonrasib has already changed the treatment landscape

The new trial comes at an unusually important moment for RAS-targeted therapy in pancreatic cancer.

In August 2026, the U.S. Food and Drug Administration approved daraxonrasib, marketed as RASONQUE, for adults with metastatic pancreatic adenocarcinoma who had received at least one previous systemic therapy or who were not candidates for multiagent systemic therapy.

The approval followed the Phase 3 RASolute 302 trial involving 500 patients with previously treated metastatic disease.

In that study, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy in the overall study population.

Median progression-free survival was 7.2 months versus 3.6 months.

Those results established that direct RAS inhibition could produce a substantial survival benefit in metastatic pancreatic cancer after prior therapy.

RASolute 309 asks a harder question

Success after previous treatment does not automatically mean the same strategy will work best at the beginning of metastatic disease.

First-line patients differ in several important ways. Their tumors have not yet been exposed to systemic therapy, their overall condition may be better, and chemotherapy can still produce substantial responses.

RASolute 309 therefore sets a much higher bar.

The new study is not comparing the experimental combination with placebo. It is comparing it directly with an active standard chemotherapy regimen that has been used for years in metastatic pancreatic cancer.

The trial will enroll only patients with KRAS G12D tumors

Participants must have documented metastatic pancreatic adenocarcinoma carrying a KRAS G12D mutation.

They must not previously have received systemic treatment for locally advanced unresectable or metastatic disease and must have an ECOG performance status of 0 or 1.

Patients will be randomized to one of two groups:

• oral zoldonrasib plus oral daraxonrasib;
• intravenous gemcitabine plus nab-paclitaxel.

The trial is open label, meaning both patients and investigators know which treatment is being given.

Early combination data provided the rationale

The decision to move the doublet into Phase 3 follows early clinical results presented at the 2026 ESMO Gastrointestinal Cancers Congress.

In a Phase 1/2 study, zoldonrasib plus daraxonrasib showed antitumor activity in previously treated patients with KRAS G12D metastatic pancreatic cancer.

In a heavily pretreated third-line-and-beyond cohort of 30 patients, Revolution Medicines reported an objective response rate of 47% and a disease-control rate of 90%.

Median progression-free survival in that small cohort was 7.6 months and median overall survival was 10.5 months.

These results are encouraging, but they come from an early-stage, small and non-randomized dataset. They cannot be assumed to predict what will happen in the new first-line Phase 3 trial.

Why an oral targeted regimen could matter

If the combination ultimately proves superior to chemotherapy, the implications would extend beyond response rates.

Both zoldonrasib and daraxonrasib are taken orally, while gemcitabine and nab-paclitaxel require repeated intravenous infusions.

A successful oral regimen could therefore potentially reduce time spent receiving intravenous chemotherapy and change the day-to-day treatment burden for some patients.

But convenience alone is not enough. In metastatic pancreatic cancer, any new first-line regimen must demonstrate strong survival benefit and an acceptable safety profile before it could displace established chemotherapy.

Targeted treatments have so far helped only selected pancreatic cancer groups

Precision medicine already plays a role in pancreatic cancer, but only for relatively small molecular subgroups.

Patients with inherited or tumor-associated DNA-repair alterations such as BRCA1, BRCA2 or PALB2 may be particularly sensitive to platinum chemotherapy, and some patients can receive PARP-inhibitor maintenance therapy.

Rare tumors with other actionable alterations, including microsatellite instability or certain gene fusions, may also qualify for targeted or immunotherapy approaches.

KRAS G12D is different because it is not rare. It represents one of the largest molecular subgroups in pancreatic cancer.

A successful KRAS G12D-specific first-line strategy could therefore apply precision oncology to a much larger proportion of patients than most currently available biomarker-directed treatments.

The study could mark a shift from chemotherapy-first treatment

The larger significance of RASolute 309 is therefore not simply that two new drugs are being combined.

For decades, metastatic pancreatic cancer has remained a disease in which the initial treatment decision is usually based on which chemotherapy combination a patient can tolerate.

The new trial tests a fundamentally different model: selecting first-line treatment based on a common tumor-driving mutation and attacking that mutation directly with an oral drug combination.

If progression-free and overall survival improve, KRAS testing could become even more important at the moment metastatic pancreatic cancer is diagnosed.

But there are no Phase 3 results yet

RASolute 309 is now recruiting, and approximately 400 participants are planned.

The study will follow overall survival and progression-free survival for up to approximately four years, while also measuring response, safety, laboratory changes and pancreatic-cancer-related quality-of-life outcomes.

The trial registration does not show that zoldonrasib plus daraxonrasib is superior to chemotherapy in first-line treatment.

Daraxonrasib's recent FDA approval applies to a different clinical setting — patients who have already received systemic treatment or are not candidates for multiagent therapy.

Zoldonrasib remains investigational, and the two-drug combination is also investigational as first-line therapy.

The importance of RASolute 309 is that it will test whether the survival benefit already seen with RAS inhibition later in pancreatic cancer can be pushed forward to the point where treatment begins.

Clinical trial: NCT07805954 (RASolute 309).

GSK is moving an experimental mRNA seasonal influenza vaccine into a large Phase 3 efficacy trial, registered as NCT07805707, involving approximately 54,000 adults aged 65 years and older.

The late-stage study follows new Phase 2 results in which the vaccine generated higher immune responses against all influenza strains tested than a licensed high-dose inactivated flu vaccine in older adults.

The crucial next question is whether those stronger immune responses actually translate into fewer cases of influenza and fewer serious flu-related complications.

A Phase 3 trial in 54,000 older adults

GSK's Phase 3 study is designed as a randomized, observer-blind, controlled clinical efficacy trial in adults aged 65 and older.

According to the clinical study register, approximately 54,000 participants are planned. Each participant will receive a single injection of either the investigational mRNA seasonal flu vaccine or a licensed influenza vaccine and will then be followed through the influenza season.

The study is scheduled to run from September 2026 through 2028.

Unlike earlier studies that primarily measured antibody responses, the Phase 3 program is intended to determine whether the vaccine prevents actual laboratory-confirmed influenza illness.

Researchers will also look at serious flu complications

The study will examine more than whether participants test positive for influenza.

Planned outcomes include influenza-related medical visits, prolonged need for oxygen, admission to an intensive care unit and major cardiovascular events occurring in association with influenza.

This is particularly relevant in adults over 65, who have a substantially greater risk of hospitalization and serious complications when they develop influenza.

The trial will also continue to measure immune responses and safety.

Why GSK is moving the vaccine into Phase 3

The decision follows results from the Flu-028 Phase 2 trial, which included 971 adults aged 18 years and older.

Participants received different doses of GSK's experimental multivalent mRNA flu vaccines or licensed age-appropriate influenza vaccines.

GSK reported that its selected candidate generated higher immune responses against all influenza strains evaluated.

Among adults aged 65 and older, the comparison was against a licensed high-dose inactivated influenza vaccine, a type of vaccine specifically used to improve protection in older adults.

The company also reported an acceptable reactogenicity and safety profile in the Phase 2 study.

The vaccine targets two major influenza proteins

One unusual feature of GSK's approach is that the vaccine is designed to target both hemagglutinin, or HA, and neuraminidase, or NA.

Both proteins sit on the surface of influenza viruses but play different roles during infection.

Hemagglutinin helps the virus attach to and enter human cells. Neuraminidase helps newly produced virus particles leave infected cells and spread.

Most currently licensed influenza vaccines are designed primarily around immune responses to hemagglutinin.

GSK's mRNA platform is intended to produce immune responses against both major viral targets.

Why targeting neuraminidase could matter

Influenza vaccines have to contend with a virus that changes continually from season to season.

Antibodies against hemagglutinin are an important component of protection, but researchers have long been interested in neuraminidase as an additional vaccine target.

An immune response against NA could potentially provide another layer of protection by limiting the ability of influenza virus to spread after infection begins.

GSK says its Phase 3 program will be the first late-stage trial of an mRNA seasonal influenza vaccine specifically designed to target both HA and NA.

Whether this approach provides better clinical protection than existing vaccines is still unknown.

Older adults are an especially difficult group to protect

Age is one of the major risk factors for severe influenza.

At the same time, immune responses to vaccination can become weaker with age, a phenomenon associated with immunosenescence.

This is why special influenza vaccines, including high-dose and adjuvanted formulations, are already used for older adults in several countries.

A new vaccine therefore has a relatively high bar to clear: it needs to demonstrate a meaningful advantage against vaccines already optimized for this age group.

Higher antibody responses do not automatically mean better protection

The positive Phase 2 results are encouraging, but they do not yet show that GSK's mRNA vaccine prevents more cases of influenza.

Phase 2 primarily evaluated immunogenicity — how strongly the immune system responded to vaccination.

A vaccine can generate higher antibody levels without necessarily producing a proportionate improvement in protection against symptomatic disease, hospitalization or other complications.

The 54,000-person Phase 3 study is designed to bridge that gap between immune response and real clinical efficacy.

mRNA flu vaccines are now becoming a competitive field

The use of mRNA technology for seasonal influenza accelerated after the large-scale deployment of mRNA vaccines during the COVID-19 pandemic.

The technology can be adapted relatively rapidly when vaccine strains change and allows developers to encode selected viral proteins directly.

GSK is not alone in pursuing the approach.

Moderna has also conducted large Phase 3 studies of an mRNA seasonal influenza vaccine. In a trial published in 2026 involving adults aged 50 and older, Moderna's mRNA-1010 demonstrated greater relative efficacy against laboratory-confirmed influenza than a licensed conventional comparator.

GSK's program is scientifically distinct because its selected candidate is designed to generate immunity against both HA and NA.

The FDA has already given the program Fast Track status

In July 2026, the U.S. Food and Drug Administration granted GSK's investigational seasonal influenza mRNA vaccine Fast Track designation for its targeted indication.

Fast Track status is intended to facilitate development and regulatory review of treatments or vaccines addressing important unmet medical needs.

It does not mean that the vaccine has been approved or that its efficacy has been established.

The Phase 3 trial will provide the decisive evidence

For older adults, the most important outcome is not simply whether a vaccine produces more antibodies.

The key question is whether it prevents more influenza illnesses — and ideally reduces the serious complications that make seasonal flu particularly dangerous in this age group.

With approximately 54,000 participants, the new Phase 3 study is large enough to evaluate those clinical outcomes directly.

If the dual HA-and-NA mRNA approach proves more effective than a licensed flu vaccine, it could provide a new strategy for seasonal influenza prevention in one of the populations most vulnerable to severe disease.

For now, however, GSK's mRNA flu vaccine remains investigational and is not approved anywhere in the world.

Clinical trial registration: NCT07805707 (GSK study 218130).

AstraZeneca has advanced its experimental once-daily oral GLP-1 drug elecoglipron into Phase III development for weight management.

The EMBOLD master protocol, registered as NCT07667803, is expected to enroll approximately 4,500 adults with obesity or overweight, including people both with and without type 2 diabetes.

Elecoglipron is a small-molecule GLP-1 receptor agonist designed to be taken as an oral tablet once daily. Unlike currently available peptide-based oral GLP-1 medicines, AstraZeneca says it does not require strict fasting restrictions when swallowed.

Two pivotal studies will enroll about 4,500 adults

The Phase III master protocol includes two independent randomized, double-blind, placebo-controlled studies.

One study will enroll approximately 3,000 adults with obesity, or overweight plus at least one weight-related condition, who do not have type 2 diabetes.

The second will include approximately 1,500 adults with obesity or overweight and type 2 diabetes.

Participants will receive one of two doses of elecoglipron or placebo alongside diet and physical-activity guidance. The primary endpoint for the trials is the percentage change in body weight after 72 weeks.

What earlier elecoglipron trials found

The move into Phase III follows positive results from two Phase IIb trials presented at the 2026 American Diabetes Association Scientific Sessions and published in The Lancet.

In the VISTA trial, which included 310 adults with obesity or overweight and at least one weight-related condition, participants receiving the 75 mg dose of elecoglipron lost an average of 10.5% of their body weight at 26 weeks, compared with 0.6% with placebo.

Weight loss continued through week 36, reaching an average of 11.8% in one 75 mg dosing regimen compared with 0.3% with placebo. Researchers reported that weight loss had not clearly plateaued by the end of the study.

The drug was also tested in type 2 diabetes

In the SOLSTICE Phase IIb trial, 404 adults with type 2 diabetes received different doses of elecoglipron, placebo or an exploratory open-label oral semaglutide comparator.

At the 75 mg elecoglipron dose, average HbA1c fell by 1.9 percentage points after 26 weeks, compared with 0.2 points with placebo.

Average body weight fell by 7.7% in that elecoglipron group versus 1.7% with placebo. The oral semaglutide arm was included for exploratory purposes and was not designed to establish a definitive head-to-head comparison.

Gastrointestinal side effects remain an important issue

As with other GLP-1 receptor agonists, the most common adverse events were gastrointestinal.

In VISTA, participants receiving the 75 mg dose reported nausea, constipation, diarrhea and vomiting more often than those receiving placebo.

AstraZeneca noted that the Phase II data were used to modify the dose-escalation strategy for Phase III in an effort to improve tolerability.

The larger and longer EMBOLD trials will therefore be crucial for determining not only how much weight people lose, but also how many can remain on treatment and what adverse events emerge over prolonged use.

Why oral GLP-1 drugs are attracting so much attention

GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes, but many of the most widely used agents require subcutaneous injections.

Oral small-molecule drugs could potentially be easier to manufacture at scale and may appeal significantly to patients who prefer tablets over needles.

Several pharmaceutical companies are now developing oral GLP-1 medicines, making this one of the most highly competitive areas in obesity drug development.

Phase III results are still needed

The Phase IIb weight-loss figures should not be treated as established Phase III efficacy.

The earlier studies were substantially smaller and shorter than the new pivotal program. EMBOLD is designed to definitively determine whether elecoglipron can produce durable weight loss over 72 weeks with an acceptable safety and tolerability profile in a much larger population.

AstraZeneca is also planning additional Phase III studies of elecoglipron in type 2 diabetes, as well as trials examining longer-term cardiovascular and kidney outcomes.

Elecoglipron remains an investigational drug and is not currently approved for weight management or type 2 diabetes anywhere in the world.

Clinical trial registration: NCT07667803.

A once-weekly experimental obesity drug is moving into Phase III testing (NCT07794397) for a condition that affects much more than body weight: obstructive sleep apnea (OSA).

The study will evaluate HDM1005 in adults who have both obesity and obstructive sleep apnea and are already receiving positive airway pressure, or PAP, therapy.

Researchers will test whether one year of treatment can reduce both body weight and the frequency of breathing interruptions during sleep.

Two trials for distinct patient groups

NCT07794397 is a multicenter, randomized, double-blind, placebo-controlled Phase III study sponsored by Hangzhou Zhongmei Huadong Pharmaceutical.

It plans to enroll approximately 200 adults. Participants will be randomly assigned in a 1:1 ratio to receive either HDM1005 or placebo by subcutaneous injection once weekly for 52 weeks, followed by four weeks of safety monitoring. All participants will also receive lifestyle counseling on diet and physical activity.

Importantly, the developer has also registered a closely related Phase III study, NCT07787260, in adults with obesity and obstructive sleep apnea who are not receiving PAP therapy. That study also plans to enroll about 200 participants and uses the exact same 52-week treatment period. Together, the two studies will allow researchers to evaluate the drug in two clinically distinct populations.

Both trials are currently listed as not yet recruiting.

Why obesity and sleep apnea are closely connected

Obstructive sleep apnea occurs when the upper airway repeatedly narrows or closes during sleep. The resulting pauses in breathing can repeatedly lower oxygen levels and interrupt sleep, even when the person does not remember waking up.

Obesity is one of the strongest risk factors for OSA. Excess tissue around the upper airway and changes in respiratory mechanics can make airway collapse much more likely during sleep.

Weight loss can therefore improve sleep apnea in some people, although OSA can have multiple causes and does not disappear automatically when body weight falls. This is why clinical trials must prove dual efficacy.

The two primary outcomes for these trials reflect this link: researchers will measure the percentage change in body weight and the change in the apnea-hypopnea index (AHI). The AHI records how many times per hour a person stops breathing completely or has substantially reduced airflow while asleep.

How HDM1005 (poterepatide) works

HDM1005, also known as poterepatide, is an investigational long-acting dual agonist of the GLP-1 and GIP receptors.

These are the same two hormone pathways targeted by tirzepatide, although HDM1005 is a completely different experimental molecule. GLP-1 and GIP signaling can influence appetite, food intake, and glucose metabolism, making the pathway an important target in modern obesity treatment.

The move into Phase III follows earlier studies of HDM1005 in people with obesity. In a randomized Phase II study involving 243 adults with obesity but without diabetes, participants receiving HDM1005 for 22 weeks lost an average of approximately 7.4% to 13.3% of their body weight, depending on the dose (compared to about 2.5% for the placebo group).

Has the drug been proven to treat sleep apnea?

Those earlier Phase II findings concern obesity treatment. They do not establish that HDM1005 improves obstructive sleep apnea.

The idea of treating obesity-related sleep apnea with metabolic drugs is clinically validated: in 2024, the U.S. FDA approved tirzepatide for moderate to severe OSA in adults with obesity. However, the success of one GLP-1/GIP drug does not guarantee that HDM1005 will produce the same results.

HDM1005 must independently prove its own efficacy, optimal dose, and long-term tolerability profile. The registration of these trials marks the beginning of that rigorous testing process.

HDM1005 remains an investigational medicine and is not approved for the treatment of obesity or obstructive sleep apnea. Furthermore, the new studies are not designed to tell patients to stop using PAP; in fact, NCT07794397 specifically evaluates patients while they continue standard PAP therapy.

Clinical trial registrations: NCT07794397 and NCT07787260.

A new randomized clinical study will test whether artificial intelligence can help doctors make faster and more consistent decisions about intravenous thrombolysis for people arriving at the hospital with an acute ischemic stroke.

The ASSIST trial, registered as NCT07785492, plans to enroll 516 adults at primary hospitals in China and is sponsored by Capital Medical University.

Utilizing a randomized parallel design with blinded outcome assessment, the study will add an AI-assisted decision-support tool to physicians’ usual assessment rather than allowing an AI system to make treatment decisions on its own. The results will be compared with standard guideline-based care.

Why speed matters in ischemic stroke

An ischemic stroke occurs when a blood clot blocks blood flow to part of the brain. For eligible patients, intravenous thrombolytic drugs can dissolve the clot and improve the chance of recovery.

However, the treatment is highly time-sensitive, and doctors must rapidly weigh potential benefits against the risk of serious bleeding. Based on 2026 AHA/ASA guidelines, eligible patients presenting within the standard 4.5-hour treatment window should receive intravenous thrombolysis as quickly as possible. Extended-window treatment (up to 24 hours) is considered only for carefully selected patients based on advanced imaging criteria.

This creates a particularly difficult challenge for smaller primary hospitals that see fewer stroke patients or do not have immediate around-the-clock access to specialist stroke expertise.

What the AI tool is supposed to do

The ASSIST study will compare two approaches. In the intervention group, doctors will use their normal clinical assessment together with an AI-assisted thrombolysis decision-support system. In the control group, physicians will follow existing clinical guidelines and hospital protocols without the additional AI tool.

Importantly, the protocol explicitly specifies that neither group is allowed to delay routine emergency care for research purposes. The AI system is therefore intended to function as a clinical support tool—helping organize and interpret relevant information—rather than as an autonomous decision-maker.

The main question: Will more eligible patients receive treatment?

The trial’s primary outcome is the proportion of patients who receive intravenous thrombolysis. Participants must have a clinical diagnosis of acute ischemic stroke, have been last known well less than 24 hours earlier, and undergo CT or MRI to exclude intracerebral hemorrhage.

ASSIST will also examine the time from hospital arrival to intravenous thrombolysis, commonly called door-to-needle time. Because delays can reduce the benefit of reperfusion therapy, researchers will assess whether AI support helps physicians reach treatment decisions more quickly.

Following patients for 90 days

Increasing the number of people who receive thrombolysis would not be meaningful if treatment were given to inappropriate patients or failed to improve clinical outcomes.

The trial includes measures of neurological recovery and disability. Among its secondary outcomes are early neurological improvement and scores on the modified Rankin Scale 90 days after stroke. This scale is widely used to measure disability, ranging from no symptoms to severe disability or death.

Earlier AI stroke systems have shown promise

Clinical decision-support systems have already been studied in stroke care. A large cluster-randomized trial across 77 hospitals in China, known as GOLDEN BRIDGE II, evaluated a broader stroke decision-support system involving 21,603 patients.

That study found improvements in several measures of guideline-based care and fewer new vascular events during follow-up, although it did not show a significant improvement in disability or all-cause mortality at three months. Additionally, prior systematic reviews of AI in stroke have noted significant heterogeneity and challenges in clinical validation.

The trial does not mean AI has been proven to improve stroke care

The registration of NCT07785492 does not show that AI increases appropriate thrombolysis rates, shortens treatment times, or improves recovery after stroke.

Physicians remain fully responsible for determining whether an individual patient is eligible for thrombolysis, and the AI tool is being tested strictly as an additional source of decision support.

If the trial shows that the system helps more appropriate patients receive treatment rapidly without increasing harm, the approach could be particularly relevant to primary hospitals that do not have immediate access to specialist stroke teams.

Clinical trial registration: NCT07785492.

AstraZeneca has advanced its experimental once-daily oral GLP-1 drug elecoglipron into Phase III development for weight management.

The EMBOLD master protocol, registered as NCT07667803, is expected to enroll approximately 4,500 adults with obesity or overweight, including people both with and without type 2 diabetes.

Elecoglipron is a small-molecule GLP-1 receptor agonist designed to be taken as an oral tablet once daily. Unlike currently available peptide-based oral GLP-1 medicines, AstraZeneca says it does not require strict fasting restrictions when swallowed.

Two pivotal studies will enroll about 4,500 adults

The Phase III master protocol includes two independent randomized, double-blind, placebo-controlled studies.

One study will enroll approximately 3,000 adults with obesity, or overweight plus at least one weight-related condition, who do not have type 2 diabetes.

The second will include approximately 1,500 adults with obesity or overweight and type 2 diabetes.

Participants will receive one of two doses of elecoglipron or placebo alongside diet and physical-activity guidance. The primary endpoint for the trials is the percentage change in body weight after 72 weeks.

What earlier elecoglipron trials found

The move into Phase III follows positive results from two Phase IIb trials presented at the 2026 American Diabetes Association Scientific Sessions and published in The Lancet.

In the VISTA trial, which included 310 adults with obesity or overweight and at least one weight-related condition, participants receiving the 75 mg dose of elecoglipron lost an average of 10.5% of their body weight at 26 weeks, compared with 0.6% with placebo.

Weight loss continued through week 36, reaching an average of 11.8% in one 75 mg dosing regimen compared with 0.3% with placebo. Researchers reported that weight loss had not clearly plateaued by the end of the study.

The drug was also tested in type 2 diabetes

In the SOLSTICE Phase IIb trial, 404 adults with type 2 diabetes received different doses of elecoglipron, placebo or an exploratory open-label oral semaglutide comparator.

At the 75 mg elecoglipron dose, average HbA1c fell by 1.9 percentage points after 26 weeks, compared with 0.2 points with placebo.

Average body weight fell by 7.7% in that elecoglipron group versus 1.7% with placebo. The oral semaglutide arm was included for exploratory purposes and was not designed to establish a definitive head-to-head comparison.

Gastrointestinal side effects remain an important issue

As with other GLP-1 receptor agonists, the most common adverse events were gastrointestinal.

In VISTA, participants receiving the 75 mg dose reported nausea, constipation, diarrhea and vomiting more often than those receiving placebo.

AstraZeneca noted that the Phase II data were used to modify the dose-escalation strategy for Phase III in an effort to improve tolerability.

The larger and longer EMBOLD trials will therefore be crucial for determining not only how much weight people lose, but also how many can remain on treatment and what adverse events emerge over prolonged use.

Why oral GLP-1 drugs are attracting so much attention

GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes, but many of the most widely used agents require subcutaneous injections.

Oral small-molecule drugs could potentially be easier to manufacture at scale and may appeal significantly to patients who prefer tablets over needles.

Several pharmaceutical companies are now developing oral GLP-1 medicines, making this one of the most highly competitive areas in obesity drug development.

Phase III results are still needed

The Phase IIb weight-loss figures should not be treated as established Phase III efficacy.

The earlier studies were substantially smaller and shorter than the new pivotal program. EMBOLD is designed to definitively determine whether elecoglipron can produce durable weight loss over 72 weeks with an acceptable safety and tolerability profile in a much larger population.

AstraZeneca is also planning additional Phase III studies of elecoglipron in type 2 diabetes, as well as trials examining longer-term cardiovascular and kidney outcomes.

Elecoglipron remains an investigational drug and is not currently approved for weight management or type 2 diabetes anywhere in the world.

Clinical trial registration: NCT07667803.

A new study will investigate whether cells and DNA collected by washing the uterine cavity can reveal early molecular signals associated with ovarian and fallopian tube cancer risk in women who carry inherited BRCA1 or BRCA2 variants.

The study, registered as NCT07772869, is being conducted by researchers at the University of Washington and Fred Hutchinson Cancer Center.

Participants will undergo uterine cell collection via lavage before their already planned risk-reducing surgery. The collected samples will then be analyzed for genetic changes, particularly mutations in the TP53 gene.

The goal is not to diagnose ovarian cancer from the collected fluid. Instead, researchers are asking whether the molecular signals found in these samples could eventually help identify which BRCA carriers show biological changes associated with greater cancer risk.

Why researchers are looking for material inside the uterus

Many high-grade serous ovarian cancers are now believed to begin not in the ovary itself but in the fallopian tube.

Cells and DNA released from the fallopian tubes can potentially travel into the uterine cavity. Researchers have therefore been studying whether a small volume of fluid used to collect material from the inside of the uterus could capture traces of abnormal cells or tumor-related DNA—a strategy sometimes called organ-adjacent sampling.

This idea has become particularly interesting for high-grade serous carcinoma, the most common and aggressive form of ovarian cancer.

Why BRCA carriers are an important group to study

Inherited pathogenic variants in BRCA1 and BRCA2 substantially increase the lifetime risk of ovarian and fallopian tube cancers as well as breast cancer.

Because there is no screening strategy proven to reliably detect ovarian cancer early and reduce mortality in these women, many BRCA carriers are advised to consider preventive removal of the fallopian tubes and ovaries after completing childbearing and at an age determined by their individual genetic risk.

This creates an unusual research opportunity.

Women undergoing preventive surgery may have no diagnosed cancer, yet their removed fallopian tubes can be examined in detail for microscopic abnormalities that may represent very early steps toward malignancy.

The study will focus on TP53 mutations

One of the key measurements in NCT07772869 is the burden of mutations in TP53, a tumor-suppressor gene that is altered in the vast majority of high-grade serous ovarian cancers.

TP53 mutations can also occur in small populations of cells before an invasive cancer develops.

The researchers plan to compare TP53 mutation patterns found in the collected samples with known cancer risk factors and with cell clusters or abnormalities identified in the fallopian tubes after surgery.

If certain mutation patterns consistently correlate with precancerous or cancer-related changes, they could potentially become part of a future risk-assessment strategy.

Earlier studies found tumor DNA in uterine samples

The concept is supported by previous research showing that tumor-derived DNA can sometimes be detected in material collected from the uterus.

In one study of women undergoing surgery for suspected ovarian cancer, researchers detected the matching tumor mutation in about 65% of ovarian cancer cases overall.

Detection was higher for serous cancers, where the corresponding mutation was found in 11 of 14 cases, or 79%.

However, detection was much lower in non-serous cancers, and the samples also contained many background mutations not clearly related to malignancy. Those findings showed both the promise and the difficulty of the approach.

Other approaches are also being explored. For example, data presented at the 2026 ASCO meeting highlighted another technique analyzing specific proteins (extracellular vesicles) rather than DNA from uterine washings, emphasizing that the uterine cavity is a highly active frontier for ovarian cancer research.

Collecting these cells is not yet an ovarian cancer screening test

The presence of a TP53 mutation does not automatically mean that a woman has ovarian cancer or will develop it.

Previous studies have found multiple somatic mutations in uterine samples from women without cancer, making it difficult to distinguish harmless age-related or background changes from truly dangerous clones.

Researchers therefore need to understand not only whether mutations are present, but also their frequency, pattern and relationship to pathological findings in the fallopian tubes.

NCT07772869 is designed to investigate those associations.

The study does not change current recommendations for BRCA carriers

The registration of this study should not be interpreted as evidence that this collection method can replace preventive surgery or established genetic-risk management.

Women participating in the research are already scheduled for standard-of-care risk-reducing surgery.

The cell collection is being used strictly as a research procedure to gather biological material before that operation.

If the study identifies a reliable molecular signature, much larger prospective studies would still be needed before this approach could be considered for routine cancer screening or risk prediction.

Clinical trial registration: NCT07772869.

Researchers are preparing a Phase 2 clinical trial that will test several new drug combinations for pulmonary tuberculosis, bringing together some of the most closely watched experimental medicines in the global TB pipeline.

The study, registered as NCT07773610, is sponsored by TASK Applied Science and is currently listed as not yet recruiting.

Its treatment arms include combinations involving experimental drugs such as TBAJ-587, BTZ-043, quabodepistat, and ganfeborole, together with established or more advanced tuberculosis medicines including pretomanid and linezolid.

The study also includes the standard HRZE regimen—isoniazid, rifampicin, pyrazinamide, and ethambutol—as a reference treatment.

Why tuberculosis still needs new drugs

Tuberculosis remains one of the world’s deadliest infectious diseases despite being both preventable and curable.

According to the World Health Organization, an estimated 10.7 million people developed TB in 2024 and approximately 1.23 million died from the disease, including people living with HIV.

One of the major challenges is treatment itself. Standard therapy for drug-susceptible pulmonary tuberculosis traditionally requires several antibiotics taken together for months.

Drug-resistant disease can be even more difficult to treat, although newer all-oral regimens have substantially improved options in recent years.

Researchers are therefore trying to build regimens that kill Mycobacterium tuberculosis more rapidly while reducing toxicity, treatment duration, and the opportunity for resistance to emerge.

The study combines drugs that attack TB in different ways

The compounds included in the new trial are particularly interesting because they target different biological processes that the tuberculosis bacterium needs to survive.

TBAJ-587 is a next-generation diarylquinoline related to bedaquiline. Drugs in this class interfere with the bacterial ATP synthase system, disrupting energy production in M. tuberculosis.

BTZ-043 targets an enzyme known as DprE1, which is required for the construction of the mycobacterial cell wall.

Quabodepistat, also known as OPC-167832, is another DprE1 inhibitor that has already demonstrated early bactericidal activity in human studies.

Ganfeborole is an experimental antibacterial compound with a different target and has also progressed through early clinical studies in people with pulmonary tuberculosis.

Combining drugs with different mechanisms is central to TB treatment because using several active agents simultaneously reduces the chance that resistant bacteria will survive.

Pretomanid and linezolid provide an important bridge to existing treatment

The trial also incorporates drugs that are already much further along in tuberculosis medicine.

Pretomanid is already part of WHO-recommended regimens for some forms of multidrug- and rifampicin-resistant tuberculosis.

Linezolid is also an important component of several modern drug-resistant TB regimens, although prolonged exposure can cause clinically significant adverse effects, including peripheral neuropathy and bone marrow toxicity.

The combination of bedaquiline, pretomanid, and linezolid previously transformed the treatment of highly drug-resistant TB by allowing some patients to be treated with a shorter, all-oral regimen.

The new study reflects the next stage of that strategy: replacing or combining existing drugs with newer compounds that could potentially maintain strong antibacterial activity while improving safety or shortening treatment further.

Several of the experimental drugs are already in the WHO pipeline

The World Health Organization tracks all four major experimental compounds included in the study among new chemical entities under clinical development for tuberculosis.

WHO has identified the development of shorter, safer, and more effective TB treatment regimens as a major research priority.

This is particularly important because new drugs cannot usually be developed for tuberculosis in isolation. Effective treatment requires combinations that work together against the bacterium and minimize resistance.

Why early bactericidal activity matters

Phase 2 tuberculosis studies frequently look at how quickly a treatment reduces viable bacteria in a patient’s sputum during the first days or weeks of therapy.

This measure, known as early bactericidal activity, helps researchers identify which drugs and combinations are promising enough to move into longer treatment trials.

A strong early antibacterial effect, however, does not automatically mean that a regimen will cure tuberculosis more reliably or allow treatment to be safely shortened.

Those questions require larger and substantially longer studies that measure treatment failure, relapse, and safety after therapy is completed.

The standard HRZE regimen remains an important benchmark

For drug-susceptible tuberculosis, the long-established first-line regimen uses four drugs during the initial phase of treatment: isoniazid, rifampicin, pyrazinamide, and ethambutol, commonly abbreviated as HRZE.

Comparing experimental combinations with a standard regimen provides researchers with a benchmark for how quickly the new therapies suppress the bacteria and what adverse effects occur.

But the registration of the Phase 2 trial does not mean that any of the experimental combinations can currently replace standard treatment.

No new treatment regimen has yet been proven

NCT07773610 is an early-stage regimen-development study. It does not yet show that TBAJ-587, BTZ-043, quabodepistat, or ganfeborole can shorten routine tuberculosis therapy.

It also does not establish that any of the experimental combinations are safer or more effective than current treatment.

The purpose of the Phase 2 study is to identify which combinations have sufficient antibacterial activity and acceptable safety to justify larger confirmatory trials.

If successful, the program could help determine which of the current generation of experimental TB drugs should be combined in future treatment-shortening regimens.

Clinical trial registration: NCT07773610.

AstraZeneca has advanced its experimental once-daily oral GLP-1 drug elecoglipron into Phase III development for weight management.

The EMBOLD master protocol, registered as NCT07667803, is expected to enroll approximately 4,500 adults with obesity or overweight, including people both with and without type 2 diabetes.

Elecoglipron is a small-molecule GLP-1 receptor agonist designed to be taken as an oral tablet once daily. Unlike currently available peptide-based oral GLP-1 medicines, AstraZeneca says it does not require strict fasting restrictions when swallowed.

Two pivotal studies will enroll about 4,500 adults

The Phase III master protocol includes two independent randomized, double-blind, placebo-controlled studies.

One study will enroll approximately 3,000 adults with obesity, or overweight plus at least one weight-related condition, who do not have type 2 diabetes.

The second will include approximately 1,500 adults with obesity or overweight and type 2 diabetes.

Participants will receive one of two doses of elecoglipron or placebo alongside diet and physical-activity guidance. The primary endpoint for the trials is the percentage change in body weight after 72 weeks.

What earlier elecoglipron trials found

The move into Phase III follows positive results from two Phase IIb trials presented at the 2026 American Diabetes Association Scientific Sessions and published in The Lancet.

In the VISTA trial, which included 310 adults with obesity or overweight and at least one weight-related condition, participants receiving the 75 mg dose of elecoglipron lost an average of 10.5% of their body weight at 26 weeks, compared with 0.6% with placebo.

Weight loss continued through week 36, reaching an average of 11.8% in one 75 mg dosing regimen compared with 0.3% with placebo. Researchers reported that weight loss had not clearly plateaued by the end of the study.

The drug was also tested in type 2 diabetes

In the SOLSTICE Phase IIb trial, 404 adults with type 2 diabetes received different doses of elecoglipron, placebo or an exploratory open-label oral semaglutide comparator.

At the 75 mg elecoglipron dose, average HbA1c fell by 1.9 percentage points after 26 weeks, compared with 0.2 points with placebo.

Average body weight fell by 7.7% in that elecoglipron group versus 1.7% with placebo. The oral semaglutide arm was included for exploratory purposes and was not designed to establish a definitive head-to-head comparison.

Gastrointestinal side effects remain an important issue

As with other GLP-1 receptor agonists, the most common adverse events were gastrointestinal.

In VISTA, participants receiving the 75 mg dose reported nausea, constipation, diarrhea and vomiting more often than those receiving placebo.

AstraZeneca noted that the Phase II data were used to modify the dose-escalation strategy for Phase III in an effort to improve tolerability.

The larger and longer EMBOLD trials will therefore be crucial for determining not only how much weight people lose, but also how many can remain on treatment and what adverse events emerge over prolonged use.

Why oral GLP-1 drugs are attracting so much attention

GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes, but many of the most widely used agents require subcutaneous injections.

Oral small-molecule drugs could potentially be easier to manufacture at scale and may appeal significantly to patients who prefer tablets over needles.

Several pharmaceutical companies are now developing oral GLP-1 medicines, making this one of the most highly competitive areas in obesity drug development.

Phase III results are still needed

The Phase IIb weight-loss figures should not be treated as established Phase III efficacy.

The earlier studies were substantially smaller and shorter than the new pivotal program. EMBOLD is designed to definitively determine whether elecoglipron can produce durable weight loss over 72 weeks with an acceptable safety and tolerability profile in a much larger population.

AstraZeneca is also planning additional Phase III studies of elecoglipron in type 2 diabetes, as well as trials examining longer-term cardiovascular and kidney outcomes.

Elecoglipron remains an investigational drug and is not currently approved for weight management or type 2 diabetes anywhere in the world.

Clinical trial registration: NCT07667803.

A new Phase 3 clinical trial will test whether AXS-05, a combination of dextromethorphan and bupropion, can improve smoking cessation in adults compared with both placebo and bupropion alone.

The study, registered as NCT07766655, plans to enroll approximately 705 adults aged 18 to 65.

Participants will be randomly assigned in equal numbers to receive AXS-05, bupropion or placebo for 12 weeks, followed by an 18-week follow-up period.

Why compare AXS-05 with bupropion?

Bupropion is already an established prescription treatment used to help people stop smoking.

AXS-05 combines bupropion with dextromethorphan, a drug better known as a cough suppressant but which also acts on several signaling systems in the brain.

The central question in the new trial is whether the combination provides an advantage over bupropion alone when people try to quit cigarettes.

Because the study includes both an active comparator and a placebo group, researchers should be able to determine not only whether AXS-05 works better than no active drug, but also whether adding dextromethorphan provides clinically meaningful additional benefit.

How AXS-05 works

AXS-05 contains fixed doses of dextromethorphan and bupropion.

Bupropion affects norepinephrine and dopamine signaling and also antagonizes nicotinic acetylcholine receptors, mechanisms that are relevant to nicotine dependence and withdrawal.

Dextromethorphan has additional effects on NMDA receptors, sigma-1 receptors and other neurotransmitter systems.

Bupropion also inhibits the CYP2D6 enzyme that normally breaks down dextromethorphan quickly, increasing the amount of dextromethorphan available in the body.

Researchers have proposed that these combined effects could influence nicotine craving, withdrawal symptoms and the learned behaviors associated with smoking.

Earlier studies suggested a signal

The Phase 3 program follows earlier clinical work in smoking cessation.

In a previous Phase 2 study conducted in collaboration with Duke University, AXS-05 was associated with a greater reduction in the average number of cigarettes smoked per day compared with bupropion.

Company-reported data indicated an approximately 25% greater reduction in cigarettes per day with AXS-05 than with bupropion.

Those results provided a rationale for moving into a larger Phase 3 study, but reducing cigarette consumption is not the same as achieving sustained abstinence.

The real endpoint is whether people can stay smoke-free

Smoking-cessation trials are challenging because many people can stop temporarily but relapse within weeks or months.

For that reason, a treatment that reduces the number of cigarettes smoked is not necessarily a successful cessation therapy.

The more important clinical question is whether AXS-05 can help a greater proportion of participants achieve and maintain abstinence over time.

The 18-week follow-up after treatment should help researchers assess whether any benefit persists after the active medication period ends.

Why better smoking-cessation treatments matter

Cigarette smoking remains a major preventable cause of disease and premature death.

Long-term smoking substantially increases the risk of lung and other cancers, chronic obstructive pulmonary disease, heart attack, stroke and peripheral vascular disease.

Many smokers want to quit, but nicotine dependence and withdrawal make sustained cessation difficult, and relapse is common even when medications and behavioral support are used.

A treatment that produces a meaningful improvement over existing options could therefore have substantial public-health importance.

AXS-05 is already used for another condition

The dextromethorphan-bupropion combination is already marketed in the United States under the brand name Auvelity for the treatment of major depressive disorder.

That approval does not establish that the drug is effective for smoking cessation.

The dose, patient population, treatment goals and outcomes being tested in the new trial are specific to nicotine dependence.

AXS-05 should therefore still be considered an investigational treatment for smoking cessation.

The study has not yet shown that AXS-05 helps people quit

NCT07766655 is currently a Phase 3 trial, and no efficacy results from this study have been reported.

The registration of the study should not be interpreted as evidence that AXS-05 is better than bupropion or that it has been proven to increase long-term quit rates.

The value of the trial is precisely that it will test those questions in a larger randomized population.

If AXS-05 demonstrates a clear benefit over bupropion with an acceptable safety profile, it could provide a new pharmacological strategy for people who struggle to stop smoking with existing treatments.

Clinical trial registration: NCT07766655.

Researchers are launching a new clinical trial to compare an investigational knee injection, known as 2107, with a standard therapy—a product called Durolane.

The study, registered as NCT07746843, will enroll people with mild to moderate knee osteoarthritis.

The goal of the research is to determine whether the experimental development can provide more significant pain relief and improved mobility compared to an established treatment already on the market.

Why knee osteoarthritis is a massive problem

Knee osteoarthritis becomes increasingly common with age and is one of the leading causes of chronic pain and mobility limitation in adults.

The disease develops gradually: the cartilage protecting the bone thins out, and the internal structures of the joint undergo degenerative changes. Symptoms include pain when walking or climbing stairs, morning stiffness, swelling, and a reduction in physical activity.

Treatment usually begins with physical therapy and weight management. When this is not enough, doctors use medications and, in some cases, offer intra-articular injections to help delay the need for surgical intervention.

The standard of care: How hyaluronic acid works

Durolane, which serves as the active comparator in the study, contains stabilized hyaluronic acid and is administered into the affected joint as a single injection.

Hyaluronic acid is naturally present in human synovial fluid, acting as a lubricant and shock absorber. Injections using its substitutes are used for symptomatic treatment: they aim to reduce friction, relieve pain, and improve joint function.

However, it is crucial to understand that this is symptomatic support. These treatments do not grow new cartilage or eliminate the underlying cause of joint wear and tear.

Why compare a new injection with an older one?

Using an established hyaluronic acid product as a control is an important step in clinical trials. It allows researchers to test the experimental drug not just against a placebo, but against a real-world therapy that patients already receive in clinics.

For patients, the clinically important questions are very straightforward: does the new injection reduce pain more effectively, does it improve daily activities, how long does the effect last, and what adverse reactions might occur?

Focusing on pain relief, not regrowing cartilage

Trials of new injections often measure various biological markers, but the ultimate measure of success remains the patient's wellbeing.

Even if a drug reduces inflammation inside the knee, it only has practical value if it makes walking easier and reduces the need for oral painkillers.

Based on public registry data, neither Durolane nor the experimental 2107 injection are claimed to reverse osteoarthritis or restore destroyed tissue.

What cannot be claimed yet

The launch of the NCT07746843 study is not proof that the 2107 injection is effective or superior to hyaluronic acid.

Until the clinical trial is completed and the results are published, it is impossible to say whether the new approach offers any advantages. If the experimental drug turns out to be comparable to or worse than the standard, it will still be an important scientific finding that shows the limits of current developments.

At this stage, the study represents a test of a new tool for symptom control, the results of which are yet to be seen.

Clinical trial registration: NCT07746843.

A new Phase 2 clinical trial will test whether nicotinamide riboside, a compound that raises levels of nicotinamide adenine dinucleotide, or NAD+, can influence the course of early Alzheimer’s disease.

The study, registered as NCT07741071, plans to enroll approximately 270 participants and follow them for about two years.

The unusually long treatment period is important because earlier human studies of nicotinamide riboside in cognitive impairment have generally been small and short. Those studies have shown that the compound can increase NAD+ levels, but they have not established that doing so improves memory or slows Alzheimer’s disease.

Why researchers are interested in NAD+

NAD+ is a molecule required for many basic cellular processes, including energy production, mitochondrial function, DNA repair and cellular stress responses.

NAD+ levels tend to decline with age, and abnormalities in energy metabolism and mitochondrial function have been linked to neurodegenerative diseases, including Alzheimer’s disease.

This has led researchers to investigate whether increasing NAD+ availability could improve cellular resilience in the aging brain.

Nicotinamide riboside, or NR, is a precursor that the body can use to produce NAD+. It is already sold commercially as a dietary supplement, which has contributed to strong public interest in the compound.

But raising NAD+ is not the same as treating Alzheimer’s

One of the central unanswered questions is whether increasing NAD+ levels leads to clinically meaningful changes in the brain.

A recently published randomized Phase 2 pilot study in older adults with amnestic mild cognitive impairment found that 12 weeks of nicotinamide riboside approximately doubled blood NAD+ levels.

However, the treatment did not improve the study’s primary cognitive outcome. Researchers also found no significant improvement in overall cerebral blood flow or blood pressure, although exploratory analyses suggested possible changes in blood flow in some brain regions, including the hippocampus.

The study was small, with 42 participants completing treatment, and was not designed to determine long-term effects on Alzheimer’s progression.

A longer trial could answer a different question

The new NCT07741071 study is substantially larger and will treat participants for approximately two years rather than several weeks.

That distinction matters because Alzheimer’s disease progresses slowly. A treatment that aims to alter neurodegeneration may need to be studied over many months or years before differences in cognition, daily functioning or biomarkers can be detected.

The study focuses on people with early Alzheimer’s disease, a stage at which researchers increasingly try to intervene before extensive neuronal loss has occurred.

Previous human evidence remains mixed and preliminary

Nicotinamide riboside has already been studied in several small trials involving mild cognitive impairment and Alzheimer’s disease.

An earlier randomized pilot involving 20 people with mild cognitive impairment showed that NR could substantially increase blood NAD+ and appeared to be tolerated, but it did not establish cognitive benefit.

Another crossover study in people with subjective cognitive decline or mild cognitive impairment evaluated 1 gram of NR per day for eight weeks and examined cognition and Alzheimer’s-related blood biomarkers.

Separately, an ongoing dose-optimization study in Alzheimer’s disease has been examining whether doses ranging from 1,000 to 3,000 mg per day can increase NAD+ within the central nervous system and alter brain metabolism.

Together, these studies support the biological feasibility of increasing NAD+, but they do not yet show that nicotinamide riboside slows Alzheimer’s disease.

Nicotinamide riboside is not the same as nicotinamide

The terminology can also be confusing.

Nicotinamide riboside and nicotinamide are related forms of vitamin B3 metabolism, but they are not interchangeable treatments.

A separate Phase 2a study tested high-dose nicotinamide in people with mild cognitive impairment or mild Alzheimer’s dementia. After 48 weeks, nicotinamide did not significantly improve the trial’s primary cerebrospinal-fluid tau biomarker or several other Alzheimer’s biomarkers.

Those findings cannot be directly applied to nicotinamide riboside, but they illustrate why promising effects on cellular pathways need to be tested against meaningful clinical outcomes.

The supplement market is far ahead of the evidence

NAD+ precursors have become popular in the commercial longevity and anti-aging market, where they are often promoted for energy, brain health or healthy aging.

Clinical evidence in Alzheimer’s disease remains far more limited than those marketing claims might suggest.

The fact that nicotinamide riboside is available as a supplement does not mean that commercially available products have been shown to prevent dementia or treat Alzheimer’s disease.

The dose, duration, patient population and clinical monitoring used in a research trial can also differ substantially from consumer supplement use.

What this Phase 2 study could tell us

The importance of NCT07741071 lies in its scale and duration.

With 270 participants treated for two years, researchers may be able to determine whether sustained manipulation of NAD+ metabolism produces measurable effects on cognitive decline, daily function or Alzheimer’s-related biological markers.

A positive signal would justify larger confirmatory studies. A negative result would also be important, because it would help determine whether raising NAD+ is biologically interesting but insufficient to alter the clinical course of Alzheimer’s disease.

For now, the study should be viewed as a test of a promising metabolic hypothesis — not evidence that an NAD+ supplement can prevent or reverse dementia.

Clinical trial registration: NCT07741071.

A large Phase 3 clinical trial is testing whether doctors should begin treating high blood pressure earlier in pregnant women who develop gestational hypertension or preeclampsia.

The GOALPOST trial, registered as NCT07746271, is expected to enroll approximately 4,120 pregnant women with pregnancy-associated hypertension that has not yet reached the severe range.

Participants will be randomly assigned to two blood pressure strategies: one that starts or adjusts medication to keep blood pressure below 140/90 mmHg, and another reflecting the more traditional approach of treating when pressure reaches the severe threshold of 160/110 mmHg.

The central question is whether earlier blood pressure treatment can reduce complications for mothers and babies without creating new risks.

Why doctors have been cautious about lowering blood pressure in pregnancy

High blood pressure during pregnancy can be dangerous, but treating it involves a delicate balance.

Very high maternal blood pressure increases the risk of serious complications including stroke and other organ injury. At the same time, doctors have historically worried that lowering blood pressure too much could reduce blood flow through the placenta and potentially affect fetal growth or wellbeing.

That concern has made the optimal treatment threshold for pregnancy-associated hypertension one of the unresolved questions in obstetric medicine.

GOALPOST is designed to provide much stronger evidence about where that threshold should be.

Who will be included in GOALPOST?

The trial focuses on women who develop gestational hypertension or preeclampsia without severe features during pregnancy.

Gestational hypertension generally refers to new high blood pressure developing after 20 weeks of pregnancy without evidence of organ damage. Preeclampsia involves hypertension together with signs that other organs or biological systems may be affected.

Severe disease can include blood pressure of at least 160/110 mmHg or evidence of significant organ dysfunction.

The women enrolled in GOALPOST are therefore in an important clinical middle ground: their blood pressure is abnormal, but they have not yet reached the severe category that clearly requires urgent management.

The trial compares two blood pressure targets

Women in the study will be randomized to one of two management strategies.

In the earlier-treatment group, antihypertensive medication will be used with the goal of maintaining blood pressure below 140/90 mmHg.

In the comparison group, medication will generally be initiated or intensified when blood pressure becomes severely elevated, reaching 160 mmHg systolic or 110 mmHg diastolic.

The trial is being conducted through the U.S. Maternal-Fetal Medicine Units Network supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Could earlier treatment help pregnancies last longer?

One of the reasons the question matters is that worsening hypertension or preeclampsia can make continuing a pregnancy unsafe.

When severe disease develops, doctors may need to deliver the baby early to protect the mother, even when the fetus would benefit from more time in the womb.

Researchers want to know whether controlling blood pressure before it reaches the severe range can stabilize maternal health and allow some pregnancies to continue safely for longer.

If that happens, earlier treatment could potentially reduce medically indicated preterm births and some neonatal intensive care admissions.

However, these are outcomes the study is designed to test. GOALPOST has not yet shown that tighter blood pressure control prevents preterm birth or improves neonatal outcomes.

Earlier research changed treatment of chronic hypertension in pregnancy

GOALPOST builds on an important shift that has already occurred in the treatment of chronic hypertension during pregnancy.

The CHAP trial, which enrolled more than 2,400 pregnant women with mild chronic hypertension, found that treating blood pressure to below 140/90 mmHg reduced a composite of serious pregnancy complications compared with waiting for severe hypertension.

Importantly, the strategy did not significantly increase the proportion of babies who were small for gestational age.

Those results helped change clinical practice for women who already had chronic hypertension before or early in pregnancy.

But gestational hypertension and preeclampsia are different conditions. They develop during pregnancy and can reflect an evolving disease process involving the placenta and multiple maternal organs.

Doctors therefore cannot simply assume that the strategy proven beneficial for chronic hypertension will produce the same results in women who develop hypertension later in pregnancy.

There is also a concern that treatment could hide worsening disease

Blood pressure is not only a risk factor in preeclampsia; a rapid or severe rise can also be a warning sign that the condition is progressing.

One concern is that antihypertensive medication could lower the measured blood pressure while the underlying disease continues to worsen.

Researchers will therefore need to determine whether earlier treatment improves outcomes without masking clinical signals that would otherwise prompt closer monitoring or delivery.

Why a trial of more than 4,000 women matters

Previous studies of tighter versus less intensive blood pressure control in pregnancy have left uncertainty about the best strategy for women with pregnancy-associated hypertension.

A Phase 3 randomized trial involving more than 4,000 participants should be large enough to examine clinically important maternal and newborn outcomes rather than blood pressure alone.

The findings could help answer whether preventing progression to severe hypertension also translates into fewer serious maternal complications, fewer premature deliveries and better outcomes for newborns.

Current treatment should not change because of the trial registration

The launch of GOALPOST does not establish that all pregnant women with gestational hypertension or preeclampsia should now have their blood pressure lowered below 140/90 mmHg.

The study exists because the balance of benefits and risks has not yet been definitively established for this population.

Hypertensive disorders of pregnancy can deteriorate quickly and require individualized medical monitoring. Decisions about medication, hospitalization and timing of delivery depend on blood pressure as well as symptoms, laboratory findings, fetal condition and gestational age.

If GOALPOST demonstrates a clear benefit without increased fetal or neonatal harm, its results could ultimately affect recommendations for one of the most common medical complications of pregnancy.

Clinical trial registration: NCT07746271.

Researchers are preparing a large study of a new approach to multi-cancer detection that looks for changes in the way DNA is chemically modified rather than searching only for individual cancer mutations.

The study, registered as NCT07741435, plans to include approximately 3,250 participants and evaluate a technology known as Methylscape using samples including blood, urine and saliva.

The project will include people with several common cancers, including cancers of the breast, lung, stomach, cervix and colorectum, as well as urologic and head and neck cancers.

The goal is to determine whether cancer-associated patterns of DNA methylation can distinguish people with cancer from those without it across different tumor types and sample sources.

What is DNA methylation?

DNA methylation is an epigenetic process in which small chemical groups called methyl groups are added to DNA. These changes do not alter the underlying DNA sequence, but they can influence how genes are regulated.

Cancer cells often show extensive changes in DNA methylation. Some regions of the genome become abnormally methylated while others lose methylation, creating patterns that differ from those seen in normal cells.

Researchers have been investigating whether these cancer-associated methylation changes can serve as biomarkers for detecting malignancy.

What makes the Methylscape approach different?

Methylscape was originally developed around the observation that cancer genomes can share a distinctive overall methylation landscape.

Instead of identifying only one particular mutation or one cancer-specific protein, the approach examines broader properties created by the distribution of methylation across DNA.

Laboratory studies have shown that these methylation differences can alter how DNA behaves in solution and how it interacts with certain surfaces, including gold. Researchers have used those properties to distinguish cancer-derived DNA from normal DNA in experimental assays.

This raises the possibility of developing relatively simple tests that detect a general cancer-associated signal without sequencing an entire tumor genome.

Why blood, urine and saliva are especially interesting

Many liquid-biopsy approaches focus on blood because tumors can release fragments of DNA into the circulation.

The new study is notable because it will also investigate other easily collected body fluids, including urine and saliva.

If a reproducible cancer-associated signal can eventually be detected in these samples, the approach could potentially make some forms of testing less invasive and easier to perform.

However, that possibility remains experimental. A tumor may release very different amounts of DNA into blood, urine or saliva depending on its location, size and stage.

A method that performs well in one sample type therefore may not necessarily work equally well in another.

Seven broad cancer groups are included

The study is designed to evaluate the technology across a wide range of malignancies rather than focusing on a single tumor.

The cancer groups include:

• breast cancer;
• lung cancer;
• gastric cancer;
• cervical cancer;
• colorectal cancer;
• urologic cancers;
• head and neck cancers.

This broad design is important for a potential multi-cancer detection test. A signal that appears only in one or two tumor types would have much more limited screening value than one that performs consistently across cancers.

The key question is not whether cancer DNA exists in these fluids

Cancer-related DNA changes have already been detected in blood and other body fluids in previous research.

The more difficult clinical question is whether a test can identify cancer with sufficient sensitivity and specificity to be useful in real patients.

High sensitivity means detecting a large proportion of people who actually have cancer. High specificity means avoiding positive results in people who do not.

For cancer screening, even a modest false-positive rate can become important when a test is applied to millions of otherwise healthy people, because positive results may lead to imaging, biopsies and additional invasive procedures.

Early-stage cancers will be the most important test

One of the biggest challenges for liquid biopsy is detecting small, early-stage tumors.

Advanced cancers often release substantially more tumor-derived DNA into body fluids, making them easier to identify. Early tumors may release only very small amounts.

For that reason, the eventual value of Methylscape will depend not only on whether it can distinguish cancer from non-cancer samples overall, but also on how accurately it performs in patients with early-stage disease.

This is not yet a saliva test for cancer

The registration of the study does not mean that doctors can currently diagnose multiple cancers from a saliva, urine or blood sample using Methylscape.

The study is being conducted to establish whether the technology performs reliably enough across different cancers, disease stages and biological samples.

It also does not mean that a positive methylation signal can automatically reveal where a cancer is located.

Earlier research on Methylscape has specifically noted that the approach, in its experimental form, could indicate the presence of a cancer-associated DNA pattern without necessarily identifying the precise tumor type or stage.

Why the study could matter

Multi-cancer early detection is one of the most active areas of cancer diagnostics.

Several experimental tests already use circulating tumor DNA, methylation patterns or combinations of molecular signals to look for multiple cancers from a single blood sample.

A platform that could work across several body fluids and require relatively simple analysis could potentially broaden access to this type of testing.

But the new Methylscape study is an evaluation step, not a clinical breakthrough already achieved.

The most important results will be whether the assay can maintain high specificity while detecting clinically meaningful cancers — particularly early-stage disease — and whether its performance remains consistent across blood, urine and saliva.

Clinical trial registration: NCT07741435.

A new once-daily oral GLP-1 drug for obesity has moved into late-stage clinical development, with two large Phase 3 trials designed to enroll more than 4,500 adults with obesity or overweight. The launch aligns with the company's previously stated plans to initiate Phase 3 studies by the third quarter of 2026.

The experimental drug, called ASC30, is a small-molecule GLP-1 receptor agonist developed by Ascletis Pharma. Unlike injectable GLP-1 medicines, ASC30 is being developed as a tablet taken once a day.

The two studies are part of the AURORA Phase 3 program and will separately evaluate people with and without type 2 diabetes.

More than 4,500 people are planned for the Phase 3 program

According to the newly registered study records, one Phase 3 trial, NCT07743463, plans to enroll approximately 3,003 adults with obesity or overweight who do not have type 2 diabetes.

A second trial, NCT07743450, is expected to include approximately 1,560 adults with obesity or overweight and type 2 diabetes.

Together, the two studies are therefore expected to involve around 4,563 participants.

The trials are designed to evaluate once-daily oral ASC30 over approximately 72 weeks. Earlier company materials describing the Phase 3 program indicated that maintenance doses of 20 mg, 40 mg and 60 mg would be studied, with gradual dose escalation lasting up to 20 weeks.

What is ASC30?

ASC30 is an investigational small-molecule GLP-1 receptor agonist. Drugs targeting the GLP-1 pathway can reduce appetite and food intake and have become an important treatment class for obesity and type 2 diabetes.

Most of the best-known GLP-1 obesity medicines have historically been given by injection. An effective oral small-molecule treatment could offer an alternative for people who prefer tablets or have difficulty using injectable therapies.

ASC30 is designed to be taken once daily and, as a small molecule, differs structurally from peptide-based GLP-1 drugs such as semaglutide.

What earlier trials found

The decision to advance ASC30 into Phase 3 follows shorter Phase 1 and Phase 2 studies.

In a 13-week U.S. Phase 2 study involving adults with obesity or overweight, Ascletis reported dose-dependent reductions in body weight. At the highest maintenance dose studied, ASC30 produced a 7.7% placebo-adjusted mean reduction in body weight after 13 weeks.

The 20 mg and 40 mg maintenance doses were associated with placebo-adjusted reductions of approximately 5.4% and 7.0%, respectively. These Phase 2 results were initially reported in December 2025 and subsequently presented at the American Diabetes Association (ADA) 2026 scientific sessions.

The company also reported that weight loss had not clearly reached a plateau by week 13, which is one reason longer trials are needed to determine the full magnitude and durability of the effect.

Gastrointestinal side effects remain important

As with other GLP-1 receptor agonists, gastrointestinal adverse events are an important part of ASC30's safety evaluation.

In the Phase 2 study, nausea, vomiting, diarrhea and constipation were reported at varying frequencies depending on the dose. Ascletis has said that slower dose escalation may improve gastrointestinal tolerability.

However, comparisons with other GLP-1 medicines should be interpreted cautiously. Results from separate clinical trials cannot establish that one drug is safer or better tolerated than another unless they are compared directly under the same study conditions.

Why the Phase 3 trials matter

Phase 3 is the stage at which an experimental treatment is tested in much larger patient populations and over substantially longer periods before regulators can consider whether its benefits outweigh its risks.

For an obesity medicine, researchers need to determine not only how much weight participants lose, but also whether the effect persists and what adverse events emerge during prolonged use.

The inclusion of a separate study in people with type 2 diabetes is also important because weight-loss responses and metabolic outcomes can differ between people with and without diabetes.

ASC30 is not yet an approved obesity treatment

The launch or registration of a Phase 3 program does not mean that ASC30 has been proven effective or approved for routine treatment.

The strongest efficacy figures currently available come from earlier, much shorter trials. The new AURORA studies are intended to establish whether those findings can be reproduced in thousands of participants over a substantially longer treatment period.

Only after Phase 3 data become available will it be possible to judge more reliably how ASC30 compares with established and emerging obesity medicines in terms of weight loss, tolerability and long-term safety.

Clinical trial registrations: NCT07743463 and NCT07743450.

A daily prebiotic fiber supplement reduced knee pain and improved several measures of physical function in people with knee osteoarthritis, according to a randomized clinical trial led by researchers at the University of Nottingham.

The study tested inulin, a type of soluble dietary fiber that feeds certain bacteria in the gut. The findings suggest that modifying the gut microbiome may influence not only digestion, but also pain processing and muscle function.

What the researchers tested

The six-week INSPIRE trial involved adults with knee osteoarthritis who were assigned to one of four groups:

• 20 grams of inulin per day;
• a digitally supported physiotherapy and exercise program;
• both inulin and physiotherapy;
• or a placebo supplement with usual care.

A total of 117 participants completed the study. The researchers measured knee pain, grip strength, lower-body function and sensitivity to painful pressure before and after the intervention.

Both inulin and physiotherapy were associated with reduced knee pain. However, the inulin intervention was also linked to stronger hand grip and reduced pain sensitivity, which may reflect changes in how the nervous system processes painful signals.

A possible link between the gut, muscles and pain

Inulin is naturally present in foods including chicory root, Jerusalem artichokes, onions and garlic. Because it is not fully digested in the small intestine, it reaches the colon, where gut bacteria ferment it.

This process produces compounds known as short-chain fatty acids. The study also found changes involving glucagon-like peptide-1, or GLP-1, a hormone produced naturally in the gut. Higher GLP-1 levels were associated with better grip strength, although this does not prove that the hormone caused the improvement.

The researchers describe the findings as evidence of a possible "gut-muscle-pain axis" that deserves further investigation.

The supplement was easier to continue than digital physiotherapy

Adherence differed substantially between the groups. About 3.6% of participants assigned to inulin left the study, compared with 21% of those assigned to the digital physiotherapy program.

This does not mean that fiber is more effective than exercise. Exercise remains a standard part of osteoarthritis management. The difference may instead indicate that taking a supplement was easier for participants to maintain over six weeks than following a daily online exercise program.

What the study cannot show (limitations)

The trial was relatively small and lasted only six weeks. It therefore cannot establish whether the benefits continue over months or years.

The study also did not show that inulin restores cartilage, slows structural damage in the knee or prevents the progression of osteoarthritis. The results concern symptoms and functional measurements rather than reversal of the disease itself.

Inulin can also cause bloating, abdominal discomfort or changes in bowel habits, particularly when taken in relatively large doses. People with irritable bowel syndrome may be especially sensitive to it.

The findings were published in the journal Nutrients. The original study is available at DOI: 10.3390/nu18050714.

Limiting sugar exposure during pregnancy and the first two years of life may be associated with better brain and mental health decades later, according to a new study involving more than 60,000 adults in the United Kingdom.

Researchers found that people who spent their first 1,000 days after conception under Britain’s historical sugar rationing had a 46% lower risk of Alzheimer’s disease and a 27% lower risk of dementia from any cause compared with people who were not exposed to rationing during this early period.

The same group also had lower rates of depression and anxiety later in life.

How a sudden policy change became a natural experiment

The researchers analyzed data from 60,394 UK Biobank participants born between 1951 and 1956.

Britain restricted sugar consumption for over a decade, but sugar rationing abruptly ended in 1953. This policy change created what researchers call a natural experiment: people born only months apart could have experienced substantially different access to sugar during pregnancy, infancy and early childhood.

Participants were grouped according to whether they had been exposed to sugar rationing only before birth, throughout pregnancy and the first two years after birth, or not during early life.

Compared with people who were not exposed to rationing, those whose exposure extended throughout approximately the first 1,000 days after conception had:

• 46% lower risk of Alzheimer’s disease;
• 27% lower risk of all-cause dementia;
• 11% lower risk of depression;
• 20% lower risk of anxiety.

The associations with depression and anxiety were stronger when sugar restriction continued for more than six months after birth.

Brain scans also showed small differences

The researchers examined brain imaging data in a subset of participants and found differences that were consistent with slightly slower brain aging.

People exposed to postnatal sugar rationing had a calculated brain age that was, on average, about 0.39 years younger relative to their chronological age.

They also had larger volumes in several subcortical brain regions, including the hippocampus and thalamus. The hippocampus plays an important role in memory and is one of the regions affected early in Alzheimer’s disease.

These imaging findings support a possible biological link between early nutrition and later brain health, but they do not establish that lower sugar consumption directly produced the differences.

Why the first 1,000 days may matter

The period from conception through roughly a child’s second birthday is a particularly rapid phase of brain development.

Nutrition during this period can influence metabolism, growth and the development of multiple organ systems. Researchers have therefore become increasingly interested in whether early dietary exposures may leave effects that remain detectable decades later.

Notably, the new study found only limited associations among people whose sugar restriction occurred during pregnancy alone. The stronger findings appeared when lower sugar exposure continued after birth, suggesting that the duration of early-life exposure may matter.

The study does not prove that sugar causes Alzheimer’s disease

Despite the striking 46% figure, the findings require careful interpretation.

This was not a randomized trial in which infants were deliberately assigned different amounts of sugar. Researchers instead used historical rationing as a quasi-experimental exposure and linked birth dates with health outcomes recorded many decades later.

The approach reduces some of the biases that affect conventional nutrition studies because participants did not choose whether they were born before or after the end of rationing. However, people living under rationing may also have differed in other dietary, social and environmental factors.

The study also did not measure exactly how much sugar each individual child consumed.

An independent neurologist interviewed by Medical News Today additionally cautioned that the Alzheimer’s finding was based on a relatively small number of cases and that many participants have not yet reached the ages when Alzheimer’s disease becomes most common.

The findings concern early life — not cutting sugar at age 50

The results also cannot answer a common question: whether reducing added sugar in middle or older age would produce the same reduction in dementia risk.

The study specifically examined exposure during pregnancy, infancy and early childhood. It therefore should not be interpreted as evidence that eliminating sugar later in life can reduce Alzheimer’s risk by 46%.

Nor does it suggest eliminating naturally occurring sugars from foods such as whole fruit. The historical exposure studied was primarily a restriction in available dietary sugar, while modern dietary recommendations generally distinguish added sugars from sugars naturally present in nutrient-rich foods.

What researchers want to understand next

The study adds to growing evidence that nutrition very early in life may influence health many decades later. Previous research using the same historical change in British sugar rationing has linked lower early-life sugar exposure with reduced risks of metabolic and cardiovascular disease.

Further studies will be needed to determine which dietary mechanisms might account for the brain findings and whether the associations persist as the study population grows older.

The research was published on July 22, 2026, in npj Aging.

Original study: Lian X, Chen A, Zhu X, et al. “Early-life sugar rationing, brain aging, and long-term neurodegenerative and psychiatric health outcomes: a population-based natural experiment study.” npj Aging. 2026. DOI: 10.1038/s41514-026-00452-z.

Illustrative photo: insomnia after treatment / Jen Theodore on Unsplash

For many women, finishing breast cancer treatment does not mean returning to their old life. The disease may recede, but sleep remains disrupted, and along with fatigue, feelings of depression, anxiety, and a loss of interest in usual activities persist.

In the new NCT07721064 study, scientists will test a digital approach to two problems simultaneously—insomnia and depressive symptoms in breast cancer survivors.

The project plans to enroll 747 participants. But this will not be a usual comparison of an app with a control group. Researchers want to understand which program is best to offer first and what to do if the initial help does not yield a sufficient result.

Why Insomnia and Depression Are Studied Together

After cancer treatment, sleep can be disrupted due to anxiety about the disease returning, pain, hot flashes, hormone therapy, fatigue, and changes in the usual lifestyle.

At the same time, insomnia and depressive symptoms can reinforce each other. A person sleeps poorly, feels exhausted during the day, and copes worse with emotional stress. A depressed mood, in turn, intensifies nighttime worries and prevents the restoration of a normal sleep schedule.

Therefore, a program targeting only one problem may prove insufficient for some patients.

Which Digital Programs Will Be Tested

One of the programs is called SHUTi. This is an automated internet program for cognitive behavioral therapy for insomnia. It helps change habits and thoughts that maintain chronic sleep problems.

Cognitive behavioral therapy for insomnia may include organizing a schedule, limiting wakeful time in bed, addressing anxious expectations, and gradually restoring the association between bed and sleep.

The second program is IntelliCare. It is a suite of digital tools to support mental health. They teach skills for managing negative thoughts, stress, low mood, and other emotional difficulties.

Both programs are behavioral interventions. They are not anti-tumor treatments and do not replace medications or face-to-face care when necessary.

What Does Adaptive Design Mean?

At the beginning of the study, participants will be randomly assigned to SHUTi, IntelliCare, or an active control program.

After nine weeks, scientists will evaluate the changes in symptoms. A clinically significant improvement in both insomnia and depressive manifestations will be considered a sufficient response.

If a participant received SHUTi but the improvement was incomplete, she may be re-assigned to a group with or without the addition of IntelliCare. Similarly, women who were initially prescribed IntelliCare may have SHUTi added if their response is insufficient.

This format is called a Sequential Multiple Assignment Randomized Trial, or SMART. It allows studying not a single fixed therapy, but an entire sequence of decisions: where to start, when to change the approach, and who needs a combination of programs.

Why the App Won't Be Prescribed Equally to Everyone

For one woman, focused work on sleep may be enough. Another primarily needs help with depressive symptoms. A third may require the sequential use of both programs.

Researchers also plan to find out which characteristics and preferences of the participants are associated with a better response to different strategies. In the future, this could help select digital support not on a "one app fits all" basis, but taking into account an individual combination of symptoms.

What Is Already Known About Digital Help

Previous studies have shown that internet programs for cognitive behavioral therapy can reduce the severity of insomnia in cancer survivors.

Digital mental health programs can also be an accessible form of support, especially when there is no specialist nearby or when it is difficult for a patient to attend regular face-to-face consultations.

However, the success of a single digital intervention does not guarantee that it will simultaneously cope with both sleep disturbances and depression. This is exactly the gap the new study is trying to close.

What Cannot Be Claimed Yet (Limitations)

The registration of NCT07721064 does not mean that the digital combination is already proven to cure insomnia and depression after breast cancer. Participant recruitment has not yet begun, and there are no study results.

The programs are also not intended for emergency care. In cases of severe depression, suicidal thoughts, a sharp deterioration in the condition, or an inability to cope with daily life, immediate medical attention should be sought.

But if the adaptive strategy proves effective, it could offer a more flexible support model: start with an accessible digital program, evaluate the real response, and add a second type of help in time for those who need more than a single intervention.

Information Sources:

• Clinical trial profile on the U.S. National Library of Medicine database (ClinicalTrials.gov): NCT07721064   
• Project R01CA295673: National Cancer Institute

Illustrative photo / Getty Images For Unsplash+

Could a standard smartphone camera help a dispatcher understand how dangerous a person's shortness of breath is during an emergency call? This idea will be tested in the NCT07726628 trial involving 778 patients.

Shortness of breath can occur during a relatively mild condition, but it can also be a sign of a heart attack, pulmonary embolism, severe infection, pulmonary edema, asthma exacerbation, or another life-threatening disorder.

During a standard phone call, the dispatcher must assess the situation based on the patient's or bystander's words, the tone of voice, and the ability to answer questions. However, not everyone can describe breathing accurately, especially when experiencing fear and air hunger.

What Video Should Change

In the experimental strategy, a live feed from the caller's phone camera will be added to the standard conversation. The dispatcher will be able to see the patient in real time and use visual information when selecting the urgency level and the necessary medical resources.

The video may reveal the respiratory rate and pattern, the use of accessory muscles, unusual body posture, the inability to speak calmly, altered mental status, and other signs of potential respiratory distress.

However, the camera does not measure blood oxygen saturation, blood pressure, or other vital signs. The video is intended to supplement the interview, not replace a medical examination.

What Are Under-Triage and Over-Triage?

The main challenge of telephone triage is the need to make rapid decisions with limited information.

In the case of under-triage, a dangerous condition is mistaken for a less urgent one. As a result, the patient may receive delayed assistance or a less-equipped ambulance crew than they actually need.

In the case of over-triage, the most urgent and specialized resources are dispatched, even though the actual severity of the condition does not require them. This approach is safer for the individual patient but may leave another person with a truly critical condition without an available ambulance.

Researchers want to find out whether a visual assessment can reduce both types of errors.

Why Shortness of Breath is Especially Hard to Assess Over the Phone

The sensation of air hunger is subjective. One patient may speak calmly even with a severe impairment, while another experiences intense fear during a less dangerous condition. Relatives also describe what they see in varying ways.

Studies on telephone assessments of shortness of breath show that the ability to speak in full sentences, altered consciousness, and signs of increased respiratory muscle effort may be linked to the need for urgent respiratory support.

Some of these signs can be clarified through questioning, but others are simply easier to see directly.

Video Does Not Guarantee the Right Decision (Limitations)

The image quality depends on lighting, internet connection, camera positioning, and the caller's ability to follow instructions. Certain signs may remain unnoticeable, and an outwardly calm appearance does not rule out a dangerous illness.

Furthermore, using a camera raises issues of consent, privacy, and data protection. Therefore, medical systems typically use a secure link that the caller activates voluntarily.

The NCT07726628 study is meant to test not the technical feasibility of video communication itself, but its impact on the real-world decisions made by emergency services. There are no results yet, so it cannot be claimed that the camera already makes remote triage safer.

But if video truly reduces the number of under-triaged and over-triaged cases, a few seconds of footage could help accurately determine what kind of help to send a person even before the medical team arrives.

Information Sources:

• Clinical trial profile on the U.S. National Library of Medicine database (ClinicalTrials.gov): NCT07726628

Illustrative photo: abdominal pain is one of the non-specific symptoms / Unsplash+ License

Could a breath test help detect a dangerous tumor earlier? The NCT07714538 study will test this technology on 1,000 patients whose symptoms have led doctors to suspect gastrointestinal cancer.

The large-scale study is being conducted by the UK's Imperial College London. The focus is on cancers of the esophagus, stomach, pancreas, liver, and bowel. Participants will provide breath samples in which researchers will look for characteristic chemical markers—specific combinations of volatile organic compounds. The study is registered under the number NCT07714538.

However, this is not a ready-made miracle test capable of delivering a definitive diagnosis after a single exhale. The study aims to determine how accurately the experimental test can distinguish patients with cancer from people whose similar symptoms are caused by benign conditions.

What Scientists Are Looking For in Exhaled Air

Volatile organic compounds (VOCs) are small molecules produced in the body during complex metabolic processes. They enter the bloodstream, reach the lungs, and are then expelled with exhaled air.

Their composition can be influenced by diet, medications, smoking, gut microbiome composition, inflammatory processes, and various diseases. Researchers reasonably hypothesize that the development of a malignant tumor also alters cellular metabolism, forming a specific, recognizable chemical profile.

Therefore, scientists are not looking for a single universal "cancer smell," but rather a complex combination of several marker substances. The collected air samples are analyzed in detail using laboratory methods (chromatography and mass spectrometry), after which the patients' chemical profiles are meticulously compared with the final results of their medical examinations.

Who the Study is For

The study plans to enroll approximately 1,000 patients with non-specific symptoms that may indicate a digestive system disorder and require mandatory cancer exclusion.

Complaints such as abdominal pain, indigestion, unexplained weight loss, changes in bowel habits, nausea, or weakness occur in a vast number of benign conditions (gastritis, irritable bowel syndrome, infections). Therefore, it can be extremely difficult for a doctor to immediately determine which patients urgently need an endoscopy, CT scan, or other complex specialized procedures, and who can wait.

This is where a breath test could potentially be useful: not as a replacement for a full examination, but as an intermediate triage tool to help doctors route patients based on their level of risk.

Why This is Not Routine Mass Screening

It is important to understand that the study is not designed to test asymptomatic people. Its participants already have concerning symptoms and are undergoing a diagnostic pathway specifically because of suspected gastrointestinal disease.

Therefore, it is more accurate to speak not of preventative population screening, but of a clinical sorting tool. If the test proves sufficiently accurate, it could in the future help fast-track high-risk patients to in-depth, life-saving examinations, bypassing queues.

At the same time, people with a low probability of cancer (based on the breath test results) could avoid some unnecessary, unpleasant, and costly invasive procedures. However, such optimization must be reliably confirmed by statistical clinical data.

Why They Are Trying to Apply One Test to Five Types of Cancer

The Imperial College London team has been studying volatile compounds in several digestive system tumors. Previous pilot projects by this research group focused on esophageal, stomach, pancreatic, liver, and bowel cancers individually.

Different tumors may have their own chemical "signatures." The innovation of the current study is that researchers want to find out whether a general breath test can first recognize the mere fact of an increased probability of GI cancer, and then accurately indicate which specific organ the suspicious VOC profile might be linked to.

This is a much more complex task than simply distinguishing one known tumor from a healthy state. The symptoms of various GI diseases overlap significantly, and the chemical composition of exhaled air is dynamic and depends on many non-oncological factors.

What the Study Should Show

Scientists will have to mathematically evaluate how many real cancer cases the test can successfully detect (sensitivity) and how often it will give a false-positive result in people without a malignant tumor (specificity).

High sensitivity is critical to avoid giving patients a false sense of security and missing dangerous diseases at an early stage. However, insufficient specificity will lead to a large number of false alarms, stress, and a massive number of additional unnecessary endoscopies, scans, and biopsies, which would overload the healthcare system.

The result of the innovative breath analysis will be compared with the final diagnosis, indisputably established using "gold standard" examinations (CT, MRI, endoscopy, histology). Only such a blind comparison will reveal the true diagnostic accuracy of the technology.

What Cannot Be Claimed Yet (Limitations)

To avoid false hopes, it must be emphasized that the NCT07714538 study does not yet prove that cancer can be reliably and flawlessly detected by breath.

Furthermore, a negative test cannot be considered a guarantee of the complete absence of a tumor, nor does it allow a patient with concerning symptoms to forego examination with a clear conscience.

Even if successfully validated, breath analysis will most likely be used exclusively as the first step in a complex diagnostic pathway. A final oncological diagnosis will always continue to require imaging, endoscopy, and, if a suspicious growth is found, microscopic examination of a tissue sample (biopsy).

But if the technology can indeed identify high-risk patients with sufficient accuracy, a simple non-invasive breath sample in a general practitioner's office could become a way to move a person through the bureaucratic medical system faster—to the examinations that will save their life.

Information Sources:

• Clinical trial profile on the U.S. National Library of Medicine database (ClinicalTrials.gov): NCT07714538
• Information on breath test research: Imperial College London, Hanna Group

Photo: Vitaly Gariev / Unsplash

Can we intervene in the development of Alzheimer's disease before a person even notices memory problems? Roche plans to test this ambitious possibility in the new Phase 3 PrevenTRON study.

The trial is registered under the number NCT07717411. It will enroll cognitively unimpaired individuals who have been found through testing to have biomarkers of Alzheimer's pathology and a confirmed high risk of progressing to the symptomatic stage.

Participants will be administered the experimental drug trontinemab. The main question is not just whether it reduces the amount of amyloid in the brain, but whether the treatment can actually delay the first confirmed signs of cognitive decline.

How You Can Have Signs of Disease Without Symptoms

Alzheimer's disease develops gradually. Pathological changes in the brain can begin many years before the person or their loved ones notice a decline in memory, loss of orientation, and a reduced ability to cope with daily tasks.

At this stage, a person may pass standard cognitive tests perfectly normal and retain their usual independence. However, a blood test, cerebrospinal fluid analysis, or a positron emission tomography (PET) scan can already reveal biological markers associated with the accumulation of beta-amyloid and pathological changes in the tau protein.

This condition is called preclinical, or presymptomatic, Alzheimer's disease. It is important to understand that this is not the same as dementia: the person does not yet have pronounced impairments in thinking and daily activities.

How Potential Participants Will Be Found

For initial screening, Roche plans to use the Elecsys pTau217 blood test. It measures phosphorylated tau protein, elevated levels of which can indicate pathology associated with Alzheimer's disease.

But a single blood test does not mean automatic inclusion in the study and does not equal a diagnosis of dementia. Potential participants will require a thorough additional assessment, including comprehensive cognitive testing and protocol-mandated confirmation of biomarkers.

It is precisely this multi-step screening that is designed to find people who currently have no symptoms but whose objective probability of clinical deterioration is higher than in the general population.

How Trontinemab Works

Trontinemab is an experimental antibody directed against beta-amyloid. It was created using the innovative Brainshuttle technology, designed to facilitate and accelerate the delivery of the drug across the blood-brain barrier directly into the brain.

Beta-amyloid can form characteristic deposits, or plaques. The drug is supposed to bind to them and promote their active removal by the immune system.

In an early Phase 1b/2a study, trontinemab significantly reduced the amyloid burden in people who already had early symptoms of Alzheimer's disease. It was these encouraging results that became one of the foundations for moving to large-scale Phase 3 trials. However, the disappearance of amyloid on a scan does not necessarily mean that the drug will prevent memory decline. PrevenTRON must verify a clinically meaningful result—the time to the onset of confirmed symptoms.

Why This is Called a Preventive Approach

This is not about preventing the disease in absolutely all healthy people. The study participants already have biological signs of a pathological process, so from a medical standpoint, it is more accurate to speak of early intervention or secondary prevention.

Researchers are trying to find out if targeting amyloid will be more effective if started before noticeable damage to cognitive functions occurs. This is one of the most important questions in modern Alzheimer's therapy: once memory impairments have appeared, the changes in the brain may be quite widespread, and removing a single pathological target is not always capable of restoring lost function.

What Risks Need to Be Evaluated

Anti-amyloid drugs carry specific risks that require strict monitoring:

• ARIA (Amyloid-Related Imaging Abnormalities): These include swelling and small microhemorrhages in the brain tissue visible on an MRI.
• Asymptomatic Course: Some cases of ARIA cause no symptoms and are only discovered during routine scanning.
• Symptomatic Complications: In some cases, therapy can be accompanied by headaches, confusion, visual disturbances, or more serious neurological complications.

The benefit-risk ratio must be evaluated especially carefully in this specific group of people, who feel completely healthy and have no cognitive complaints at the time treatment begins.

What Cannot Be Claimed Yet (Limitations)

To avoid false hopes, it is important to emphasize a few facts:

• Prevention has not yet been found: The start of a Phase 3 trial does not mean a cure for dementia is ready. It is not yet known whether trontinemab can truly delay the onset of symptoms.
• Risks vs. Benefits: It is unknown how significant the potential effect will be and whether it will justify the risks of long-term intravenous treatment in seemingly healthy people.
• A blood test is not a sentence: A positive biomarker test cannot accurately predict when a specific person will develop symptoms, or if they will develop them at all during the observation period.

PrevenTRON is testing one of the most appealing, yet unproven, ideas in Alzheimer's research: whether sufficiently early (presymptomatic) removal of amyloid can change a person's future clinical trajectory.

Information Sources:

• Clinical trial profile on ClinicalTrials.gov (U.S. National Library of Medicine database): NCT07717411
• Official materials from Roche.

Illustrative photo: early detection via diaper photos

Could a simple photo of a diaper help spot a dangerous liver disease in a newborn earlier? This is exactly what British researchers are testing in The Dirty Nappy Study.

The large-scale study is registered under the number NCT07697872. It is being conducted by the Birmingham Women’s and Children’s NHS Foundation Trust and led by pediatric liver specialist Dr. Girish Gupte.

Parents are being asked to photograph their baby's stool using a smartphone. The images are used to train and validate an algorithm designed to distinguish normal stool color from changes that could indicate cholestasis or biliary atresia.

Why Doctors Look at Stool Color

Bile is produced in the liver and travels through the bile ducts into the intestines. It plays a key role in digestion and gives stool its characteristic color.

In cholestasis, the flow of bile is disrupted. One of the most serious causes in infants is biliary atresia—a rare disease in which the bile ducts are damaged, narrowed, or blocked.

When this happens, the baby's stool may become unusually pale, grayish, or almost white. At the same time, the infant may have persistent jaundice and dark urine. The main problem is that parents do not always know which shade to consider dangerous, and the color in a photograph heavily depends on lighting, the smartphone camera, and the material of the diaper itself.

How the Study is Being Conducted

The current observational study plans to enroll approximately 5,350 infants. It is taking place across four British hospitals and aims to collect around 59,200 images from both healthy babies and infants with cholestasis.

Parents of healthy newborns are invited to take photos of diapers when the baby is 14, 21, and 28 days old, and then again at three and six months of age. Separately, researchers are collecting images from infants referred to a specialized unit with suspected cholestasis.

The algorithm will be evaluated for its sensitivity, specificity, and overall accuracy. Additionally, the team wants to understand how convenient and psychologically acceptable this form of medical screening is for parents.

Why an Early Signal is Critical

Biliary atresia is rare, so its early signs can easily be missed or mistaken for common (physiological) newborn jaundice. Meanwhile, the disease gradually and irreversibly damages the liver, and the success of surgical treatment largely depends on how early the correct diagnosis is made.

In the future, an automated photo check could become an accessible preliminary filter: parents would receive an alert to consult a doctor, allowing the baby to undergo tests and specialized examinations much sooner.

A Photo Does Not Replace Diagnosis (Limitations)

It is important to note that the study does not yet prove that artificial intelligence can reliably detect biliary atresia. The algorithm is currently only being developed and tested on real-world data, and its final clinical accuracy remains unknown.

Even after successful validation, a photograph will not be able to provide a diagnosis on its own. Suspected cholestasis must always be confirmed by blood tests, ultrasounds, and other medical examinations.

The main value of the idea lies not in a "diagnosis by diaper," but in the ability to spot a warning sign earlier that is easy to miss without specialized medical training.

Information Sources:

• Clinical trial profile (ClinicalTrials.gov): NCT07697872
• UK Health Research Authority: The Dirty Nappy Study
• Press release from Birmingham Women’s and Children’s NHS Foundation Trust: How a snap of a dirty nappy could detect life-threatening liver condition

Illustrative photo: breast cancer screening / National Cancer Institute (Unsplash)

A new Phase 3 trial will test an experimental combination for patients with triple-negative breast cancer who have residual invasive disease following pre-surgical treatment and surgery.

The clinical trial, registered as NCT07679360, plans to enroll approximately 1,000 patients. They will receive post-surgical (adjuvant) treatment using trastuzumab rezetecan in combination with the immunotherapy adebrelimab.

The main question is not just whether the combination can further reduce the tumor burden. Researchers need to find out whether it can critically lower the risk of the disease returning after intensive treatment has already been administered.

What "Residual Invasive Disease" Means

In triple-negative breast cancer (TNBC), drug therapy is often started before surgery. This approach is called neoadjuvant treatment. Its goal is to shrink the tumor and destroy as many cancer cells as possible prior to surgical intervention.

After surgery, the removed tissues are carefully examined by a pathologist. In some patients, no live invasive tumor cells are found—this is called a pathological complete response, which is an excellent prognostic sign.

However, if cancer cells persist in the breast or lymph nodes, it is referred to as residual invasive disease. This does not mean that the initial treatment was useless, but this group objectively has a higher probability of relapse. That is why oncologists are looking for ways to strengthen the "safety net" of post-surgical therapy.

How the New Combination Should Work

Trastuzumab rezetecan belongs to a promising class of antibody-drug conjugates (ADCs). These drugs combine an antibody that recognizes a specific target on a tumor cell with a highly toxic substance attached to it.

In simple terms, this principle can be compared to targeted delivery: the antibody acts as a navigator, helping to bring the anti-tumor component closer to the cells that have the required target on their surface.

The drug targets the HER2 protein. In triple-negative breast cancer, the tumor, by definition, does not have a HER2-positive status (the protein levels are low). However, a small amount of this receptor may still be present on some cells. A new direction of research is testing whether such low expression (HER2-low) is sufficient for modern antibody-drug conjugates to work effectively.

The second component, adebrelimab, blocks the PD-L1 protein. Tumors often use this signaling pathway as a disguise to weaken the activity of immune cells. Blocking PD-L1 should "release the brakes" and help the immune system better recognize and attack hidden cancer cells.

Why This Specific Patient Group Was Chosen

Triple-negative breast cancer is unique because it lacks estrogen and progesterone receptors and is not classified as a classic HER2-positive tumor. Because of this, many standard types of hormonal and traditional HER2-targeted therapies are unavailable for it.

A particularly complex clinical situation arises when an invasive tumor remains after pre-surgical treatment. Even after its complete surgical removal, individual microscopic cells may continue to circulate in the body, undetected by MRI, CT scans, or routine examinations.

Adjuvant therapy is designed precisely to combat such hidden risks. The combination of targeted cytotoxic drug delivery and immune blockade represents an attempt to attack resistant residual tumor cells using two independent methods simultaneously.

Why Phase 3 Is So Important

Phase 3 is a large and decisive stage in clinical development. At this step, the experimental treatment is rigorously compared against an already established therapeutic strategy (standard of care), and clinically meaningful outcomes are evaluated.

The scale of approximately 1,000 participants should help the medical community determine not only the potential efficacy but also the true frequency of serious side effects.

For antibody-drug conjugates, the risks of decreased blood counts, interstitial lung disease, nausea, and other toxic reactions are important to monitor. PD-L1 inhibitors (immunotherapy), in turn, can cause autoimmune complications when an overactive immune system begins to attack the patient's healthy organs.

What Cannot Be Claimed Yet (Limitations)

The fact that the trial has been registered and initiated does not mean that the combination is already proven to prevent the recurrence of triple-negative breast cancer. There are no Phase 3 results yet.

Furthermore, it cannot be assumed that absolutely any triple-negative breast cancer will be sensitive to a drug targeting HER2. The initial level of the target on the cells, the genetic characteristics of the tumor, prior treatments, and individual sensitivity to immunotherapy will all play significant roles.

The news lies in the launch of a major, scientifically grounded test of a promising strategy for patients at high residual risk. The final answer to the main question—whether this regimen can keep the disease at bay longer and extend lives—will only emerge after extensive data collection and independent clinical analysis.

Information Sources:

• Clinical trial profile on the U.S. National Library of Medicine database (ClinicalTrials.gov): NCT07679360

Illustrative photo: moving away from daily pills / Unsplash

Gilead Sciences has registered two Phase 3 trials in which an experimental long-acting HIV-1 treatment regimen will be compared with daily oral therapy and an existing injectable regimen.

The new combination is based on lenacapavir, teropavimab, and zinlirvimab. The trials are registered under the numbers NCT07682961 and NCT07683000.

The main question scientists need to answer is extremely simple and important for patients: whether it will be possible to reliably maintain viral suppression without the need to take medication every day.

What Exactly Gilead Will Test

Both studies are strictly for people with HIV-1 whose viral load is already suppressed on effective antiretroviral therapy. These are treatment switch trials, not trials for people who are just starting therapy or have uncontrolled infection.

• In the first study, the experimental combination will be compared with cabotegravir and rilpivirine—a long-acting injectable regimen administered every eight weeks.
• In the second study, participants in the control group will continue taking their usual daily oral antiretroviral therapy (pills).

Researchers will evaluate whether the new regimen can maintain viral suppression and how safe it is compared to the already used and proven treatment options.

How the New Combination Works

Lenacapavir is an HIV capsid inhibitor. It targets the protein shell that protects the virus's genetic material and disrupts several stages of its life cycle at once.

However, when treating a person with an existing HIV infection, one drug is not enough: the virus can quickly develop resistance. That is why lenacapavir is combined with other active components.

Teropavimab and zinlirvimab belong to a class of broadly neutralizing antibodies (bNAbs). These are long-acting antibodies designed to recognize relatively conserved regions of HIV and physically prevent the virus from infecting new cells. Using two different antibodies at once should target the virus from multiple angles and reduce the likelihood of it escaping therapy through a single mutation.

Why Eliminating Daily Pills Is So Important

Modern antiretroviral therapy (ART) allows people with HIV to maintain an undetectable viral load and live a full life (the "Undetectable = Untransmittable" principle). But the treatment must be taken regularly, without missing doses, and for life.

For some patients, a daily pill is not a big problem. But for many others, it becomes a constant psychological reminder of their diagnosis. In addition, daily medication can create a risk of unwanted disclosure of HIV status to loved ones or complicate adherence during travel, shift work, and in unstable life circumstances.

Long-acting regimens do not cancel the treatment, but they radically change its format: instead of taking pills at home every day, the patient regularly visits a clinic to receive the medications.

It Is Not a Vaccine or a Cure for HIV (Important Limitations)

Despite the inclusion of antibodies in the therapy, the experimental combination is not a vaccine. The antibodies are administered as drugs—they work only as long as they are in the bloodstream and do not teach the body to produce long-term immunity on its own.

The regimen also does not eliminate the hidden cellular reservoirs of HIV and is not considered a cure. Its sole purpose is to continue suppressing viral replication after switching from another effective therapy.

What Cannot Be Claimed Yet

At this stage, it is unknown whether the combination of lenacapavir, teropavimab, and zinlirvimab can maintain viral suppression as reliably as daily pills or injections of cabotegravir and rilpivirine.

Scientists will also have to evaluate the tolerability of long-acting drugs, possible injection site reactions, the convenience of medical visits for patients, and the risk of resistance (viral resistance) developing in the event of a missed or delayed dose.

If the Phase 3 trials yield positive results, the new combination could significantly expand the choices for people who want to switch from daily pills to less frequent treatment. But for now, this is a promising clinical program, not an available, approved regimen.

Information Sources:

• Study profile on ClinicalTrials.gov (U.S. National Library of Medicine database): NCT07682961
• Study profile on ClinicalTrials.gov: NCT07683000

Illustrative photo: Electronic biosensor and a drop of liquid / Unsplash

A few drops of tears could in the future become a reliable source of data about the state of our brain. Researchers from the Federal University of Pelotas (Brazil) have introduced an innovative electrochemical sensor based on laser-induced graphene. Its main task is to capture dopamine in a fluid simulating human tears.

Why Dopamine?

Dopamine is a key neurotransmitter involved in movement control, the motivation system, and emotions. Disruptions in the dopamine system are directly linked to serious illnesses such as Parkinson's disease and schizophrenia.

The problem is that tracking dopamine levels is currently technologically challenging. It requires prolonged clinical observations, expensive brain scans, and invasive laboratory tests (such as blood draws or cerebrospinal fluid collection).

How the New Technology Works

Scientists have long been looking for ways to measure brain biomarkers more simply and painlessly for the patient. The new sensor offers an elegant approach. The device uses a special graphene surface that chemically reacts to the slightest presence of dopamine.

During laboratory tests, the device successfully and quickly detected various concentrations of this substance in a fluid that completely replicates the chemical composition of human tears.

From the Lab to a Real Hospital (Limitations)

The study's authors make an important caveat: there is no ready-made home test for Parkinson's disease yet. The main limitation of the current stage is that the sensor was tested exclusively on artificial tears, not on real patients with confirmed neurological disorders.

However, as a first technological step (proof-of-concept), this is a breakthrough. If the device confirms its accuracy on real biological samples and passes clinical trials, tears will become the most convenient material for medical monitoring. Such an analysis will be simpler, cheaper, and more comfortable for the patient.

Cheap Monitoring Instead of Expensive Tests

For modern medicine, what is especially valuable is not a one-time diagnosis, but continuous observation. It is critically important for doctors to understand how biomarker levels change over time, whether the prescribed treatment is helping, and whether the disease is progressing. A non-invasive sensor is ideal for such a routine.

A separate advantage of the development is its low cost. The authors emphasize that producing a graphene electrochemical sensor is very cheap. For mass medicine, this is a key factor: screening tools must be financially accessible.

Scientists have proven the main point: dopamine can be found quickly and accurately in tear fluid using inexpensive materials. The next stage is to test the technology in real clinical conditions on humans.

Information Sources:

• Scientific journal ACS Omega (American Chemical Society): pubs.acs.org
• Science portal Technology Networks: technologynetworks.com
• News agency Infobae: infobae.com

Illustrative photo: Cardiovascular disease prevention / Unsplash

The Medical University of Innsbruck is launching a massive project: The Austrian Digital Heart Study. The main goal is to test whether detecting hidden heart rhythm disorders using a smartphone can save older adults from severe strokes.

Atrial fibrillation (AFib) is a condition in which the heart beats irregularly. The main danger of this pathology is that it often proceeds asymptomatically: the patient feels no pain and may be unaware of the problem for years. However, this "silent" arrhythmia is one of the leading factors in the formation of blood clots in the heart, which, upon reaching the brain, cause an ischemic stroke. Often, the diagnosis is made in the hospital when the time for prevention has been irretrievably lost.

How the Austrian Digital Heart Project Works

The officially registered randomized trial received the number NCT07684053 in the international clinical trials registry. The project stands out for its colossal scale: it plans to enroll around 100,000 people aged 65 and older registered in the Austrian social insurance system.

The study consists of a strictly regulated two-step diagnostic system:

• Step 1: Smartphone Camera (Photoplethysmography). Participants in the experimental group will install a special app called "Pulskontrolle." Using the smartphone's built-in camera, the app will record the pulse wave (PPG) directly from the patient's finger for an initial arrhythmia search.
• Step 2: Medical Confirmation (ECG patch). If the phone suspects an irregular rhythm, it does not constitute a diagnosis. The patient will be sent a 7-day wearable ECG patch for continuous monitoring. Only if the patch confirms the diagnosis will the patient proceed to the treatment stage.

Such a filter is crucial for mass digital healthcare: it avoids overdiagnosis, unnecessary anxiety, and the unjustified prescription of serious blood-thinning medications (anticoagulants).

Focusing on Real Outcomes: Strokes, Not Just Statistics

The key difference between this experiment and simply testing new gadgets is the choice of the primary clinical outcome. Researchers are not just interested in the "number of arrhythmias found."

The main endpoint of the project is the hospitalization rate for stroke of any type within 48 months after the start of the study. Scientists need to prove the entire chain of efficacy: whether digital screening leads to timely treatment, and whether this treatment reduces the actual risk of ending up in a hospital with a severe neurological diagnosis.

Why This Matters and the Limits of the Technology (Limitations)

The idea of such screening is attractive because of its unprecedented accessibility—almost every senior citizen has a phone. However, it cannot be claimed yet that a smartphone prevents strokes. The study's design is merely testing this bold hypothesis.

It is important to remember that no consumer app replaces a classic electrocardiogram and a visit to a cardiologist. Moreover, the presence of atrial fibrillation itself requires an individual risk assessment (taking into account age, blood pressure, and coexisting diabetes), and only a doctor can make a decision about prescribing therapy.

If the Austrian Digital Heart Study is successful, it could become a global standard for how low-cost digital solutions are integrated into public healthcare systems to save lives.

Information Sources and Registry Links:

• Study profile on ClinicalTrials.gov (U.S. National Library of Medicine database): NCT07684053
• Clinical trial registry data on the Austrian Digital Heart Study design: Digital Screening for Atrial Fibrillation to Prevent Stroke (ADHP)

Illustrative photo: Knee pain during physical activity / Unsplash+

Researchers from the University of Colorado Boulder, CU Anschutz, and Colorado State University have reported preclinical results of experimental osteoarthritis treatments that, in animal studies, helped damaged joints repair themselves within weeks.

It sounds like news from the future: not just relieving arthritis pain, but forcing the joint to repair its own tissues. But the main caveat must be stated upfront: this is not yet a ready-made treatment for patients, nor are these the results of human clinical trials. The technologies are currently in the preclinical stage.

Nevertheless, the topic is important. Osteoarthritis is one of the most common causes of chronic pain, limited mobility, and joint replacement surgeries. Modern medicine can often reduce pain, improve function, or replace the joint with an artificial implant, but it cannot reliably "reverse" the very process of cartilage and bone destruction.

What the researchers developed

The Colorado team is working on two approaches. The first is an injection therapy administered directly into the joint. It uses an already FDA-approved drug but delivers it in a new way: through a patented particle system capable of releasing the medication in the joint incrementally over several months.

The second approach is designed for more pronounced cartilage or bone damage. It is an engineered protein-based biomaterial that can be introduced arthroscopically. Once administered, it sets in place and is designed to attract the body's own cells involved in tissue repair.

According to CU Boulder, in animal experiments with osteoarthritis and joint injuries, the injection method returned the affected joints to a healthier state in four to eight weeks. When filling cartilage or bone defects, researchers also observed the repair of the damaged areas.

Why this is not the same as a "cure for osteoarthritis"

The most dangerous mistake in such news is to claim that scientists have already "cured osteoarthritis." This is not true. Preclinical results in animals can be very promising, but they often do not fully replicate in humans. Joint size, mechanical load, age, comorbidities, immune responses, and disease duration all differ.

Furthermore, the animal data mentioned in the university's press release is yet to be published in a peer-reviewed scientific journal. This means that the independent scientific community has not yet received the full dataset for evaluation.

What is ARPA-H NITRO and why it matters

The team's work is part of the ARPA-H NITRO program — Novel Innovations for Tissue Regeneration in Osteoarthritis. The program's goal is to develop minimally invasive methods that can restore damaged joint tissues, rather than just controlling pain.

ARPA-H reported that the program's teams have met their preclinical milestones over the past two years and are now moving to the next phase. For the University of Colorado project, this means moving toward the studies necessary for future authorization for initial human trials.

When might this reach patients?

According to the researchers' estimates, if subsequent stages proceed successfully, clinical trials could begin in about 18 months. ARPA-H also points out that NITRO technologies are not yet recruiting participants: specific sites, inclusion criteria, and timelines will be determined by the teams later, following the necessary regulatory steps.

Therefore, patients with osteoarthritis should not view this news as an invitation to seek "the shot that repairs the joint." Right now, it is a promising development, not an available medical procedure.

Why the news is still significant

The strength of this story lies not in the promise of immediate treatment, but in the shift in thinking. Instead of the usual logic of "numb the pain or replace the joint," researchers are trying to create methods that help the joint rebuild cartilage and bone.

If future human trials confirm safety and efficacy, this could change the approach to treating early and moderate osteoarthritis. But before reaching that stage, the most important path must be completed: publication of full preclinical data, regulatory review, and human clinical trials.

Sources:

• University of Colorado Boulder: A simple shot shows promise to reverse osteoarthritis within weeks
• ARPA-H: ARPA-H fast-tracks regenerative breakthroughs to transform osteoarthritis care
• ScienceDaily: Material from June 30, 2026

Illustrative photo: A healthcare worker administers a vaccine to a child / Unsplash

Pneumococcal vaccination is usually associated with the infant schedule: several doses in the first months of life, followed by a booster. But in practice, there are children who started their vaccination course later, missed some doses, or need additional protection at an older age. For such situations, pediatrics uses a strategy called catch-up vaccination.

Pfizer is launching a randomized, triple-blind Phase 3 clinical trial in which the new multivalent pneumococcal vaccine PG4 will be compared with the 20-valent pneumococcal conjugate vaccine 20vPnC, known by the brand name Prevnar 20. Study profile on ichgcp.net: NCT07660198.

What makes pneumococcus dangerous

The bacterium Streptococcus pneumoniae (pneumococcus) is the cause of a number of diseases, including otitis, sinusitis, pneumonia, bacteremia (blood infection), and meningitis. In children, some of these infections can pass relatively mildly, but invasive pneumococcal disease can be extremely severe and require urgent medical care.

The main feature of pneumococcus is that there are many serotypes—variants of the bacterium with different protective capsule structures. The level of protection provided by vaccines directly depends on exactly which serotypes are included in their composition. Modern vaccines do not "cover" absolutely all possible variants, but include a specific set of serotypes that most often cause severe forms of infections.

Who will be included in the study

The new clinical trial plans to enroll 1,200 healthy children and adolescents aged 15 months to 18 years. Participants will be divided into three age cohorts:

• from 15 months to 2 years;
• from 2 to 5 years;
• from 5 to 18 years.

For the youngest group, a mandatory criterion will be the documented receipt of previous doses of a pneumococcal conjugate vaccine. For children in the 2–5 and 5–18 age windows, previous vaccination may or may not be in their medical history, depending on the specific subgroup.

This design accurately reflects the real clinical challenge of catch-up vaccination: it is critically important for doctors to understand how a new vaccine works not only in infants strictly following the schedule, but also in children who joined the immunization program later.

How the vaccines will be compared

According to Pfizer, the official goal of the study is to evaluate the safety, tolerability, and immune response of the new catch-up vaccine in a direct comparison with 20vPnC.

Participants within the age groups will be randomly assigned in a 2:1 ratio. This means that approximately two-thirds of the children will receive the experimental PG4 vaccine, and one-third will receive the active comparator 20vPnC. The vaccine will be administered intramuscularly (in the arm or thigh, depending on the child's age).

Each participant will be monitored by doctors for about 6 months. In the post-vaccination period, specialists will carefully track local reactions at the injection site, systemic symptoms, and any adverse events. To check the immune response, blood samples will be taken from the children. The main indicators are the levels of serotype-specific IgG and OPA titers. Simply put, researchers will test how actively the child's body produces functional antibodies against the serotypes included in the vaccine.

Why this is not just "another childhood shot"

Pneumococcal vaccines have already radically changed the landscape of pediatric prevention worldwide. But the bacterium itself has not disappeared, and the epidemiological distribution of active serotypes changes over time. This is why manufacturers and regulators continue to develop vaccines with broader serotype protection and an enhanced immune response.

For parents, the practical aspect is of greatest importance: if a child missed doses or has already outgrown the standard infant schedule, which vaccine will provide the most reliable and safe immunity? The upcoming Phase 3 clinical trial aims to clarify this part of the picture.

What cannot be claimed yet (study limitations)

At this stage, it cannot be claimed that the PG4 vaccine is superior to Prevnar 20 or that it is guaranteed to provide children with broader clinical protection against diseases. The current study is focused on evaluating safety, tolerability, and immunogenicity (blood markers). It does not prove in advance that children vaccinated with PG4 will have statistically fewer cases of pneumonia or otitis in real life.

It is also important to emphasize: conducting this study does not cancel or change current national vaccination schedules. Parents should not postpone already recommended vaccinations for their child in anticipation of a new candidate vaccine. Vaccination decisions should be made together with a pediatrician based on currently available vaccines.

Information sources:

• Study profile on ClinicalTrials.gov: NCT07660198
• Pfizer Clinical Trials: NCT07660198
• CDC (Centers for Disease Control and Prevention): Pneumococcal Vaccination
• WHO (World Health Organization): Pneumococcal disease and vaccine standards

Illustrative photo: A pulmonologist discussing a chest X-ray with a patient, explaining the treatment course for a lung disease/ Unsplash

For a person hearing a "tuberculosis" diagnosis for the first time, a difficult journey lies ahead. Even if the bacteria are sensitive to standard medications, treatment is rarely quick. A patient has to take a combination of several drugs for many months. This is also a challenge for doctors: the longer the treatment course, the higher the risk that the patient will miss doses, experience severe side effects, or interrupt treatment, leading to a relapse and the development of drug resistance.

Can treatment become shorter and more tolerable? To answer this question, the non-profit organization TB Alliance is launching a new clinical trial. It will test 17-week, all-oral (pill-based) treatment regimens for drug-susceptible pulmonary tuberculosis. Study profile on ichgcp.net: NCT07672405.

What exactly will be tested: introducing the SPaL regimen

The Phase 2b trial aims to evaluate the safety and efficacy of a regimen called SPaL. The trial plans to enroll about 100 adult patients (ages 18 to 65) with newly diagnosed pulmonary tuberculosis.

The acronym SPaL stands for a combination of three drugs taken orally once a day with food:

• Sorfequiline — a new experimental antibiotic;
• Pretomanid — an already known anti-tuberculosis drug;
• Linezolid — a powerful antibiotic used to treat severe infections.

Participants will be randomly divided into two groups to test different dosing strategies for sorfequiline. The first group will start with a higher initial dose (200 mg for the first 4 weeks, then 100 mg), while the second group will receive a stable dose of 100 mg throughout the entire 17 weeks.

Why this news matters for medicine

The main intrigue of this study lies not just in testing another pill, but in attempting to change the very architecture of TB treatment.

The drug sorfequiline (formerly known as TBAJ-876) belongs to the diarylquinoline class. TB Alliance is developing it as the next, potentially more advanced step in the evolution of anti-tuberculosis drugs. In a previous study (NC-009), the SPaL combination has already shown encouraging results. Now scientists need to take the next step: determining exactly which of the 17-week dosing regimens works better and safer in order to advance it to large-scale final trials.

Cautious optimism: why shortening the course is difficult

According to the WHO, tuberculosis remains one of the deadliest infections in the world: in 2024, it claimed the lives of about 1.23 million people. This disease is curable, but only if the bacteria in the body are completely eradicated.

Short regimens have a huge advantage—they are much easier to complete. However, in the fight against tuberculosis, comfort cannot come at the expense of reliability. Researchers will have to meticulously prove three things:

1. The new 17-week regimen completely suppresses the infection.
2. The risk of the disease returning (relapse) after the medication is stopped remains minimal.
3. The combination is safe for the patient (especially considering that long-term use of linezolid can cause serious side effects, and data on the cardiac safety of the new candidate, sorfequiline, is still being collected).

What this means for patients right now

It is important to understand: at the moment, the 17-week SPaL regimen is not an approved standard of care. The trial is just getting ready to launch (status "Not yet recruiting"), and there are no ready results yet.

Patients must absolutely not change their dosages or shorten the duration of their current therapy on their own. However, this news sends a powerful signal of hope: science is not standing still, and researchers are purposefully working to ensure that in the near future, the treatment for one of the world's most severe infections becomes faster, simpler, and safer.

Sources and additional reading:

• Study profile on ClinicalTrials.gov: NCT07672405
• TB Alliance: Information on the development of Sorfequiline
• TB Alliance: Results of the previous phase trial (NC-009)
• World Health Organization: Tuberculosis fact sheet

Illustrative photo: diabetesmagazijn.nl / Unsplash

For most people, a diagnosis of type 1 diabetes sounds like the starting point of a completely new life. From the very first days, insulin, constant blood glucose monitoring, and lifestyle changes are required. However, few people know that immediately after diagnosis, the pancreas usually does not stop working entirely.

In the first months after the disease's onset, a portion of the insulin-producing β-cells remains viable. It is precisely this short window of time that many research groups around the world are fighting for today. A new clinical trial, SHIELD-T1D, registered under the number NCT07614412, is dedicated to this exact challenge.

Why the first months are so important

Type 1 diabetes develops because the immune system mistakenly attacks the β-cells of the pancreas. However, this process rarely ends on the day of diagnosis. Usually, a certain number of cells continue to function.

If these cells can be preserved longer, the patient can continue to produce at least a small amount of their own insulin. Even this residual function is often associated with more stable glucose levels, a lower risk of severe hypoglycemia, and easier disease management.

What exactly will be studied

The researchers have chosen an unusual combination of two well-known medications.

The first is Shingrix, a vaccine against shingles (herpes zoster). In this case, it is being studied not as a means of preventing infection, but as a potential way to influence the immune system's activity.

The second is semaglutide, a GLP-1 receptor agonist widely used for type 2 diabetes and obesity. It is hypothesized that it may reduce the metabolic load on the remaining β-cells and help preserve their function.

It is important to emphasize: both drugs are being used in a research concept that has not yet proven its efficacy in type 1 diabetes.

Why this work is generating interest

In recent years, several approaches have emerged aimed not just at replacing insulin, but at preserving the body's own β-cells after disease onset. If the period of their function can be extended even by a few months or years, it could significantly impact patients' quality of life.

This is exactly why SHIELD-T1D is drawing attention: the trial is attempting to address two sides of the problem simultaneously—the immune attack and the metabolic stress on the cells.

What remains unknown

To date, there is no evidence to suggest that the Shingrix vaccine or semaglutide can stop type 1 diabetes or free a person from the need to take insulin.

The trial is only just beginning and must demonstrate whether this combination actually helps preserve β-cell function compared to standard treatment.

The news lies not in the arrival of a new diabetes treatment, but in the testing of an unusual strategy that could open up a new direction for research if successful.

Primary source (clinical trials registry): ClinicalTrials.gov: NCT07614412.

Material for patients: Breakthrough T1D (formerly JDRF) — Information on current research directions for beta-cell preservation and cell therapies.

Material for doctors: American Diabetes Association (ADA) — Standards of Care in Diabetes (2026), including sections on early diagnosis and disease-modifying therapies.

Illustrative photo: Roman Matveev / Unsplash

Cardiologists have long adhered to a simple rule: the lower the level of low-density lipoprotein (LDL-C) cholesterol, the lower the likelihood of a heart attack or stroke. However, a question remains that does not yet have a definitive answer: how low should this metric be in patients with the highest cardiovascular risk?

A new international clinical trial, registered under the number NCT07615296, is dedicated to exactly this problem. It will enroll approximately 6,000 patients at extreme risk for atherosclerotic cardiovascular disease (ASCVD).

What will be compared

Scientists intend to compare two treatment strategies. In the first group, doctors will aim to lower LDL cholesterol to ultra-low levels—less than 1.0 mmol/L. In the second group, the target will remain the range of 1.0 to 1.39 mmol/L, which is already considered a very strict metric according to current clinical guidelines.

Why the question remains open

In recent years, powerful drugs (such as PCSK9 inhibitors and inclisiran) have entered the medical arsenal, allowing LDL to be lowered much more significantly than was previously possible with statins alone. However, along with this, a new practical question has arisen: does lowering cholesterol to extremely low values bring additional clinical benefit, or does the effect become minimal after a certain point?

In addition to a potential reduction in the number of recurrent heart attacks and strokes, researchers are interested in the safety of such an aggressive approach, as well as its cost-effectiveness for healthcare systems.

What will be evaluated

The trial will not be limited to laboratory blood tests alone. The main goal will be to compare real-world clinical outcomes: the frequency of severe cardiovascular events, the safety profile of intensive treatment, and the overall cost of achieving various target cholesterol levels.

This is exactly why the results of this work have enormous potential: they could directly influence future international clinical guidelines (ESC, ACC/AHA).

Why this matters for patients

It is important to understand that most people with elevated cholesterol do not require such an aggressive LDL reduction. This trial specifically concerns patients with extreme risk—for example, those who have already suffered severe vascular events or have pronounced, progressive atherosclerosis.

If the lower target (less than 1.0 mmol/L) indeed proves to be safe and provides additional vascular protection, it could radically change the standards of life-saving care for the most vulnerable category of cardiology patients.

What is still unknown

The trial is just beginning, so it cannot yet be claimed that lowering LDL below 1.0 mmol/L is necessarily better than existing target levels. This is exactly what the researchers have to test.

The news lies not in the introduction of a new drug, but in the attempt to determine exactly how intensive modern lipid-lowering therapy should be.

Primary source (clinical trials registry): ClinicalTrials.gov: NCT07615296.

Illustrative photo: Unsplash+

Duchenne Muscular Dystrophy (DMD) is a severe, progressive, rare genetic disease that leads to loss of muscle strength. The disease is caused by mutations in the gene responsible for producing dystrophin, a protein that protects muscle fibers from breakdown. To better understand the daily challenges patients face and how they overcome them, we recommend reading the educational material and inspiring story of Sachin Munshi living with this diagnosis.

In modern medicine, one of the promising areas of DMD support is exon skipping therapy. This method does not "fix" the damaged gene permanently but allows the cell, when reading genetic instructions, to "jump over" the defective segment. As a result, a shortened but partially functional version of the dystrophin protein is produced.

FORZETTO Trial Design

Biotechnology company Dyne Therapeutics has begun recruitment for a Phase 3 clinical trial named FORZETTO (international registry number NCT07608432). It studies the experimental drug zeleciment rostudirsen (DYNE-251). Important clarification: this drug is being developed not for all DMD patients, but exclusively for those whose genetic mutations are suitable for exon 51 skipping.

The trial status is currently "Recruiting". Key trial parameters include:

• Participants: The project will involve 90 male patients aged 4 to 18 with a confirmed DMD diagnosis and the corresponding mutation.
• Intervention: Participants will receive DYNE-251 as an intravenous infusion once every 4 weeks.
• Evaluated Outcomes: The main goal of the trial is to assess the impact of therapy on the physical motor function of patients, as well as to confirm the drug's safety and its ability to increase dystrophin production in muscles.

Why the Transition to Phase 3 is Important

Launching Phase 3 means that the drug has shown an encouraging safety and activity profile in previous stages. While exon skipping technology is not a complete cure, for families facing Duchenne muscular dystrophy, the emergence of new therapy options (especially with a convenient once-every-4-weeks administration schedule) represents a crucial step forward.

Primary source (clinical trial registry): ClinicalTrials.gov: NCT07608432 (FORZETTO).

Educational material about the disease: Rare Disease Day: Resilience in the face of Duchenne Muscular Dystrophy.

Illustrative photo: Rauf Alvi / Unsplash+

Observing the fast during the holy month of Ramadan involves complete abstinence from food and drink during daylight hours. For millions of people with type 2 diabetes, this means a significant change in their diet and medication regimen, which can lead to dangerous blood glucose fluctuations or hypoglycemia. Managing diabetes during this period requires special attention and careful therapy selection.

GLP-1 receptor agonist drugs have proven effective in lowering blood sugar and body weight; however, most of them require injections. The pharmaceutical company Eli Lilly is developing orforglipron (LY3502970)—a novel oral (pill-based) non-peptide GLP-1 receptor agonist taken once daily. In previous phase 3 trials, it has already shown the ability to reduce HbA1c and weight, but its use during prolonged daytime fasting has not yet been studied.

ACHIEVE-RAM trial design

To close this gap in clinical data, a new multinational phase 3 trial called ACHIEVE-RAM (registry number NCT07613307) has been registered. The sponsor is Eli Lilly and Company.

The main goal of the project is to evaluate the safety and efficacy of orforglipron in adult patients with type 2 diabetes who plan to fast during Ramadan. According to the registry, the trial's status is "Not yet recruiting". The planned start is scheduled for July 2026, with completion in May 2027.

• Participants: The trial plans to enroll 130 patients with type 2 diabetes.
• Geography: The project will be conducted in a multinational format. The list of participating countries includes India, Saudi Arabia, South Africa, and the United Arab Emirates (UAE).

Why this matters for real-world practice

ACHIEVE-RAM is a prime example of how clinical trials are adapting to the real lives of patients. For endocrinologists in Muslim countries (and nations with large Muslim diasporas), having evidence-based protocols for prescribing new medications is crucial. If an oral GLP-1 shows good tolerability and stable glycemic control without a high risk of hypoglycemia during daytime fasting, it could significantly simplify patient management during Ramadan.

Primary source (clinical trials registry): ClinicalTrials.gov: NCT07613307 (ACHIEVE-RAM).

Illustrative photo: Getty Images / Unsplash+

Preeclampsia is one of the most dangerous pregnancy complications, associated with high blood pressure and serious health risks for both mother and child. According to current recommendations by the US Preventive Services Task Force (USPSTF), pregnant women at high risk for developing preeclampsia are advised to take low-dose aspirin (81 mg/day) starting after 12 weeks of gestation. However, the decision must always be made by a physician, taking into account the individual risk profile and potential contraindications.

In real-world clinical practice, however, doctors do not always recognize the necessary risk factors in the patient's medical history in time, missing the window for preventive treatment. To close this gap between medical guidelines and routine care, a new clinical trial has been registered in the US under the identifier NCT07614893.

Initiated by researchers at Massachusetts General Hospital (Mass General Brigham), the project does not test a new drug, but rather a digital tool—a Clinical Decision Support (CDS) system integrated into the electronic health record (EHR).

How the trial will work

This is a pragmatic clinical trial that will take place in standard outpatient settings. Currently, the project status is "Not yet recruiting". The intervention is structured as follows:

• Intervention: An algorithm built into the EHR will analyze the patient's data. If the system identifies high-risk factors for preeclampsia, the attending physician will receive an automated pop-up notification (a prompt) recommending they consider prescribing low-dose aspirin.
• Control group: Doctors providing care according to the Standard of Care, without additional automated system reminders.
• Primary goal: To evaluate whether such a digital notification statistically significantly increases the proportion of properly selected patients who are prescribed timely prevention.

Why this is important

Prescribing low-dose aspirin is a simple, accessible, and proven measure, but it only works when applied on time. Integrating smart notifications directly into the obstetrician-gynecologist's workflow could be the missing link that helps doctors, who face strict time limits during appointments, not to overlook vital preventive measures.

Primary source (clinical trials registry): ClinicalTrials.gov: NCT07614893.

Additional context: USPSTF Recommendation: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia.

Illustrative photo: Towfiqu Barbhuiya / Unsplash+

Modern clinical guidelines clearly outline how to protect the kidneys and heart in patients with type 2 diabetes. However, in real-world daily practice, doctors do not always prescribe vital therapies—such as SGLT2 inhibitors or GLP-1 receptor agonists—on time. The gap between medical theory and actual patient care remains a major healthcare challenge.

To find a practical solution, a new clinical trial called RAPID-CKM (international registry number NCT07605390) has been registered in the US. The project is initiated by the Baylor Research Institute. The uniqueness of the trial lies in the fact that it tests not the effect of a new drug, but the performance of a digital tool—automated clinical advisories within a patient's electronic health record (EHR).

Trial design and details

RAPID-CKM is a pragmatic randomized trial, which means it is conducted in real-world clinical settings rather than in an idealized environment. Currently, the project status is "Not yet recruiting". Key parameters of the trial include:

• Participants: Primary care physicians and their patients suffering from type 2 diabetes, chronic kidney disease (CKD), and albuminuria.
• Intervention: Integration of targeted Best Practice Advisories into the Epic electronic health record system. Right during the appointment, the doctor will receive an unobtrusive prompt indicating that this patient is eligible for specific kidney-protective treatment (Guideline-Directed Medical Therapy, GDMT).
• Control group: Doctors providing care according to the Standard of Care, without additional pop-up alerts.
• Primary Outcome: Assessing whether the digital "nudge" increases the proportion of patients who are prescribed recommended medications within 6 months after the visit.

Why the focus on CKM syndrome is important

The abbreviation CKM stands for Cardiovascular-Kidney-Metabolic syndrome. This is a concept actively promoted by the American Heart Association (AHA) and nephrologists, emphasizing that diabetes, obesity, kidney disease, and cardiovascular risks are inextricably linked and require a comprehensive approach.

For patients with CKM syndrome, the early prescription of the right medications can significantly slow down kidney damage and prevent heart attacks. However, due to strict time limits during appointments, doctors are often forced to focus only on current acute complaints, missing the window for preventive prescribing. RAPID-CKM aims to verify whether automation can close this gap.

What to expect from the results

If the trial proves that simple and timely EHR notifications statistically significantly increase the frequency of correct prescriptions, this experience could be scaled up. Integrating such algorithms into clinic software could become one of the fastest and cheapest ways to improve the quality of care for patients with diabetes and CKD.

Primary source (clinical trials registry): ClinicalTrials.gov: NCT07605390 (RAPID-CKM).

Additional information on disease links: National Kidney Foundation: CKM Syndrome.

Illustrative photo: Getty Images / Unsplash+

Knee osteoarthritis is one of the most common causes of chronic pain and loss of mobility. When pills, injections, and physical therapy stop helping, joint replacement surgery becomes the standard solution. A new study published in the journal Radiology evaluates a minimally invasive alternative for patients who are not yet ready for a knee replacement.

The method is called genicular artery embolization (GAE). During the procedure, interventional radiologists insert a microcatheter through a small puncture into the blood vessels supplying the joint capsule. Then, resorbable microspheres are injected into the abnormally overgrown small arteries that sustain chronic inflammation. This restricts blood flow to the inflamed tissues and helps reduce pain.

What the study results showed

Researchers conducted a prospective single-center observational study involving 194 patients. A total of 239 genicular embolization procedures were performed. According to the authors, the technical success rate of the intervention was 100%.

Pain was assessed using a numeric rating scale (NRS) from 0 to 10. Before the procedure, the median pain score was 7. Twelve months after embolization, this score dropped to 3.

Clinically significant pain improvement at one year was achieved by 80% of patients. Additionally, participants completed the KOOS questionnaire to evaluate joint function in daily living and quality of life. Depending on the specific questionnaire subscale, an improvement exceeding the minimal clinically important difference was noted in 55–80% of participants.

How safe is it

The procedure demonstrated a favorable safety profile. Mild, self-resolving adverse events were recorded in 6.7% of cases. No moderate or severe complications were registered during the follow-up period.

Limitations and takeaways for patients

It is important to understand that embolization does not regenerate destroyed cartilage or reverse the progression of osteoarthritis. It is not a guaranteed pain relief for every patient, nor is it a proven way to "delay surgery for years."

Furthermore, the published work was an observational study. It lacked a control group (for example, patients receiving a placebo or a sham procedure), which is a significant limitation for assessing the true efficacy of pain relief.

Nevertheless, the results indicate that genicular embolization could become an important intermediate option for a specific group of patients: those who no longer benefit from conservative therapy but for whom surgery is not yet indicated or desirable.

Primary source: Radiological Society of North America (RSNA), scientific journal Radiology.

Illustrative photo: Getty Images / Unsplash+

GLP-1 class drugs have become famous for the successful treatment of type 2 diabetes and impressive results in weight loss. But as millions of people have started using them, doctors are increasingly asking another question: what happens to reproductive health when a patient's weight, blood sugar levels, insulin resistance, and hormonal balance improve?

The final answer is not yet ready. However, several recent scientific reports have heightened interest in the topic of fertility—in both women and men. It is important to set the record straight right away: GLP-1 drugs are not a treatment for infertility and should not be viewed as a way to "boost the chances of pregnancy" without strict medical supervision.

What the data in women showed

One of the new reasons for discussion is linked to the RESTORE research program, which is being conducted at the University of Colorado (CU Anschutz). The project is studying the use of semaglutide in girls and women with obesity and PCOS/PMOS. PCOS stands for polycystic ovary syndrome, and PMOS is used as an updated term for a condition that combines menstrual irregularities, elevated androgens, infertility risk, and deep metabolic issues.

An early proof-of-concept analysis focused on participants aged 12–35 who achieved at least a 10% reduction in body weight during treatment. According to the CU Anschutz research team, some patients experienced reproductive improvements (including the restoration of ovulation) sooner than expected, so the team presented preliminary results before the main study concludes.

The point of these data is not that semaglutide directly "cures infertility." A more cautious and scientifically sound interpretation is this: in women with polycystic ovary syndrome and obesity, the normalization of their metabolic state may be accompanied by the restoration of ovulation. But the durability of this effect, the safety of the strategy, and its place in clinical guidelines have yet to be confirmed.

What is known about men

The second major newsmaker was ENDO 2026, the annual meeting of the Endocrine Society. A team from University Hospitals Coventry and Warwickshire and Warwick Medical School analyzed published randomized trials of GLP-1 drugs in men aged 18–65.

The systematic review included five clinical trials. The authors assessed testosterone levels, sperm parameters, body weight, glucose, lipids, and overall metabolic health. The data showed no consistent harm to male hormones, sexual function, or sperm quality. Moreover, in some studies, positive signals were observed: for instance, a 24-week study with semaglutide noted improvements in sperm morphology and cholesterol profile, while a 16-week study of liraglutide in men with obesity showed an increase in testosterone levels.

Why this is biologically plausible

Obesity and insulin resistance can severely disrupt reproductive function in both sexes. In women, they are often linked to irregular ovulation and hyperandrogenism. In men, excess fat tissue can be accompanied by decreased testosterone, worsening sperm parameters, and chronic systemic inflammation.

If GLP-1 therapy helps reduce weight and improve the metabolic profile, some of the reproductive changes are a logical indirect consequence of this improvement. The drug "fixes" the metabolism, rather than acting as a fertility stimulant.

Where the risk zone begins

The most dangerous mistake is to turn these early data into everyday advice and start injecting GLP-1 "to get pregnant" or to continue taking the drug while trying to conceive without consulting a specialist.

The current FDA label for semaglutide explicitly states that the weight loss drug should be discontinued at least 2 months before a planned pregnancy due to its long washout period from the body. For tirzepatide, there is also a strict warning: the drug may reduce the efficacy of oral hormonal contraceptives. When starting therapy or increasing the dose, patients are advised to temporarily use non-hormonal or barrier methods of contraception.

There are two sides to this topic. On the one hand, improving health increases the likelihood of ovulation. On the other hand, this can lead to an unplanned pregnancy in women who are used to menstrual irregularities or who do not take into account drug interactions with oral contraceptives.

What cannot be claimed yet

It cannot be said that GLP-1 drugs cure infertility. Pregnancy cannot be promised after weight loss. Preliminary data on PCOS cannot be generalized to all women with reproductive issues, and the review on men cannot be applied to all patients with male factor infertility.

It is possible that in some people with obesity and metabolic disorders, these drugs do help the reproductive system work better. But incorporating this into clinical protocols requires large, long-term studies.

The practical takeaway for patients is simple: if you are taking a GLP-1 and planning a pregnancy, undergoing infertility treatment, or using oral contraception, this must be discussed with a doctor. Changing the treatment regimen on your own is strictly prohibited.

Sources: CU Anschutz: semaglutide and reproductive outcomes in women with PMOS; CU Anschutz RESTORE Study; Endocrine Society: GLP-1s and male fertility in men with obesity; FDA label: Wegovy / semaglutide; FDA label: Mounjaro / tirzepatide.